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Abstract 
 
Anti-ganglioside antibodies have been implicated in autoimmune neuropathies 
for several decades. They are thought to elicit injury through binding to sites in 
the peripheral nervous system, where they activate the complement pathway to 
induce cell death. Patient serum is therefore regularly screened for these 
antibodies to aid in the diagnosis of various conditions. Recent work has found 
that complexes composed of gangliosides and other glycolipids can improve the 
detection of these antibodies beyond the signals detected to the single 
ganglioside species.  
In MMN research, complexes comprised of GM1 and GalC have been found to 
significantly enhance antibody detection in patient sera. In certain patients, 
however, antibody binding was only detected against these complexes and not 
the single antigens. This led some researchers to hypothesise that an 
unidentified class of antibody may have arisen that binds specifically to a neo-
epitope formed by the combination of the two glycolipids. It has also been 
hypothesised that that this complex may be the true target of immune mediated 
attack in MMN. 
This thesis sought to address this hypothesis by either cloning these antibodies 
directly from patient serum or through active immunisations with mice. Analysis 
of previously generated human monoclonal antibodies indicated that their 
behaviours were modified by complexes containing particular gangliosides or 
glycolipids. Furthermore, the antibodies behaviours were found to diverge, when 
they were screened against complexes comprised of gangliosides and different 
concentrations of accessory lipids. These findings suggested that the accessory 
lipids were interacting with the ganglioside headgroups to modify the 
presentation of different binding epitopes. This indicated that conformational 
modulation, rather than neo-epitope formation, may be responsible for complex 
enhancement  
Cloning antibodies from patient sera was unsuccessful but examination of the 
screening techniques suggested that the appearance of complex-dependent 
antibodies may have been an artefact. Attempts to induce complex-specific 
responses in mice were similarly unsuccessful but several anti-ganglioside and 
anti-sulfatide antibodies were created. The subsequent chapters focused on the 
characterisation of these antibodies and indicated that most of them bound well 
to solid-phase assays, cells and tissue and may therefore be of use in future 
studies. 
Taken together, the data from this thesis suggests that complex-dependent 
antibodies may not exist but are merely low concentrations of anti-ganglioside 
antibodies that are cis-enhanced by particular lipids. Future work should 
therefore focus on assessing how the ganglioside microenvironment modifies 
epitope presentation and how this affects the binding capabilities of anti-
ganglioside antibodies. 
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1  INTRODUCTION 
1.1 Autoimmune Neuropathies 
 
Autoimmune neuropathies (AN) describe a diverse range of conditions in which 
an abnormal immune response results in inflammation of the peripheral nervous 
system (PNS). These conditions vary widely in their presentation, appearing in 
both acute and chronic forms, with symptoms affecting distal or proximal 
locations in a symmetrical or multifocal pattern. The inflammation produced can 
lead to demyelination or axonal degeneration resulting in permanent disability, 
respiratory paralysis or death.  
The implications of such neuropathies are far reaching, having not only a 
substantial impact upon both the lives of patients and their families but also the 
healthcare system. A study showed that the pre-eminent acute AN, Guillain-
Barré syndrome, was estimated to have cost the US economy $1.8 billion in 2004 
alone, signifying the continued importance of the research and treatment of 
these conditions (Frenzen, 2008). 
1.2 History 
 
The first modern description of an autoimmune neuropathy was by Jean Landry 
in 1859 (Landry, 1859). He described a set of 10 patients suffering from 
ascending muscular paralysis accompanied by loss of reflexes and parasthesia. 
The onset of disease in one patient in particular was described in detail. This 
patient’s condition deteriorated rapidly with the paralysis spreading to the 
trunk, resulting in asphyxia and death. No known cause was identified and 
autopsy results were inconclusive as nervous tissue was not examined. This 
condition was eventually termed Landry’s paralysis.  
In France in 1916, three physicians described a similar condition (Guillain et al., 
1916). Georges Guillain, Jean Alexandre Barré and André Strohl were army 
physicians who examined two soldiers suffering from motor weakness and 
parasthesia. Upon examination of the cerebrospinal fluid they discovered raised 
Chapter 1 – INTRODUCTION  2 
 
albumin levels but without pleocytosis indicating that no other infection was 
causing the symptoms. This was essential to distinguish the condition from 
Poliomyelitis which was the most common cause of acute flaccid paralysis at the 
time. Both patients recovered spontaneously and the condition was termed 
Guillain-Barré Syndrome (GBS) in 1927 (Dragnesco & Claudian, 1927). 
For a period of time both diseases were considered separate entities. George 
Guillain, in particular, stressed the differences between Landry’s paralysis and 
GBS due to the lack of pleocytosis in his patients (lumbar puncture had not been 
invented when Landry examined his patients) and the benign nature of their 
symptoms in comparison to those suffering from Landry’s Paralysis. Despite his 
objections the diseases were grouped together in 1949 under the name of 
Landry-Guillain-Barré syndrome by Haymaker and Kernahan.   
Research into GBS began to intensify following Haymaker and Kernahan’s 
descripton of 50 patients with fatal GBS (Haymaker & Kernohan, 1949). At the 
same time a physician called Charles Miller-Fisher described several patients 
suffering from ophthalmoplegia, ataxia and areflexia (Fisher, 1956). Some of 
these patients suffered palsy and weakness but all recovered spontaneously. As 
some GBS patients suffer from ophthalmoplegia Miller-Fisher accurately 
concluded that his patients were suffering from a subtype of GBS. This was 
dubbed Miller-Fisher Syndrome (MFS), which is now known to be a specific 
subtype of GBS in which antibodies target gangliosides found enriched in the 3rd 
and 4th cranial nerves producing ophthalmoplegia.   
Due to the increase in GBS cases associated with the 1976 swine flu outbreak in 
the United States, Asbury & Cornblath established strict diagnostic criteria for 
the condition (Asbury & Cornblath, 1990). These criteria cited motor weakness 
and areflexia as required symptoms for diagnosis which could be supported by 
different features often associated with the condition. These included 
electrophysiology which showed conduction slowing or block within the nerves. 
These data, alongside autopsy reports, were consistent with demyelination of 
the nerve roots and trunk which led to the assumption that GBS was a 
homogenous condition synonymous with Acute Inflammatory Demyelinating 
Polyradiculoneuropathy (AIDP).  
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It was not until the description of a seasonal outbreak of a GBS-like illness in 
rural China that further subtypes of GBS were described. This condition, 
originally called Chinese paralytic syndrome, produced acute ascending flaccid 
paralysis leading to quadraparesis and respiratory failure (McKhann et al., 1990). 
It was commonly mistaken for GBS but electrophysiological examination 
suggested that the patients were suffering from denervation rather than 
demyelination of the motor nerves, whilst the sensory nerves remained 
unaffected. Research into this condition intensified and it was found to be an 
axonal variant of GBS which was more prevalent in Asian countries(Yuki, 
Yoshino, & Miyatake, 1993; McKhann et al., 1993). It was eventually termed 
acute motor axonal neuropathy (AMAN) (Ho et al., 1995). 
As research developed into acute subtypes of GBS, clinicians began to describe 
chronic forms of autoimmune neuropathies. These chronic conditions are all 
closely related and can be considered to be part of a spectrum of disease. 
Chronic inflammatory demyelinating polyneuropathy (CIDP) was the first to be 
described by Austin in 1958. He examined patients from the literature and two 
of his own who had suffered from recurring bouts of paralysis. These patients 
tended to present with muscle weakness in the extremities, which eventually 
spread to the trunk with increased severity. Following treatment with cortisone 
and prednisone he was able to control the symptoms in his own patient but was 
not able to prevent relapse (Austin, 1958). 
Clinicians began to report patients with similar chronic neuropathies that had 
differing symptoms. Lewis and Sumner reported five patients who were suffering 
from a variant of CIDP (Lewis et al., 1982). The patients presented with 
asymmetric sensorimotor weakness focussed in the upper extremities with 
multifocal nerve involvement. This condition, known as Lewis-Summer syndrome 
or multifocal acquired demyelinating sensory and motor neuropathy (MADSAM), 
can be distinguished from CIDP by the electrophysiology data, namely the 
prolonged conduction block seen in the MADSAM patients. However, the two 
conditions are closely related and share many of the same diagnostic criteria.  
The most recent chronic neuropathy to be described was multifocal motor 
neuropathy (MMN). MMN was first observed in five patients in 1982 who 
presented with an asymmetric motor neuropathy predominantly affecting the 
upper limbs. Diagnostic tests revealed the presence of conduction block in the 
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motor nerves but none in the sensory nerves. Two of the patients were treated 
with steroids and it was assumed that the condition was a variation of CIDP 
(Lewis et al., 1982). 
Between 1985 and 1986 three separate papers also reported patients with 
similar symptoms (Chad et al., 1986; Parry & Clarke, 1988; Roth et al., 1986) but 
it was not until 1988 that Pestronk et al discovered the presence of antibodies 
targeting structures predominantly found in the peripheral nervous system called 
gangliosides, in particular GM1 (Pestronk et al., 1988). Treatment of these 
patients with immunomodulating therapy was shown to be successful, indicating 
the role of these antibodies in producing the aforementioned muscle weakness.  
1.3 Multifocal Motor Neuropathy 
 
Although not widely researched, the incidence rate of MMN is between 1 and 2 
people per 100,000 population, similar to that of GBS. It is found more 
commonly in males than females in a 2.6:1 ratio with an average age of onset of 
approximately 40 years (Slee et al., 2007).   
1.3.1 Clinical Criteria  
1.3.1.1 Core Criteria 
 
There is no definitive test for MMN; rather patient symptoms must fulfil certain 
diagnostic criteria (Table 1 and 2). Most patients initially present with slowly 
progressing asymmetric muscle weakness, most commonly in the fore arms. 
Although no paralysis occurs, this weakness results in the patients experiencing 
foot drop, wrist drop and grip weakness. These are commonly accompanied by 
fasciculations and loss of tendon reflexes within the affected limb. Sensory 
symptoms, other than minor vibration sense abnormalities, should not be 
present although parasthesia and minor numbness may be experienced in a small 
number of patients, particularly as the disease progresses (Léger & Gavriliuc, 
2012). As symptoms vary significantly between patients, these criteria can be 
substantiated by various diagnostic tests including electrophysiology and 
serology.  
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1.3.1.2 Electrophysiology  
 
Nerve conduction studies (NCS) are one of the main diagnostic tests performed 
to confirm the presence of MMN. They allow for the detection of conduction 
block (CB), demyelinative slowing or loss of motor axons. This is achieved 
through stimulation of the nerves by an electrode which generates an action 
potential recorded at a distant point on the same nerve. This same electrical 
impulse activates the target muscle supplied by the nerve and produces a 
compound muscle action potential (CMAP). As shown in Table 1, a proximal 
CMAP with an area reduction of at least 30% compared to the distal CMAP 
suggests the presence of CB.  
Table 1-1 - Electrophysiological Requirements for Motor Conduction Block 
1     Definite Motor CB* 
Negative peak CMAP area reduction on proximal versus distal stimulation of at 
least 50 % whatever the nerve segment length (median, ulnar, peroneal). 
Negative peak CMAP amplitude on stimulation of the distal part of the 
segment with motor CB must be >20 % of the lower limit of normal and >1mV. 
Increase of proximal to distal negative peak CMAP duration must be ≤30 % 
2     Probable Motor CB* 
Negative peak CMAP area reduction of at least 30 % over a long segment 
(e.g. wrist to elbow or elbow to axilla) of an upper limb nerve with an 
increase of proximal to distal negative peak CMAP duration ≤30 %  
Or: negative CMAP area reduction of at least 50 % (same as definite) with  
an increase of proximal negative CMAP duration of >30 % 
3     Normal Sensory Nerve Conduction in Upper Limb Segments with CB 
 
Electrophysiological Requirements for Motor CB as defined by Joint Task Force of 
the European Federation of Neurological Societies and the Peripheral Nerve 
Society (EFNS/PNS), 2010 *Evidence for CB must be found at sites distinct from 
common entrapment and compression sites. CB = conduction block; CMAP = 
compound muscle action potential. (EFNS/PNS MMN Guideline, 2010) 
 
Conduction block is defined as the failure of action potential propagation at a 
given site in a structurally intact axon (Kaji, 2003).  The CMAP area is used to 
determine CB over CMAP amplitude as the latter can be greatly influenced by a 
process known as temporal dispersion (TD). Temporal dispersion is a result of 
loss of synchronisation between nerve fibres which leads to phase cancellation. 
It therefore strongly mimics the effects of CB with some animal studies  
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Table 1-2 - Clinical criteria for MMN diagnosis 
Definite MMN  
Clinical criteria 1, 2 and 8–11 and electrophysiological criteria 1 and 3  
in one nerve (see Table 1) 
Probably MMN 
Clinical criteria 1, 2 and 8–11 and electrophysiological criteria 2  
and 3 in two nerves (see Table 5); clinical criteria 1, 2 and 8–11  
and electrophysiological criteria 2 and 3 in one nerve and at least  
two supportive criteria 1–4 (see Table 1) 
Possible MMN 
Clinical criteria 1, 2 and 8–11 and normal sensory nerve conduction  
studies and supportive criteria 4; clinical criteria 1 with clinical signs  
present in only one nerve, clinical criteria 2 and 8–11 and  
electrophysiological criteria 1 or 2 and 3 in one nerve (see Table 1) 
Clinical Criteria 
Core Criteria (Both must be present) 
1. Slowly progressive or stepwise progressive, focal, asymmetric* limb weakness, that 
is, motor involvement in the motor nerve distribution of at least two nerves for 
more than 1 month.** If symptoms and signs are present only in the distribution of 
one nerve, only a possible diagnosis can be made. 
2. No objective sensory abnormalities except for minor vibration sense abnormalities 
in the lower limbs*** 
Supportive Clinical Criteria 
3. Predominant upper limb involvement † 
4. Decreased or absent tendon reﬂexes in the aﬀected limb ‡ 
5. Absence of cranial nerve involvement § 
6. Cramps and fasciculations in the affected limb 
7. Response in terms of disability or muscle strength to immunomodulatory treatment 
Exclusion Criteria 
8. Upper motor signs 
9. Marked bulbar involvement 
10. Sensory impairment more marked than minor vibration loss in the lower limbs 
11. Diffuse symmetrical weakness during the initial weeks 
Supportive Criteria 
1. Elevated IgM anti-ganglioside GM1 antibodies 
2. Laboratory: increased CSF protein (<1 g/l) 
3. MRI showing increased signal intensity on T2-weighted imaging associated with 
a diffuse nerve swelling of the brachial plexus 
4. Objective clinical improvement following IVIg treatment 
 
Clinical criteria for MMN diagnosis as defined by by Joint Task Force of the 
European Federation of Neurological Societies and the Peripheral Nerve Society 
(EFNS/PNS), 2010 *Asymmetric: a difference of 1 Medical Research Council (MRC) 
grade if strength is MRC >3 and 2 MRC grades if strength is MRC ≤3. **Usually 
more than six months. ***Sensory signs and symptoms may develop over the 
course of MMN. † At onset, predominantly lower limb involvement accounts for 
nearly 10 % of the cases. ‡Slightly increased tendon reflexes, in particular in the 
affected arm, have been reported and do not exclude the diagnosis of MMN 
provided criterion 8 is met. § Twelfth nerve palsy has been reported. (EFNS/PNS 
MMN Guideline, 2010) 
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suggesting that a reduction in CMAP amplitude of up to 80% can be attributed to 
TD alone. (Rhee et al., 1990) 
The use of CMAP area is therefore required for an accurate diagnosis although a 
decreased CMAP area in proximal versus distal locations of up to 50% can still be 
caused by TD. This has led to strict guidelines determining that a definitive 
diagnosis of MMN must have a CMAP area reduction of 50% or above. 
Smaller reductions can still indicate MMN but must be supported by other 
diagnosis criteria. This includes the measurement of sensory nerve action 
potentials (SNAPs) in nerves with conduction block. The presence of motor CB 
alongside normal SNAPs is a strong indication of MMN whereas decreased SNAPs 
would be more indicative of MADSAM. 
1.3.1.3 Treatment 
 
Part of the supportive clinical criteria of a MMN diagnosis is an improvement in 
disability or muscle strength in response to immunomodulating agents. The most 
effective of these treatments is intravenous immunoglobulin (IVIG), which 
consists of pooled IgG antibodies from more than a thousand different blood 
donors. Patients undergoing treatment with IVIG show a marked clinical 
improvement with up to 94% of patients showing an improvement in disability 
score and muscle strength (Cats, van der Pol, et al., 2010). This significant 
improvement reinforces the hypothesis that antibodies are responsible for 
disease pathogenesis in MMN.  
The mechanism of action of IVIG has yet to be fully elucidated but it is 
considered to exert its effects upon several different pathways. Several studies 
have indicated that it prevents B cell proliferation and antibody production and 
inhibits the ability of these antibodies to cross the blood-nerve barrier (BNB) 
(Hartung, 2008; Kondo et al., 1994; Stohl & Elliot, 1996). It is also thought that 
IVIG can interfere with the complement cascade and thus prevent complement 
induced injury to nerves (Jacob & Rajabally, 2009). It is unclear whether it is 
just one of these mechanisms or a combination of them all that helps prevent 
autoantibody induced damage but as serum antibody levels tend to remain 
stable during treatment it has been hypothesised that IVIG acts to prevent 
antibody binding and complement activation (Malik et al., 1996). 
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There are several drawbacks of IVIG treatment despite its effectiveness. The 
increased off-label use of the treatment for a wide number of conditions has led 
to a worldwide shortage of the drug, which has also led to a substantial increase 
in its cost (Deparment of Health, 2011; O’Riordan et al., 2010). This coupled 
with the requirement of patients to attend hospital regularly to receive 
treatment has resulted in a drive to investigate other immunotherapies (Nobile-
Orazio & Gallia, 2013). 
Subcutaneous immunoglobulin (SCIG) is a relatively new treatment option that 
addresses the issues with intravenous administration. SCIG contains the same 
dose of immunoglobulin as standard IVIG but can be self-administered by 
patients at home. This results in reduced costs for healthcare systems who no 
longer need to provide staff to administer the immunotherapy and also results in 
an improvement in the quality of life for the patient (Ozerovitch, 2013). 
Studies have shown that SCIG is as effective at maintaining muscle strength and 
disability score as IVIG but was scored higher by patients in regards to their 
health related quality of life (Eftimov et al., 2009; Harbo et al., 2009; Misbah et 
al., 2011). Further studies are needed to establish the long term safety profile of 
SCIG but it is becoming popular with physicians and patients as an alternative 
form of treatment.  
Aside from immunoglobulin therapy, researchers have also examined the 
effectiveness of B cell depletion in treating MMN.  This has primarily been 
carried out using the humanised monoclonal antibody Rituximab, which 
specifically targets the B cell surface antigen CD20 (Anderson et al., 1997). Once 
bound, this antibody is able to initiate cell death via complement activation, 
antibody-dependent cell-mediated toxicity and apoptosis (Kosmidis & Dalakas, 
2010).  
Although it was initially approved for treating B cell lymphoma, Rituximab has 
been shown to effectively treat a variety of autoimmune conditions including 
rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus. It has 
also been demonstrated to be effective in treating MMN, with several studies 
showing an improvement in muscle strength and a reduction in circulating anti-
GM1 antibodies following administration (Gorson et al., 2007; Pestronk et al., 
2003; Rüegg et al., 2004). Despite this work, the antibody has only been shown 
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to be effective alongside IVIG and has not yet been proven as a useful 
standalone therapy.  
Very limited research has also been performed with complement inhibitors, with 
one study examining their effects on MMN patients (Fitzpatrick et al., 2011). The 
study used a humanised monoclonal antibody, ecluzimab, which targets and 
neutralises terminal complement component 5 (C5). This prevents the formation 
of the membrane attack complex (MAC) on cell membranes and thus reduces 
complement induced injury. When used in conjunction with IVIG treatment it 
showed an improvement in conduction block and select motor performance tests 
in a number of patients. This effect appeared independent of the IVIG benefits 
but a fully blinded study would need to be performed on a larger number of 
patients to establish the full effectiveness of complement inhibitors.  
Certain therapies used to treat other ANs are not suitable for MMN patients and 
can actually exacerbate symptoms. A prime example is plasma exchange in 
which the plasma is removed from the body and filtered to extract auto-
antibodies. This treatment is commonly used to reduce nerve injury and 
demyelination in GBS and CIDP patients but in MMN patients it causes a 
worsening of their symptoms (Carpo et al., 1998). It is unclear why plasma 
exchange is unsuccessful in treating MMN, although it has been hypothesised that 
filtering the plasma also removes beneficial antibodies and cytokines which 
regulate the pathogenic antibodies. The pathogenic antibodies would therefore 
be able to produce higher levels of inflammation and cell death, which would 
result in a deterioration in the patient’s condition (Claus & Specht, 2000). This 
reiterates the importance of an accurate diagnosis as plasma exchange is an 
undesirable treatment option for a MMN patient.   
1.3.2 Exclusion Criteria  
 
As MMN shares many of the symptoms of other neurological diseases, it is 
necessary to exclude particular symptoms, which may be indicative of other 
conditions. This is important to prevent the misdiagnosis of patients who may be 
suffering from conditions with much worse prognoses such as motor neuron 
disease (MND). 
Chapter 1 – INTRODUCTION  10 
 
Motor neuron disease is a rapidly progressive condition in which the motor 
neurons become damaged leading to muscle weakness and eventual paralysis 
and death. Although the symptoms of both are very similar in the earlier stages, 
there are certain symptoms unique to MND which exclude patients from a MMN 
diagnosis.  These include weakness in the absence of fasciculations, involvement 
of large groups of muscles, brisk reflexes, and a positive Babinski sign.  
These symptoms would suggest the involvement of upper motor neurons which 
are not affected in MMN. Other exclusion criteria include marked bulbar 
involvement, where patients have difficulty swallowing, chewing and breathing, 
which would also be suggestive of a MND subtype known as bulbar palsy.  
Sensory symptoms, beyond those already discussed, would be more suggestive of 
a different chronic autoimmune neuropathy such as CIDP or MADSAM. The 
presence of any of these exclusion criteria would prevent a diagnosis of MMN and 
would be more suggestive of different conditions affecting the lower motor 
neurons. 
1.3.3 Supportive criteria 
 
There are certain other diagnostic and laboratory tests which can support a MMN 
diagnosis but are not specific enough to act as essential criteria. These include 
measurements of CSF protein, MRI scans and serology screening to identify anti-
ganglioside antibodies.  
1.3.3.1 Raised Cerebrospinal Fluid Protein 
 
A lumbar puncture is performed to test for the presence of raised CSF protein, 
which is indicative of an autoimmune neuropathy. The main function of the test 
is to preclude any infective agents such as poliomyelitis as possible causes of the 
symptoms (Hadden & Hughes, 2003). If these were the cause then the CSF 
protein would expect to be within its normal range and the physician could 
search for an alternative diagnosis.  
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1.3.3.2 Magnetic Image Resonance  
 
Limited research has been performed using magnetic resonance imaging (MRI) 
scanners to detect nerve swelling in MMN patients. This takes the form of an 
increased signal in T2-weighted images of the brachial plexus, which is similar to 
that seen in CIDP patients. The main benefit of this test is to distinguish MMN 
from lower motor neuron disease (Van Es et al., 1997). 
1.3.3.3 Serology 
 
The presence of anti GM1 antibodies in patient sera is a distinguishing feature in 
MMN but, due to the high variability between studies, it is not part of the 
required diagnostic criteria. Publications suggest that antibodies targeting GM1 
can range from between 30 to 80% in different laboratories which could be an 
indication of differences in population dynamics or simply differences in 
laboratory technique (Harschnitz et al., 2014; Nobile-Orazio et al., 2013). This 
number tends to increase when the serum is screened against complexes 
composed of GM1 and other gangliosides or glycolipids with some studies 
detecting antibodies in 100% of patients (Galban-Horcajo et al., 2013).  
Currently there is no specific biomarker for MMN but it is hoped that the use of 
ganglioside complexes may reveal an epitope that has not been previously 
discovered. This would be greatly beneficial in MMN diagnosis as it would 
alleviate the requirement for the more specialist tests previously mentioned and 
reduce diagnosis time.   
1.3.4 Pathophysiology 
 
Although the presence of anti-GM1 antibodies and the response to immune 
modulating treatments are good indications that MMN is an autoimmune 
condition, no studies have directly demonstrated the pathophysiological 
mechanisms responsible for the onset of disease.  
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1.3.4.1 Molecular Mimicry 
 
Part of the difficulty in assessing the pathogenicity of MMN is that the cause of 
the disease is unclear. One possibility is that the condition is a post infectious 
disease, in which the development of an immune response to a previous 
infection leads to autoimmunity. The best example of this is GBS, which tends to 
arise 2-3 weeks following exposure to a triggering antigen. These can range from 
vaccinations to upper respiratory and gastrointestinal infections, but GBS is most 
commonly associated with Campylobacter jejuni (C. jejuni) (Nyati & Nyati, 2013; 
Willison & Yuki, 2002).  
This bacterium is commonly found in animal faeces and as a result tends to 
affect rural communities more than those found in urban areas. During the 
original descriptions of AMAN, it was noted that outbreaks tended to occur at 
the same time as the seasonal C. jejuni infections, which peaked in the summer 
months (McKhann et al., 1990). This gave rise to the theory that the bacterium 
was responsible for triggering AMAN. Subsequent research proved this theory by 
demonstrating that a degree of molecular mimicry existed between the lipo-
oligosaccharide coats of the bacterium and human gangliosides, particularly GM1 
and GD1a (Figure 1.3) (Aspinall et al., 1994; Yuki et al., 2004).    
From an evolutionary stand point, it appears that the bacteria has evolved to 
resemble gangliosides in an effort to mask itself from the immune system (Moran 
et al., 1996). Unfortunately, in certain patients, this results in the antibodies 
cross reacting with host gangliosides bringing about neurological injury.  
This has also been demonstrated in animal models, where immunisations with C. 
jejuni led to the development of specific anti-ganglioside antibodies (Goodyear 
et al., 1999), which, in the case of rabbits, led to acute flaccid paralysis (Yuki et 
al., 2004). Molecular mimicry is therefore a major factor in the development of 
anti-ganglioside antibodies and may be of relevance in MMN.   
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1.3.4.2 Adaptive Immune Response 
 
The mechanisms responsible for the development of autoimmunity in GBS are 
well established.  Upon exposure to bacteria, such as C. jejuni, epithelial cells 
in the gut secrete chemokine ligand 20 and interleukin 8 in order to recruit 
antigen presenting cells to the site of infection. Dendritic cells in the gut then 
rapidly internalise the bacterium, which triggers the release of cytokines, NF-Kβ 
and tumour necrosis factor-α (Jones et al., 2003). These cells then either 
undergo apoptosis or migrate to the mesenteric lymph nodes, where they trigger 
a predominant Th1 response to aid in bacterial clearance (Willison & Goodyear, 
2013).  
In addition, the immune response also triggers IgA secretion by B cells, which 
aids in resolving the infection. In individuals that are susceptible to GBS, it is 
thought that this response is altered due to differences in the gut microbiota 
(Willison & Goodyear, 2013). This results in a more substantial antibody response 
and the involvement of different classes including IgM, IgG1 and IgG3 (Willison & 
Veitch, 1994). 
This is surprising, especially considering that carbohydrate antigens are typically 
of the IgG2 subclass (Willison & Veitch, 1994). In addition, class switching 
strongly implies that T cell help is involved but it is unclear how the 
carbohydrate antigens are presented to the immune system.      
One possible mechanism is that antigen presenting cells process and present the 
carbohydrates on their MHCII receptors to trigger CD4 T cell activation (Cobb et 
al., 2004). Alternatively, it is possible that the cells migrate to the spleen where 
they trigger plasmablast differentiation in marginal zone B cells in a T cell 
independent manner.  
A newly discovered population may also be able to aid B cells generate anti-
ganglioside antibodies without the aid of T cells. This neutrophil population, 
known as inducible B cell helper neutrophils (iNBHs), are able to prime marginal 
zone B cells to produce IgM antibodies (Puga et al., 2011). Furthermore, the 
presence of lipo-oligosaccharides allows these cells to interact with the marginal 
zone B cells to induce non classical class switching (Willison & Goodyear, 2013). 
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This may lead to the break down in tolerance that is found in GBS; however, the 
specific mechanisms responsible are still not clear.       
Although the adaptive immune response appears to be responsible for the onset 
of GBS, the slow progression and chronic nature of MMN make this a difficult 
aspect to study within this disease. Furthermore, unlike GBS, MMN is not 
associated with any specific infection (Terenghi et al., 2002), which suggests 
that the adaptive immune system may not be responsible for the development of 
anti-ganglioside antibodies. In fact, recent evidence appears to suggest that the 
source of these antibodies may be an abnormality in the natural B cells of the 
innate immune system.  
1.3.4.3 Innate Immune Response  
 
In mice B1 cells are responsible for the secretion of a subset of antibodies that 
do not require prior immune activation. These antibodies are termed “natural” 
antibodies as they are present from birth without external antigenic exposure 
(Grönwall et al., 2012). As they recognise self-antigens it has been proposed that 
they evolved for immunoregulatory roles, particularly the suppression of the 
innate immune system and clearance of apoptotic cells (Grönwall et al., 2012).    
The B1 cells themselves are found predominantly in the peripheral and pleural 
cavities  (Hayakawa et al., 1986) but it is splenic B1 cells that are thought to 
secrete the majority of immunoglobulin. There is some debate as to whether a 
human equivalent of B1 cells has been discovered (D. O. Griffin et al., 2011) but 
this topic is highly controversial (Covens et al., 2013; Tangye, 2013). Regardless 
of this, natural antibodies are still found in humans and evidence suggests that 
they may have roles in the development of certain autoimmune neuropathies.  
In particular, it has been proposed that abnormal proliferation of these B cells 
may be responsible for the development of anti-GM1 antibodies in MMN 
(Harschnitz et al., 2014). This same process is also thought to occur in the 
development of anti-MAG antibodies in various neuropathies. 
It is possible in these conditions that the antibody secreting B cell is either 
mutated or transformed leading to immortalisation (Steck et al., 2013). These 
immortal cells will secrete large titres of IgM antibodies, which will eventually 
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build up in the circulation and begin targeting their respective antigens. This will 
lead to cell injury and thus neurological dysfunction.  
Analysis of the anti-GM1 antibody populations in MMN support this hypothesis as 
they have shown restricted immunoglobulin light chain use, which suggests that 
they arise from a limited number of B cell clones (Cats et al., 2015).A few 
studies have also shown that lymphoma patients can develop MMN (Lefaucheur 
et al., 2003; Noguchi et al., 2003; Stern et al., 2006), which further supports the 
theory that the condition may arise due to an abnormal B cell. Unfortunately, 
bone marrow populations have not yet been examined in MMN patients so the 
roles of B cell proliferation in the disease have yet to be fully elucidated.   
1.3.4.4 Motor nerve susceptibility 
 
It has been demonstrated that the titres of anti-GM1 antibodies in MMN correlate 
with the severity of muscle weakness (Cats et al, 2010). From this observation it 
could be assumed that GM1 is expressed solely by the motor nerves, which would 
explain why the sensory nerves remain unaffected in the condition.   
Examination of GM1 distribution in different nerves, however, produced 
conflicting results. Whilst one group found higher GM1 expression in the ventral 
roots (Ogawa-Goto et al., 1992), other researchers found little difference 
between either tissue (Gong et al., 2002; Svennerholm et al., 1994).   
Even if the motor nerves did have a higher expression of GM1, the lack of injury 
in the sensory nerves cannot be explained. They will still express the ganglioside 
to a certain degree, suggesting that another feature of the nerve must protect it 
from injury.  
One possibility is that the molecular composition of GM1 may differ between 
tissues. This has been demonstrated previously, with a study showing that the 
ceramide core of gangliosides differs in the sensory nerves compared to the 
motor nerves, characterised by an increase in the number of long chain fatty 
acids (Ogawa-Goto et al., 1990). This may impact how the gangliosides are 
distributed in the plasma membrane, which may in turn alter the presentation of 
different binding epitopes.  
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Similarly, the content of the gangliosides microenvironment has also been shown 
to influence the orientation of GM1, which may also affect the availability of 
binding epitopes (Fantini et al., 2013; Greenshields et al., 2009).   
Alternatively, it is possible that the antibodies are capable of binding both 
tissues but, due to an unknown property, are less able to injure sensory nerves. 
There is some support for this theory, as patients with chronic MMN have an 
increased chance of developing minor sensory abnormalities (Cats, van der Pol, 
et al., 2010; Léger & Gavriliuc, 2012); however, further research is needed.  
1.3.4.5 Anti-GM1 antibody immune mediated injury 
 
As with GBS, it is thought that the axons are injured in MMN through activation 
of the complement cascade. This is based upon research, which has found a 
significant correlation between the high complement activating capacity of anti-
GM1 antibodies and more severe muscle weakness and axonal loss (Vlam et al., 
2015). 
Unfortunately, there is no animal model of the condition so it has not been 
possible to replicate these findings in live tissue. However, there are animal 
models of AMAN, the motor form of GBS, which is thought to have a similar 
mechanism of disease (Harschnitz et al., 2014). 
In rabbits it was found that immunisations with purified GM1 or C Jejuni with 
GM1 like structures led to the development of axonal polyneuropathy in the 
motor nerves, resulting in acute flaccid paralysis (van Sorge et al., 2007). The 
conclusion from this study was that AMAN only occurs in animals that develop 
anti-GM1 IgG antibodies with pro-inflammatory responses.  
Assuming that a similar process occurs in MMN, it could be postulated that anti-
GM1 antibodies will bind GM1 enriched target sites, such as the nodes of Ranvier 
(NoR) and activate the complement cascade to bring about cell death. This will 
result in disruption of the sodium channels leading to CB (Franssen & Straver, 
2014; Susuki et al., 2007).  
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1.3.4.6 Complement  
 
Complement is the name given to a series of distinct plasma proteins that form 
one of the main arms of the innate immune system (Janeway et al., 2001). It has 
three main pathways dubbed the classical, alternative and  mannose-binding 
lectin pathway but in MMN it appears that only the classical pathway is activated 
by anti-GM1 antibodies (Piepers et al., 2010; Yuki et al., 2011).   
In the classical pathway, once a complement fixing antibody binds its target, it 
is recognised by complement protein C1q. This produces a conformational  
 
Figure 1.1 – Auto-Antibody Mediated Injury 
Auto-antibodies can arise through two different mechanisms. 1: Infections, such 
as C. jejuni, can give rise to antibodies that target LOS, which closely resembles 
GM1. This molecular mimicry causes the antibodies to target the ganglioside. 2: 
The B cells that produce natural anti-ganglioside antibodies can mutate to form 
immortal plasma cells that produce antibodies indefinitely. 3: Once bound, 
antibodies from both pathways can kill cells by activating the complement 
system. This leads to MAC pore deposition, which results in a large calcium influx 
and by extension cell death. 4: Alternatively, NK cells can bind the antibody’s Fc 
portion via CD16. Once bound the NK cell releases granzymes, which invade the 
antigen presenting cells to induce apoptosis.  
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change that triggers a cascade reaction culminating in the formation of a 
membrane attack complex (MAC) (Muller-Eberhard, 1986). This MAC pore inserts 
into the plasma membrane of a cell causing an uncontrolled influx of 
extracellular fluid, which disrupts the osmotic balance. This causes cell lysis and 
thus death (Figure 1.1).  
The role of complement in GBS is well established particularly in mouse models, 
where the use of complement inhibitors has been shown to abrogate antibody 
mediated injury (Goodfellow et al., 2005; Halstead, Humphreys, et al., 2005; 
McGonigal et al., 2010).  Its roles in MMN, however, are less well established due 
to the lack of animal models but it is thought to initiate cell injury in the same 
manner as GBS (Harschnitz et al., 2014).   
1.3.4.7 Antibody-dependent cell-mediated cytotoxicity  
 
Instead of activating the complement cascade, antibodies can induce cell death 
via NK cells in a process known as antibody-dependent cell-mediated 
cytotoxicity (Figure 1.3).  NK cells express the cell surface antigen CD16, which 
specifically binds the Fc portion of IgG antibodies. Upon binding the antibody 
molecule, NK cells release granzymes and perforins, which are able to enter the 
target cell to induce apoptosis (Seidel et al., 2013).  
Whilst it may have been assumed that this mechanism would be irrelevant in 
MMN due to the presence of IgM antibodies, it appears that NK cells are raised in 
MMN patient blood (Mizutani et al., 2005). This may be related to the breakdown 
of the BNB as NK cells have been shown to bind vascular endothelial cells and 
induce lysis (Damle et al., 1987). Their presence would therefore exacerbate 
symptoms through secondary injury. This may also explain the effectiveness of 
IVIG, as NK cells are able to bind and inactivate monomeric IgG (Sulica et al., 
1993). The NK cells would therefore be removed from circulation, which would 
lead to a possible improvement in the patient’s condition.  
1.4 The Peripheral Nervous System  
 
The various components of the peripheral nervous system (PNS) can be targets of 
antibody mediated attack in autoimmune neuropathies. It is therefore essential 
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to understand the normal structure and function of the PNS to truly appreciate 
how these antibodies elicit their pathogenic effects. 
1.4.1 Axons  
 
All voluntary movements are transmitted to the periphery via axons, which are 
lengthy extensions of the cell bodies of neurons that originate in the CNS. Due to 
the distance between the terminals and the cell bodies, axons are insulated 
from one another and bundled together by 3 protective tissue layers. Axons, 
Schwann cells and endoneurial components are grouped together and surrounded 
by the perineurium to form a nerve fascicle. These fascicles in turn are bundled 
together by epineurial tissue to form a nerve (Topp & Boyd, 2006).  
1.4.2 Nodes of Ranvier (NoR) 
 
Within the endoneurium, a single Schwann cell is intimately associated with a 
single myelinated axon to form an internode. The gaps between these internodes 
are called Nodes of Raniver (NoR). These are specialised domains of the 
myelinated axon, which facilitate propagation of action potentials along the 
nerve.  
The presence of CB in MMN is a good indication that anti-GM1 antibodies are 
targeting the NoR; however, they may also produce this effect through 
segmental demyelination of the axon. It has been shown that the NoR in distal 
sites are more susceptible to anti-ganglioside antibody mediated attack than 
proximal locations, which correlates with the distal dominant pattern observed 
in MMN (McGonigal et al., 2010). However, there is still no definitive evidence 
showing the site of injury in this condition.   
1.4.3 Blood Nerve Barrier  
 
The PNS like the CNS is an immune privileged site. It is protected from leukocyte 
infiltration by an interface, known as the blood nerve barrier (BNB),which forms 
between the endoneurial microenvironment and the surrounding extracellular 
space (Kanda, 2013). Despite the assumption that the BNB is weaker than the 
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blood brain barrier (BBB), evidence suggests that both are equally matched in 
preventing molecules entering the neural parenchyma (Poduslo et al., 1994).  
There is some evidence to suggest that BNB disruption may be a factor in MMN 
pathogenesis, particularly due to the large size of IgM molecules. Limited 
experimental work in vitro has shown that addition of MMN patient sera to BNB 
cultures resulted in disruption of the tight junction molecules between epithelial 
cells in the BNB (Shimizu et al., 2014). This was thought to be related to the 
autocrine secretion of the cytokine VEGF but research into this area is limited.  
1.4.4 Neuromuscular Junction  
 
Although the neuromuscular junction (NMJ) is not thought to be targeted in 
MMN, it is a site of particular interest in autoimmune neuropathies due to the 
absence of any BNB (Yu, 2011). The NMJ is a specialised synapse, which 
facilitates the transmission of electrical impulses from the nerve terminal to the 
skeletal muscle. It comprises three main parts: the presynaptic region, the 
synaptic cleft and the postsynaptic surface (Hughes et al., 2006). 
When the nerve terminal receive an action potential, vesicles containing pools of 
acertylcholine (ACh) fuse with the plasma membrane to release the 
neurotransmitter into the synaptic cleft. A large number of proteins including 
SNARE then recycle this transmitter and traffic it back to reserve pools to allow 
for continuous muscle stimulation (Südhof, 2004). This site is also enriched with 
a variety of gangliosides, which are easily accessed by anti-ganglioside 
antibodies. Immune mediated damage to the NMJ is therefore thought to be 
partially responsible for the acute flaccid paralysis observed in GBS (Goodfellow 
et al., 2005; Halstead, Humphreys, et al., 2005; Halstead, Morrison, et al., 
2005).   
Once Ach is released, it diffuses across the synaptic cleft and binds to the 
nicotinic acetylcholine receptor. This results in contraction of the innervated 
muscle.     
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1.5 Glycosphingolipids 
 
Most autoimmune neuropathies are associated with antibodies which target a 
family of cell surface receptors known as glycosphingolipids (GSL) (Chiba et al., 
1992a; IIyas et al., 1991; Kusunoki et al., 1995; Nobile-Orazio et al., 1992; van 
den Berg et al., 1992). These are specialised amphipathic molecules that contain 
a lipid that is anchored to the cellular membrane and a carbohydrate group that 
projects into the extracellular space. The three main types of GSLs are 
globosides, cerebrosides and gangliosides, which are all ubiquitously expressed 
throughout the body but are particularly enriched within the nervous system. 
They have various roles in cell-cell interactions, signal transduction and are 
strongly associated with the maintenance and repair of the nervous system. 
(Furukawa et al., 2004; Hakomori et al., 1998; Kasahara et al., 1997; Kittaka et 
al., 2008) 
1.5.1 Biosynthesis 
 
All sphingolipids contain a hydrophobic core called ceramide, which anchors the 
molecules to the cell membrane. Ceramide is synthesised on the cytosolic side of 
the endoplasmic reticulum (ER) but is capable of alternating between the 
cytosolic and luminal sides via a carrier protein called FAPP2 (D’Angelo et al., 
2007) (Figure 1.2). This transference of ceramide allows it to be used by luminal 
enzymes such as cerebroside galactose transferase (CGT) which forms 
galactocerebroside (GalC) through the addition of a galactose molecule. After 
transport to the Golgi apparatus, GalC can be further modified by the enzyme 
cerebroside sulfotransferase (CST) which adds a sulfate group to the 3-O-position 
of GalC to form sulfatide (Eckhardt, 2008).  
Ceramide can also be translocated by the transport protein CERT to the golgi 
apparatus, where it can be glycosylated to form gangliosides (Hanada et al., 
2007). The enzyme glucosylceramide (GlcCer) synthase adds a glucose group to 
the ceramide which is then flipped inside the golgi body by flippase. The 
addition of a galactose group by Gal T-1 then forms lactosyl ceramide (LacCer), 
which can then be sialyated by various enzymes to form the simple gangliosides. 
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Figure 1.2 - Synthesis of Glycosphingolipids 
Ceramide is synthesised in the cytosolic ER and can be internalised into the 
lumen by FAPP2 where GalCer Synthase can synthesise GalC. CERT can also 
transport ceramide to the golgi apparatus where it can be converted into SM or 
GlcCer. GlcCer is internalised by flippase and can be glycosylated by 
sialyltransferases to form gangliosides. These lipids migrate via transport 
vesicles to the plasma membrane where they are displayed to the extracellular 
environment. ER: endoplasmic reticulum; FAPP2: four-phosphate adaptor protein 
2; GalCer: galactose cerebroside; CERT: ceramide transfer protein; SM: 
Sphingomyelin; GlcCer: Glucose Ceramide   
 
The complex gangliosides of the O, a, b and c series are then formed by the step 
by step addition of sugar and sialic acid moieties by several different 
glycosyltransferases (Figure 1.3). Alternatively instead of forming gangliosides, 
the ceramide on the golgi apparatus can flip into the luminal side and be 
converted to sphingomyelin (SM) by the enzyme sphingomyelin synthase.  
Once synthesised, these newly formed lipids concentrate in the luminal side of 
transport vesicles, which then migrate to the plasma membrane (Crespo et al., 
2004). The vesicles fuse with the membrane and the embedded lipids are 
displayed into the extracellular environment where they are able interact with 
other cells.  
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1.5.2 Gangliosides  
 
The most diverse species of GSL are gangliosides. These lipids have the same 
basic characteristics as both globosides and cerebrosides but have a large degree 
of variation in their headgroup and are unique in their expression of sialic (N- 
 
 
Figure 1.3 – Biosynthesis of Cerebrosides and Gangliosides 
All cerebrosides and gangliosides are formed from a ceramide backbone. The 
addition of a galactose molecule by CGT forms GalC, which can by further 
modified by CST to form sulfatide. Alternatively sphingomyelin synthase can add 
a phosphocholine group to ceramide to form sphingomyelin. Gangliosides are 
formed by the addition of different oligosaccharide moieties to ceramide 
through the actions of several different glycosyl transferases. Several knockout 
mice have been created that are unable to synthesise particular glycolipids 
(outlined in boxes). These include CST-/- mice, which are unable to synthesise 
sulfatide (blue), GalNAcT-/- mice which are unable to synthesise complex 
gangliosides (red) and GD3 S-/- mice which are unable to synthesise b-series 
gangliosides (green).  
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acetylneuraminic) acid residues (Figure 1.3). They were first isolated from the 
brain of a patient suffering from Tay Sachs disease (Klenk, 1935) but it was not 
until subsequent characterisation studies that they were found to be enriched in 
the ganglion cells of the brain, leading to the adoption of the name gangliosides 
(Klenk, 1942).      
1.5.2.1 Nomenclature 
 
There are now over 200 described gangliosides which have been named 
according to the nomenclature laid out by Svennerholm (Svennerholm, 1964; Yu 
et al., 2007). This simplified system employs the use of a code where “G” 
denotes a ganglioside, whilst the use of a numeral prefix represents the number 
of sialic acids e.g. mono – M, di – D, tri – T, quad – Q. This is followed by a 
number which is determined by the migration of the lipids on TLC and is related 
to the size of the oligosaccharide chain. Finally, the use of a lowercase letter 
denotes the isometric arrangement of the sialic acids on the headgroup.  
1.5.2.2 Distribution 
 
Gangliosides are widely distributed in most vertebrae tissues (Table 1.3). They 
are particular enriched in the grey matter of the brain but are also found to be 
abundantly expressed in most tissues of the central and peripheral nervous 
systems (Rueda & Gil, 1998). The diversity of the ganglioside species are higher 
in these tissues compared to those elsewhere in the body, which is presumably 
related to their different functions.  
GM1, for example, has been shown to act a co-receptor for fibroblast growth 
factor by binding and exposing the ligand for receptor binding. A similar process 
has been proposed to occur with neurotransmitters, such as glutamate and 
GABA, where GM1 binds the ligand and pulls it into a closer association with the 
membrane to optimise binding and neurotransmission (Reviewed by Fantini & 
Barrantes, 2009). This may explain the higher expression of GM1 in neural 
tissues; however, this has yet to be definitively proven.  
Aside from differences in the ganglioside distribution, it has also been noted that 
the ganglioside profiles in tissues, particularly within the brain, change during  
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Table 1-3 – Ganglioside Distribution in Various Rat Tissues 
Tissue GM3 GM2 GM1 GD3 GD2 GD1a GD1b GT1b GQ1b Others 
Cerebrum Tr Tr 9.4 1.5 Tr 40.2 16.4 24.3 8.2  
Cerebellum Tr Tr 4.5 3.5 7.9 31.2 8.8 30.0 13.6  
Spinal Cord Tr Tr 9.3 4.3 Tr 14.3 22.1 31.1 18.8  
Thymus 15.2   7.1      77.7 
Lung 72.9   2.2  16.8    8.4 
Heart 93.1 Tr  2.4  2.5    2.0 
Liver 52.3 Tr 2.5 0.7  32.0 5.2   7.3 
Stomach 62.9  Tr 14.8  10.5    11.8 
Spleen 55.7 Tr Tr 4.0  30.7 2.4   7.2 
Intestine 74.9 Tr  20.7  1.2    3.2 
Kidney 64.9 Tr  28.8  0.8    4.3 
Testis 16.4     66.8    16.8 
Bone Marrow 27.6 7.1 1.6   59.7    4.0 
Buffy Coat      100.0     
Erythrocytes   36.5 22.3  41.2     
 
Gangliosides are expressed throughout the body but their distribution varies 
between tissues. Distribution is expressed as a percentage of total ganglioside 
content. Others refers to unidentified gangliosides. Tr: Trace Amounts 
 
development and aging. The predominant species during embryogenesis is the 
simple gangliosides GM3 and GD3; however, at later stages the ganglioside 
profiles switch to contain significantly more complex gangliosides (Yu & Saito, 
1989). The distribution of these gangliosides decreases again during aging (Posse 
de Chaves & Sipione, 2010), with their loss being linked to a number of 
neurodegenerative disorders, such as Alzheimer’s and Parkinson’s disease 
(Yamamoto et al., 2008).   
1.5.2.3 Function 
 
Gangliosides have a wide array of functions ranging from the modulation of 
protein activity and signalling to the maintenance of myelin-axon interactions 
and the formation of glycosynapses (Posse de Chaves & Sipione, 2010). The 
essential roles of gangliosides in the normal function of the nervous system have 
been best demonstrated through the generation of GalNAc T-/- mice, which lack 
the ability to synthesise complex gangliosides (Chiavegatto et al., 2000; 
Takamiya et al., 1996).   
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These knockout mice have been shown to develop tremors and deficits in 
balance, strength and coordination. As would be expected they also experience 
Wallerian degeneration and myelination defects, which indicates the essential 
roles complex gangliosides have in maintaining normal neural physiology.  
1.5.3 Sulfatide  
 
Sulfatide is another GSL that is often implicated in autoimmune neuropathies. It 
is composed of a GalC molecule that is sulfated in the 3-O position and is highly 
enriched in a variety of tissues including the kidneys, gastrointestinal tract, 
islets of Langerhans, trachea and myelin (Takahashi & Suzuki, 2012). It is a 
major component of the myelin sheath, where it forms approximately 6% of the 
total lipid content (Norton & Cammer, 1984) and is therefore of significant 
interest to autoimmune neuropathy researchers.  
Prior to the creation of CST-/- mice, which lack the ability to synthesise 
sulfatide, very little was known about the glycolipids biological function. This 
was due to the limitations of in vitro experiments, which were only able to 
establish its most basic characteristics, such as its biosynthesis and its 
interactions with other proteins and lipids (Ishizuka, 1997).  
Once the CST-/- mice were created, the physiological roles of sulfatide became 
clearer, particularly within the nervous system. Initial studies indicated that the 
glycolipid had a minimal role in development, as the mice were healthy up until 
the age of 6 weeks. However, after this point they began to develop hindlimb 
paralysis, pronounced tremor and progressive ataxia, which suggested that 
sulfatide was responsible for myelin sheath maintenance (Honke et al., 2002).  
Surprisingly, the compact myelin was preserved in these mice but abnormalities 
were observed in the paranodal junctions, which were found to turn away from 
the axon. Subsequent studies also shown that certain nodal proteins such as 
neurofascin 155 and Caspr were incorrectly localised, suggesting that sulfatide 
has a role in protein trafficking (Ishibashi et al., 2002; Schafer et al., 2004).  
These findings correlated well with observations made in patients suffering from 
demyelinating conditions, which are often associated with anti-sulfatide 
antibodies (Alpa et al., 2007; Andersson et al., 2002; Ilyas, 2003; Souayah et al., 
Chapter 1 – INTRODUCTION  27 
 
2007). This suggests that they may be responsible for disease pathogenesis; 
however, this has yet to be proven due to a lack of experimental evidence. 
1.5.4 Plasma Membrane 
 
The fundamental structure of the plasma membrane is the lipid bilayer. It 
consists of a number of major phospholipids and GSLs, which due to their 
amphipathic nature are able to form a barrier between the cytoplasm and the 
extracellular environment. This prevents the free diffusion of ions and proteins, 
which allows the cell to maintain its osmotic balance (Cooper & Sunderland, 
2000).    
The four major phospholipids of the plasma membrane include 
phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine 
(PS) and sphingomyelin (SM), (Cooper & Sunderland, 2000). These lipids are 
asymmetrically distributed between the two layers, with the inner leaflet 
consisting mainly of PS and PE; whilst PC and SM form the majority of the outer 
leaflet. 
1.5.4.1 Lipid Rafts  
 
The classical hypothesis for the organisation of the plasma membrane was the 
fluid mosaic model (Singer & Nicolson, 1972). In this model, proteins were 
likened to icebergs freely floating in a sea of lipids but subsequent research has 
established that membranes are much more highly organised than originally 
proposed (Pike, 2003).  
They are now known to contain lipid rich microdomains called lipid rafts. Unlike 
the general membrane of the outer leaflet, which is enriched with PC, rafts are 
found to express high quantities of Chol, SM, GSLs and lipid associated proteins. 
The identification of these rafts, however,  has been a controversial topic due to 
the methods by which they were first isolated (K. Simons & Ikonen, 1997). 
Initially research focussed on identifying raft components based upon their 
resistance to non-ionic detergent solubilisation at 4°C. If these components were 
solubilised following treatment with methyl-β-cyclodextrin, then it strongly 
supported their classification as raft proteins (K. Simons & Gerl, 2010). The 
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artificial nature of these techniques, however, coupled with the inability to 
directly observe these rafts in cells, led some researchers to dispute their 
existence (Shaw, 2006).  
Recent advances in new technology appear to have addressed these doubts. 
Biophysical analysis, in particular, has demonstrated the presence of two 
membrane phases: liquid ordered and liquid disordered. It appears that raft 
lipids, such as SM, Chol and GSLs, are associated with the liquid ordered phase, 
whilst other lipids such as PC are found in the liquid disordered phase 
(Feigenson, 2006). Studies using giant unilamellar vesicles have demonstrated 
how altering the composition of the lipid mixture can change the size of these 
domains (Elson & Genin, 2010). This acts as proof that they can spontaneously 
form in membranes; however, this has yet to be directly observed in biological 
tissue.  
Additional improvements in microscopy techniques and the employment of 
fluorescently labelled lipids and proteins have also provided good evidence for 
the existence of rafts but further work is required to localise them in the plasma 
membrane.   
1.6 Anti-Glycolipid Antibodies 
 
As discussed previously, anti-glycolipid antibodies are associated with a wide 
range of autoimmune neuropathies. These antibodies can target various antigens 
depending upon their initial causative factor and, as such, can bind and injure a 
host of different tissues throughout the body.  
1.6.1 Anti-Sulfatide Antibodies 
 
Anti-sulfatide antibodies have been associated with a variety of different 
diseases including systemic lupus erythematosus, GBS, MS and type 1 diabetes 
(Alpa et al., 2007; Andersson et al., 2002; Ilyas, 2003; Souayah et al., 2007). The 
extensive range of these antibodies is related to the diverse expression of 
sulfatide, which is found in many tissues but is particularly enriched in the 
myelin sheath.  
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It is the roles of antibodies which bind to this tissue that are of significant 
interest to neuropathy researchers. This is due to evidence that patient’s with 
demyelinating neuropathies produce anti-sulfatide antibodies that are capable 
of binding and injuring myelin (Petratos et al., 2000). Similarly, experimental 
evidence has shown that the pre-eminent mouse anti-sulfatide antibody, O4, can 
produce demyelination and dysmyelination in cultures (Elliott et al., 2012; 
Rosenbluth & Moon, 2003) and is capable of inducing spinal cord lesions when 
implanted in vivo in a model of MS (Rosenbluth et al., 2004).  
Despite this evidence, certain studies have suggested that human anti-sulfatide 
antibodies may be incapable of binding live tissue (Brennan et al., 2011). This 
may be related to antibody diversity; however, this has yet to be definitively 
proven as most experimental studies have limited themselves to the use of O4. 
Further studies of anti-sulfatide antibodies are therefore required to more fully 
establish their roles in disease.   
1.6.2 Anti-Ganglioside Antibodies  
 
The first study to associate anti-ganglioside antibodies with disease was 
performed in 1992, in which researchers discovered high titres of anti-GQ1b 
antibodies in the sera of MFS patients (Chiba et al., 1992b). Subsequent studies 
established that the cranial nerves responsible for ocular control were enriched 
in GQ1b, which suggested that the antibodies themselves were responsible for 
the ophthalmoplegia that is strongly associated with the disease (Chiba et al., 
1993, 1997).  
Leading on from this discovery, other autoimmune neuropathies were associated 
with specific anti-ganglioside antibodies.  AMAN was associated with IgG 
antibodes targeting GM1 and GD1a (Yuki & Hartung, 2012), whilst MMN was 
associated with IgM antibodies targeting GM1 (Pestronk et al., 1997). As with 
MFS, researchers began associating the presence of these antibodies with 
specific symptoms as it was assumed that they were the cause of pathogenesis.    
This led to some anomalies, however, as certain gangliosides are located 
throughout the nervous system but not all tissues are targeted in disease. 
Several theories were put forth to explain these behaviours including differences 
in the gangliosides molecular composition, local microenvironment and density 
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(Corbo et al., 1992; Ganser et al., 1983; Ogawa-Goto et al., 1990) but it was not 
until the use of ganglioside complexes that researchers were able to adequately 
explain differences in antibody binding patterns.  
1.6.2.1 Ganglioside Complexes 
 
Ganglioside complexes are a relatively new feature of clinical research (Figure 
1.4). They were first employed in a study in 2004 in an attempt to increase 
antibody detection in GBS patient serum (Kaida et al., 2004). In this study 
antibodies were detected against complexes composed of GD1a and GT1b but 
minimal signals were detected against the single species. It was therefore 
concluded that the antibodies were binding to clustered epitopes formed by the 
combination of the two gangliosides.   
Subsequent research by the same group found that 17% of GBS patients had 
antibodies against a series of ganglioside complexes (Kaida et al., 2007). 
Furthermore, they identified an association between the presence of antibodies 
against GD1a:GT1b and GD1a:GD1b complexes and the requirement for 
mechanical ventilation. This suggested that ganglioside complexes may be useful 
indicators for the severity of the disease and could be useful for establishing 
effective treatment plans.  
Following on from these findings other researchers found that the interactions of 
different gangliosides may shield binding epitopes from antibody access. This 
was first demonstrated in a study using an anti-GM1 antibody that was incapable 
of binding live tissue (Greenshields et al., 2009). Examination of the antibody’s 
binding patterns in solid phase assays indicated that it was inhibited from 
binding GM1 when it was in complex with most other gangliosides. GD1a was 
found to cause the most inhibition, which led the researchers to postulate that 
this ganglioside may be preventing the antibody from accessing its binding 
epitope. This was confirmed by treating the tissue with neuraminidase, which 
cleaves the terminal sialic acid of GD1a to form GM1. Antibody binding was 
detected following this treatment, proving that GD1a was having an inhibitory 
effect. 
This same phenomenon was discovered in a clinical study of MMN patient sera. 
GM1:GD1a complexes were found to inhibit or severely reduce the binding ability 
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of anti-GM1 antibodies in all MMN positive patients (Nobile-Orazio et al., 2010). 
This raised the possibility that the restricted binding patterns observed in this 
condition were related to antibody access.  
 
Figure 1.4 – Impact of Ganglioside Complexes on Antibody Binding 
The presence of other gangliosides or glycolipids influences the presentation of 
different binding epitopes on the GM1 headgroup. This has differential effects on 
the binding abilities of antibodies as follows: complex-independent antibodies 
can bind to GM1 regardless of its configuration; complex-attenuated antibodies 
are unable to bind GM1 in the presence of particular glycolipids; complex-
enhanced antibodies are better able to access their epitope when certain lipids 
are present. Another antibody subtype, termed complex-dependent antibodies, 
has been proposed to exist (orange box). These antibodies bind to a neo-epitope 
formed by the combination of two different lipids.     
 
Further analysis of ganglioside complexes in MMN led to the discovery of the 
enhancing effects of GM1:GalC. Although this had been described almost 15 
years previously (Pestronk et al., 1997), the findings from this study had been 
largely overlooked by researchers. It was not until 2013 that there was a 
resurgence of interest in GM1:GalC complexes following a study that found 
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antibody enhancement in 100% of patients screened (Galban-Horcajo et al., 
2013).  
These results were confirmed by other research groups (Nobile-Orazio et al., 
2013), but there was some debate as to the cause of enhancement. Whilst some 
researchers believed that GalC was altering the orientation of GM1 to better 
expose certain binding epitopes, others thought that the two glycolipids were 
interacting to form a neo-epitope.  
There was some evidence to support the latter theory as a subset of patients in 
these studies were found to have antibodies that bound solely to the GM1:GalC 
complex. This suggested that a complex-dependent antibody was forming in 
these patients but this is an antibody class that has yet to be isolated from 
either patients or animal models.  
1.7 Aims 
   
The discovery of antibodies that appear to bind specifically to GM1:GalC 
complexes has opened up a new avenue of research in MMN. As these antibodies 
appear to be more prominent in patient sera than those against single 
gangliosides, we have hypothesised that they may be responsible for the 
pathogenesis of the disease. Furthermore, it may be that GM1:GalC complexes 
are the true targets of immune mediated attack in MMN, which may explain the 
selective injury of the motor nerves found in this condition.  
To investigate the existence of these antibodies this thesis therefore proposed 
the following: 
• Detailed analysis of the binding patterns of current human monoclonal 
antibodies to establish their cis-inhibitions and cis-enhancements 
• Determine the effect that secondary lipid concentration has upon 
antibody binding  
• Clone a complex-dependent antibody directly from MMN patient serum 
• Clone a complex-dependent antibody through active immunisations with 
mice  
• Establish a high throughput screening method for hybridoma supernatant 
that is optimised for detecting complex-dependent antibodies 
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• Characterise the binding behaviours of any new antibodies through the 
use of solid phase assays, tissue section staining and ex vivo preparations 
In addition to these aims, this thesis also sought to address several important 
questions relating to CST-/- mice and sulfatide. As such it also aimed to: 
• Determine the susceptibility of CST-/- mice to immunisation with 
sulfatide liposomes 
• Produce a series of new anti-sulfatide antibodies 
• Determine the binding behaviours of these antibodies to solid phase 
assays and live tissue  
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2 METHODS 
2.1 Materials 
2.1.1 Buffer Solutions  
 
Phosphate buffered saline (PBS) was prepared in deionised water at a final 
concentration of 140 mM NaCl, 1.5mM KH2 PO4 , 2.7 mM KCl and 77 mM Na2 HPO4 
Ringer’s solution was prepared to a final concentration of 116 mM NaCl, 4.5 mM 
KCl, 23 mM NaHCO3 , 1 mM NaH2 PO4 , 11 mM glucose, 1 mM MgCl2 and 2 mM 
CaCl2 in distilled water. Oxygen was bubbled through the solution for 10 minutes 
prior to its use. Its pH was adjusted to approximately 7.2 using 1mM HCl.  
2.1.2 Glycosphingolipids 
 
All gangliosides and some glycolipids including GalC, sulfatide, and PS were 
derived from bovine brain and were purchased from Sigma Aldrich (St Louis, MO, 
USA). Cholesterol and DCP were also purchased from Sigma Aldrich. 
Sphingomyelin and PC were derived from egg and purchased from Carbosynth 
(Compton, UK) and Avanti Polar Lipids (Alabaster, USA) respectively. LM1 and 
whole lipid extract (WLE) were kindly gifted by Robert Yu (Institute of Molecular 
Medicine and Genetics, Medical College of Georgia, Augusta, USA). 
2.1.3 Secondary Antibodies 
 
A variety of secondary antibodies were used for imaging solid phase assays, cells, 
fixed tissue sections and live tissue preparations. These antibodies are listed in 
Table 2.1 alongside their specificities, manufacturers and working concentrations.   
2.1.4 Fluorescently Labelled Markers 
 
Cholera toxin B subunit (CTx) conjugated to Alexafluor 647 acted as a 
ganglioside marker, specifically GM1, and α-bungarotoxin (BTx) conjugated to 
either Alexafluor 555 or Alexafluor 488 was used to delineate the NMJs by 
Chapter 2 – MATERIALS AND METHODS  35 
 
Table 2-1 – List of Secondary Antibodies 
  Target 
 Antigen 
Target 
Species 
Host 
Species 
Conjugate Manufacturer Function 
Concentration 
or Dilution 
IgG (Fcγ) Mouse Goat FITC 
Southern Biotech 
(Birmingham, AL, USA) 
Tissue Staining 3.33μg/ml 
IgG (Fcγ) Mouse Goat TRITC 
Southern Biotech 
(Birmingham, AL, USA) 
Tissue Staining 3.33μg/ml 
IgG (Fcγ) Mouse Goat AF 555 
Jackson Immuno 
(West Grove, PA, USA) 
Tissue Staining 3.33μg/ml 
IgG (Fcγ) Mouse Goat AF 647 
Jackson Immuno 
(West Grove, PA, USA) 
Tissue Staining 
Arrays 
Tissue: 6.7μg/ml 
Arrays: 2μg/ml 
IgG (Fcγ) Mouse Goat HRP 
Southern Biotech 
(Birmingham, AL, USA) 
ELISA 1:3000 
IgG1 Mouse Goat HRP 
Southern Biotech 
(Birmingham, AL, USA) 
ELISA 1:3000 
IgG2a Mouse Goat HRP 
Southern Biotech 
(Birmingham, AL, USA) 
ELISA 1:3000 
IgG2b Mouse Goat HRP 
Southern Biotech 
(Birmingham, AL, USA) 
ELISA 1:3000 
IgG3 Mouse Goat HRP 
Southern Biotech 
(Birmingham, AL, USA) 
ELISA 1:3000 
IgM (μ) Mouse Goat TRITC 
Southern Biotech 
(Birmingham, AL, USA) 
Tissue Staining 6.7μg/ml 
IgM (μ) Mouse Goat AF 555 
Jackson Immuno 
(West Grove, PA, USA) 
Tissue Staining 
Arrays 
Tissue: 6.7μg/ml 
Arrays: 2μg/ml 
IgM (μ) Mouse Goat AF 647 
Jackson Immuno 
(West Grove, PA, USA) 
Tissue Staining 
Arrays 
Tissue: 6.7μg/ml 
Arrays: 2μg/ml 
IgM (μ) Human Goat AF 647 
Jackson Immuno 
(West Grove, PA, USA) 
Arrays 2μg/ml 
IgG (H+L) Rabbit Goat FITC 
Life Technologies, 
Carslbad, CA, USA 
Tissue Staining 3.33μg/ml 
IgG (H+L) Rabbit Goat TRITC 
Life Technologies, 
Carslbad, CA, USA 
Tissue Staining 3.33μg/ml 
IgG (H+L) Rat Goat FITC 
Life Technologies, 
Carslbad, CA, USA 
Tissue Staining 3.33μg/ml 
 
binding to the post-synaptic nicotinic acetylcholine receptors on the muscle 
surface. Both of these toxins were purchased from Life Technologies, Carlsbad, 
CA, USA. Rabbit anti-S100 acted as a Schwann cell marker and was purchased 
from Dako, Santa Clara, CA, USA.   
2.1.5 Tissue Culture Media  
 
Roswell Park Memorial Institute (RPMI) 1640 media (Sigma Aldrich, St Louis, MO, 
USA) was used for growing all hybridoma cultures and frozen cell lines. RPMI 
1640 with glutamax was used for long term culture to reduce the build up of 
ammonia and improve the long term growth of the cells.  Media was normally 
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supplemented with 10% or 20% heat inactivated foetal calf serum (FCS) (Gibco 
Life Technologies, Carlsbad, CA, USA) and was marked as 10% or 20% 
accordingly. All media was supplemented with pen/strep (20U/ml, 20µg/ml) 
(Life Technologies, Carlsbad, CA, USA), fungin (10µg/ml) (San Diego, CA, USA) 
and gentamicin (50µg/ml) (Life Technologies, Carlsbad, CA, USA). 
Hybridoma cells were originally cultured with 10% Opticlone (Santa Ana, CA, 
USA) but this product was discontinued. This was replaced with 5% HyMax 
(Antibody Research Corporation, St Charles, MO, USA). Media containing these 
feeder supplements were marked as “+FS”.  
Schwann cells were grown in two different media referred to as basic growth 
media (BGM) and Schwann cell growth media (SGM). The BGM consisted of high 
glucose DMEM + L-glutamine (Life Technologies, Carslbad, CA, USA), 10% horse 
serum (Life Technologies, Carslbad, CA, USA), 2ng/ml human heregulin-β1 
(Sigma Aldrich, St Louis, MO, USA), 0.5µM forskolin (Sigma Aldrich, St Louis, MO, 
USA), pen/strep (20U/ml, 20µg/ml) (Life Technologies, Carlsbad, CA, USA), 
fungin (10µg/ml) (San Diego, CA, USA) and gentamicin (50µg/ml) (Life 
Technologies, Carlsbad, CA, USA).The SGM consisted of the same components as 
the BGM plus 10ng/ml human basic fibroblast growth factor (Sigma Aldrich, St 
Louis, MO, USA) and 20µg/ml bovine pituitary extract (Sigma Aldrich, St Louis, 
MO, USA). 
2.2 Animals 
 
Mice were all housed in the university central research facility under controlled 
conditions. These consisted of 12 hour light/dark cycles in temperature and 
humidity controlled rooms with food and water provided ad libitum. All 
immunisations were performed on 6-10 week old male and female mice weighing 
at least 15g unless otherwise stated. The weights of the mice were monitored 
throughout the immunisation cycles to ensure that the antigens were not having 
any adverse effects. Immunofluorescence studies were all carried out on 4-10 
week old male and female mice.  
Animals were euthanized with a rising concentration of CO2 as per Home Office 
guidelines. Following cessation of breathing, death was ensured through a 
secondary measure, such as cervical dislocation or cardiac puncture.  
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2.2.1 Transgenic Mice 
 
Different transgenic mice were used for active immunisations and tissue staining 
depending upon the requirements of the specific experiment. These mice and 
their uses are listed in Table 2.2.  
Mice lacking the enzyme GalNAc transferase (GalNAc T-/-) only synthesise simple 
gangliosides and were a good candidate for the production of anti-GM1 complex 
antibodies (Chiavegatto et al., 2000). These were therefore used for all 
experiments involving immunisations against gangliosides complexes.  
A knockout mouse lacking the enzyme cerebroside sulfotransferase (CST) was 
unable to synthesise sulfatide  (Honke et al., 2002). These mice were used for 
immunisations with sulfatide, as it was hypothesised that they would be antigen 
naïve and, as a result, produce higher titres of antibody. The intention was to 
use these mice for immunisations involving ganglioside:sulfatide  complexes.  
A mouse known as GD3 S-/- lacked the enzyme GD3 synthase and was unable to 
synthesise any of the b series gangliosides (Handa et al., 2005). As a result of 
this modification, the mice overexpress the a-series ganglioside, especially GM1 
and GD1a. These were therefore useful in determining the binding capabilities of 
anti-GM1 and anti-GD1a antibodies in tissue studies.  
Litter mates that contained the normal repertoire of gangliosides or sulfatide 
were used as controls in both immunisations and tissue staining experiments.  
2.2.2 Fluorescent Mice 
 
Some lines of the GalNAc T-/- and GD3-/-  mice also had green fluorescent 
protein (GFP) and cyan fluorescent protein (CFP) endogenously expressed in cells 
utilising the S100B (neural crest cells) and Thy1 (neuronal) promoters 
respectively (Kang et al., 2004; McGonigal et al., 2010; Rupp et al., 2012). This 
resulted in mice that had fluorescent axons and Schwann cells which allowed 
direct imaging of the tissue. These mice were used for immunofluorescent 
staining with antibodies and not for the immunisations themselves.  
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Table 2-2 – Use of Transgenic Mice Throughout Thesis  
Genotype Background Fluorescence  Number Experiment  
GalNAc T-/- C57Bl/6 N/A 23 Immunisations 
GalNAc T+/+ C57Bl/6 N/A 24 Immunisations 
GalNAc T-/- C57Bl/6 N/A 10 Ex vivo preparations 
GalNAc T+/+ C57Bl/6 N/A 10 Ex vivo preparations 
GalNAc T-/- C57Bl/6 
Axon-CFP 
Glial-GFP 
10 Ex vivo preparations 
GalNAc T+/+ C57Bl/6 
Axon-CFP 
Glial-GFP 
17 Ex vivo preparations 
GalNAc T-/- C57Bl/6 N/A 2 Sciatic Nerve Sections 
CST-/- C57Bl/6 N/A 6 Immunisations 
CST+/+ C57Bl/6 N/A 3 Immunisations 
CST-/- C57Bl/6 N/A 4 Ex vivo preparations 
CST+/+ C57Bl/6 N/A 4 Ex vivo preparations 
CST-/- C57Bl/6 N/A 1 Schwann Cell Cultures 
CST+/+ C57Bl/6 N/A 1 Schwann Cell Cultures 
CST-/- C57Bl/6 N/A 1 Sciatic Nerve Sections 
CST+/+ C57Bl/6 N/A 2 Sciatic Nerve Sections 
GD3 S-/- C57Bl/6 
Axon-CFP 
Glial-GFP 
12 Ex vivo preparations 
GD3 S+/+ C57Bl/6 
Axon-CFP 
Glial-GFP 
12 Ex vivo preparations 
C57Bl/6 C57Bl/6 
Axon-CFP 
Glial-GFP 
2 Ex vivo preparations 
C57Bl/6 C57Bl/6 N/A 2 Ex vivo preparations 
B6CGTGNxDBA C57Bl/6 + DBA 
Axon-CFP 
Glial-GFP 
3 Control Sera 
B6CGTGNxDBA C57Bl/6 + DBA 
Axon-CFP 
Glial-GFP 
3 Immunisations 
DBA DBA N/A 3 Immunisations 
CST-/-xGalNAcT-/-Thy1 C57Bl/6 N/A 1 Immunisations  
 
2.2.3 Genotyping and Phenotyping 
 
The mice were all bred and genotyped by a colleague prior to commencement of 
the experiments. Once the mice had been euthanized, additional tissue was 
retained in case unusual serological responses were detected. In this situation, 
the tissue was re-genotyped to confirm that it was from the correct strain.  
Fluorescence was confirmed phenotypically by examination of ear punches 
removed from each mouse. The skin from the ear punches was split apart and 
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mounted on a slide with Citifluor and coverslipped. The sample was then excited 
at 474nm and 433nm using an epifluorescent microscope to identify GFP and CFP 
fluorescence respectively.  
2.3 Human Serum Samples 
 
Serum samples were collected from MMN, ALS, and CMT patients alongside 
healthy controls by the referral centre for ALS and neuromuscular diseases in 
Nice, France. Patients gave informed consent and the research was approved by 
the South Glasgow and Clyde Research Ethics Committee. Upon collection, blood 
was centrifuged at 400xg for 10 minutes. The serum was then aspirated, 
aliquoted into microtubes and frozen at -80°C prior to use.  
2.4 Screening for Anti-Ganglioside Antibodies  
2.4.1 Preparation of Lipid Stocks 
 
Stock solutions of lipids were made up in a 1:1 (v/v) methanol:chloroform 
mixture, at 1-10mg/ml and stored at -20°C. GalC was more difficult to dissolve 
than the other lipids and was made up in a 1:2 (v/v) methanol:chloroform 
mixture at 1mg/ml. Working solutions were prepared for w:w arrays by further 
dissolving the lipids in 300µl of methanol to a concentration of 0.1mg/ml. 
Complexes were prepared by adding 150µl of each single lipid to a vial and 
mixing.  
All the lipids were stored in glass micro vials (Chromacol, Waltham, MA, USA), 
which were compatible for use with the combinatorial glycoarray. Mol:mol 
arrays were prepared by dissolving the main target lipid in the array in 300µl of 
methanol to a concentration of 0.1mg/ml. All other lipids were prepared at an 
equivalent number of moles to the original lipid. The only exception was 
cholesterol, which was consistently made as 5 times the number of moles of 
other lipids to more closely resemble the proportion in cell membranes (Bowes 
et al., 2002).  
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2.4.2 ELISA 
 
The traditional method for screening for anti-ganglioside antibodies is the 
enzyme linked immunosorbent assay (ELISA), which was performed according to 
the methods developed at the Southern General Hospital, Glasgow, UK (Willison 
et al., 1999). Working solutions of single glycosphingolipids were prepared at 
2µg/ml in methanol. Complexes were created to the same final concentration by 
mixing equal volumes of the component lipids and then sonicating the mixture 
for 15 minutes. Negative wells consisted of methanol only.  
 
Immulon 2 HB 96-well ELISA plates (Thermo Scientific, Waltham, MA, USA) were 
prepared by adding 100µl of glycosphingolipid to every odd row and 100µl of 
methanol to every even row so that each sample also had a negative control. 
These plates were then dried in a fume hood overnight. Plates were blocked by 
adding 200µl of 2% BSA/PBS to each well for 1 hour at 4 °C. The solution was 
tipped off and the plate tapped dry before the primary solution was added.   
 
The primary solutions were prepared as follows: serum samples were prepared 
at a 1:100 dilution in 0.1% BSA/PBS; monoclonal antibodies were added at 
10µg/ml in 0.1% BSA/PBS and tissue culture supernatant was added neat. 100µl 
of primary solution was added to both the glycosphingolipid and the control wells 
except for tissue culture supernatant which had only 50µl added to each well due 
to the limited volumes. The plates were incubated for either 4 hours at 4°C or 
overnight. They were then washed 4 times in an ELISA plate washer (RDX Dynex 
microtiter dispensing system, Chantilly, VA, USA) by cyclically adding 300µl of 
PBS to each well and tipping it off.  
 
100µl of the appropriate secondary HRP conjugated antibody was then added at 
a 1:3000 dilution to each well and incubated at 4°C for 1 hour. The plates were 
washed on the ELISA plate washer as above. They were developed by adding 
100µl of an o-phenylenediamine (OPD) solution to each well for 20 minutes at 
room temperature. This reaction produces a colour change from clear to 
orange/brown when antibody is detected. It was terminated through the 
addition of 50µl of 4N H2SO4 and then read on an ELISA plate reader (Sunrise, 
Tecan, Männedorf, Switzerland) at 492nm.  
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2.4.3 Quantitative ELISA  
 
Quantitative ELISAs were performed to determine the concentration of IgM 
monoclonal antibodies in tissue culture supernatant. These were performed 
using kits provided by Bethyl Laboratories, Montgomery, TX, USA. The 
appropriate capture antibody was diluted 1 in 100 in coating buffer and 100µl 
was added to each well in the odd numbered rows of an ELISA plate (Immulon, 
Thermo Scientific, Waltham, MA, USA). The even numbered rows contained 
100µl of coating buffer alone.  
Once, the coating buffer was added the plates were incubated at room 
temperature for 1 hour. This was followed by 6 wash cycles in 0.05% Tween 
20/PBS (Sigma Aldrich, St Louis, MO, USA). The wells of each plate were then 
blocked with 200µl of 2% BSA/PBS at room temperature for 1 hour followed by a 
wash cycle as described.  
To establish the concentration of the antibodies a standard was prepared as per 
the manufacturer’s instructions. This consisted of a serial dilution of a reference 
serum in 0.1% BSA to give specific concentrations. A 1:1 serial dilution was also 
prepared of the supernatant samples being tested and 100µl of each was added 
to both the antibody coated wells and the control wells at room temperature for 
1 hour. This was followed by another wash cycle in 0.1% Tween 20. 100µl of the 
appropriate HRP conjugated secondary antibody was then added to each well at 
a dilution of 1:10000. The plates were then washed one last time before they 
were developed following the same method as per the standard ELISA.  
The optical density (OD) readings of the standard were plotted against the 
corresponding log concentration to give a sigmoidal curve. Only sample ODs 
which fell between the steepest points in the curve were used to extrapolate 
the concentration of the antibody. Multiple OD readings of the unknown 
antibody were taken, and the corresponding concentrations of the standards at 
these OD values were then multiplied by the dilution factors of the unknown 
antibody. The final concentration of the unknown was calculated from the 
average of these readings. 
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2.5 Screening Development 
2.5.1 Fluorescent Secondary Antibodies 
 
Screening of the antibodies on arrays employed the use fluorescent secondary 
antibodies which had not been previously tested. The benefit of using 
fluorescent antibodies was that different fluorophores could be conjugated to 
different isotypes and used for screening simultaneously. An experiment was 
performed prior to their use to ensure the antibodies were not capable of 
binding to one another. If this occurred then artificial signals could be produced 
suggesting the presence of an antibody that was in fact not present.  This was 
tested by printing the different secondary antibodies on slides using the 
microarray and then screening them against the opposing antibody. This was 
performed following the protocol in Section 2.5.4 except that the primary step 
was omitted. The result indicated that the secondary antibodies did not bind to 
one another and were suitable for use in screening.  
2.5.2 Mouse Control Serum 
 
The variability between print runs on the combinatorial glycoarray could 
occasionally be high depending upon a number of factors related to the normal 
operation of the equipment. To ensure that this variation was not skewing the 
sample results, a control serum was created which was applied during each 
experiment and used to normalise the data.  
Three DBA mice were immunised with GM1 liposomes created as per the section 
2.6. These mice were selected as they had previously been shown to respond 
well to immunisation and were readily available. The mice were injected with 
100µg of liposome each three times a week. After six immunisations the mice 
were killed and their serum was collected and pooled.  
This serum was screened against a standard grid of lipids at several different 
dilutions to establish the antibody response as per section 2.5.4. The optimal 
dilution was selected and used in each screening of mouse serum to normalise 
the data.  
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2.5.3 IgG Monoclonal Control 
 
The mouse serum did not have a high IgG response so an in-house monoclonal 
antibody called DG2 was used to normalise IgG data. A serial dilution was 
created of the antibody as per the mouse control serum and the optimal 
antibody concentration was used to normalise all mouse IgG data.  
2.5.4 Combinatorial Glycoarray 
 
Slides were prepared by affixing a low fluorescence PVDF membrane (Millipore) 
to 26x75 mm slides (Thermo Scientific, Waltham, MA, USA) using a PhotoMount 
spray adhesive (3M, St Pauls, MN,USA). Excess membrane was removed using a 
scalpel blade and the bottom right hand corner was cut out to orientate the 
slides. Lipids were printed onto slides using an automatic TLC autosampler from 
CAMAG, Switzerland. The lipid vials were fitted with rubber caps which could be 
pierced by the autosampler and the vials were sonicated for 15 minutes prior to 
use. The slides were marked with a pencil and secured in a metal grid in the 
autosampler to ensure that they did not move during printing. The winCATS 
software (CAMAG, Muttenz, Switzerland) was used to create programs that 
printed 0.1µl of the lipids onto a predefined area of the slides. Once printing 
was complete, the slides were air dried for 10 minutes and a hydrophobic pen 
(Vector Laboratories, Peterborough, UK) was used to mark the boundaries of the 
array. The slides were then stored at -4°C overnight.  
The protocol for probing the slides was adapted from the standard ELISA. All 
incubations were carried out in a humid chamber which consisted of a sealable 
slide holder box that contained tissue soaked in dH2O. The slides were blocked in 
100ml of 2% BSA/PBS at room temperature and placed on an orbital shaker set to 
100rpm for 1 hour. The concentration of the primary sample differed depending 
upon the specific experiment but generally serum was applied at a 1:100 dilution 
and antibodies were applied at 10µg/ml. After blocking, excess liquid was tipped 
off and 300µl of the primary sample was applied to each slide at 4°C for 1 hour. 
The samples were then tipped off the slides and they were washed twice in 1% 
BSA/PBS on an orbital shaker set to 100rpm at room temperature for 15 minutes. 
The appropriate secondary antibodies were applied at the concentrations 
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described in section 2.1.2. 300µl was applied to each slide and these were 
incubated at 4°C for 1 hour. This was followed by two wash cycles in 1% BSA/PBS 
for 30 minutes, a wash cycle in PBS for 5 minutes and then a wash cycle in dH20 
for another 5 minutes. These all took place at room temperature on an orbital 
shaker set to 100rpm. The slides were then air dried at 4°C for approximately 30 
minutes prior to imaging.  
2.5.5 Lipid Microarray 
 
The lipid microarray (Scienion, Berlin, Germany) was an alternative form of 
printing large arrays of lipids. The machine was capable of producing 20 slides, 
each consisting of 16 arrays, which could each be composed of up to 400 lipids 
targets. Slides were prepared for the microarray in the same way as the 
combinatorial glycoarray except that the hydrophobic pen was not used to mark 
the working area. Stock lipids were also prepared in a similar way but were 
made at a concentration of 200 µg/ml. The slides were locked in place in the 
microarray to prevent movement during printing. To limit sample loss through 
evaporation, each lipid was sonicated 4 minutes prior to use and 40µl was added 
to the machine. The microarray then collected the sample using a glass needle 
and printed 6 spots of 300 pl onto each array. A row of fluorescent markers, 
above and below each array, were also printed to allow for orientation of the 
slides and individual targets in the scanner. Once printing was complete the 
slides were stored at 4°C until required.  
These slides were probed in the same way as the combinatorial glycoarray slides 
with some minor differences. A FAST Frame (Maine manufacturing, USA) was 
used to secure a 16 well incubation chamber to each slide which allowed 
different samples to be applied to each array. An IgG and an IgM monoclonal 
antibody were also added to each slide to act as positive controls. The 
incubation times and wash cycles were the same as the combinatorial glycoarray 
protocol except that after the primary incubation 100µl of 1% BSA/PBS was 
added to each well and aspirated 3 times to prevent transference of samples 
between wells.  
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2.5.6 Array Imaging 
 
The arrays were imaged using either a PerkinElmer Scan Array Express 
(PerkinElmer, Waltham, MA, USA) or a Sensovation FLAIR scanner (Sensovation, 
Radolfzell, Germany). The former employed the use of a 633nm laser to excite 
the fluorescent secondary antibodies on each slide. Different photomultiplier 
tube (PMT) settings could be used to visually enhance the signals and the images 
produced could be optimised by manipulating their colour or black settings (this 
did not alter the raw data used for quantification). The images were quantified 
using the accompanying software which associated a number between 0 and 
65535 with each pixel. Adaptive circles were used to identify each spot which 
had the local background subtracted from the median spot intensity. This value 
was taken as a representation of the binding capabilities of each antibody to the 
specific antigen contained within that spot.  
The Sensovation scanner used high power LED illumination with a green/red 
channel which was capable of exciting at 549/647nm. Each channel had a 
corresponding emission filter to prevent bleed through of opposing signals 
however it was found that intense signals or prolonged exposure of the 647 
channel were detectable in the 549 channel. In such cases the exposure time 
was reduced, for all arrays within the same experiment, to circumvent this 
issue. Four slides could be scanned at the same time and once processed were 
quantitated using the accompanying software which was similar to the other 
scanner. The images produced were in gray scale and had to be copied and 
modified using the PerkinElmer software to produce colour images.    
2.6 Liposome Production 
 
Liposomes were produced based upon the method previously described by Bowes 
et al, 2002, with some minor modifications. The liposomes were composed of a 
ganglioside, cholesterol, SM, DCP, and the complex partner in a 1:5:4:1:1 molar 
ratio although some GM1:GalC liposomes omitted SM. The concentration of the 
liposomes was based upon the ganglioside and was 1mg/ml for immunisations.  
Whole lipid extract (WLE) liposomes were produced by adding 5mg of WLE to the 
same proportion of chol, SM, DCP that were used with GM1 liposomes.   
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They were prepared by sonicating the stock lipids for 5 minutes before the 
different components were added together in a 15ml conical tube. The mixture 
was then sonicated for a further 5 minutes before the chloroform/methanol was 
dried off under a stream of nitrogen. For immunisations, 25mg of ovalbumin 
(Sigma Aldrich, St Louis, MO, USA) was added to 5ml of PBS and heated to 37°C. 
This was added to the dried lipid film and vortexed for 2 minutes and then 
sonicated for 15 minutes.  A series of freeze/thaw cycles were then performed 
by plunging the conical tube into liquid nitrogen and then thawing it in a water 
bath set to 37°C. The liposomes were then centrifuged at 600xg for 20 minutes 
(Jouan, Saint-Herblain, France) after which the supernatant was removed and 
heated to 37°C. This was followed by extruding the solution through a 0.4µm 
membrane (Whatman, Little Chalfont, UK) in a hand held extruder (Avanti Polar 
Lipids, Alabaster, US) 11 times over a heat block set at 37°C. The extruded 
liposomes were then ultra-centrifuged using a Ti-70 rotor (Beckman Coulter, 
Brea, CA, USA) at 152300xg for 1 hour at 16°C. The supernatant was disposed of 
and the liposome pellet was resuspended in 1ml PBS and stored at 4°C for up to 
one week.  
2.7 Immunisation Protocol 
 
All mice selected for immunisations were bled at regular intervals, so that the 
immune response could be monitored. 100µl was collected from each mouse via 
venesection of the tail vein. Once collected it was allowed to clot at room 
temperature for 30 minutes after which the blood was centrifuged at 21000xg on 
a Hermle Z216MK microcentrifuge (Wehingen, Gemrany) at 4°C for 20 minutes. 
The serum was removed and aliquoted into microtubes and stored at -20°C. 
2.7.1 Liposome Immunisation  
 
Mice were bled prior to the start of the immunisation cycle (Day 0) before being 
primed with 100µl of ovalbumin suspended in aluminium hydroxide (Sigma 
Aldrich, St Louis, MO, USA) at a concentration of 0.6mg/ml. The mice were then 
bled and injected intraperitoneally (i.p.) with 100µl of liposomes once a week 
for three consecutive weeks (Day 7, 14, 21). This ensured that each mouse 
received 100µg of ganglioside liposomes in each injection. The blood collected 
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on the 4th time point was screened for anti-ganglioside antibodies so that mice 
could be selected for hybridoma fusion. All mice received 50µl intravenous 
injections (i.v.) of liposomes at 200µg/ml on days 25, 26 and 27. The mice were 
then culled on day 30 through asphyxiation with CO2 after which the blood and 
tissue was harvested.  
2.7.2 CFA/IFA Immunisation 
 
Mice were immunised against whole lipid extract (WLE) by suspending the 
antigen in complete Freund’s adjuvant (CFA) (Sigma Aldrich, St Louis, MO, USA) 
containing 1mg/ml heat killed mycobacterium tuberculosis. The WLE was first 
prepared by sonicating the stock (242mg/ml) for 5 minutes after which 50µl was 
transferred to a glass bijou. The chloroform that the WLE was stored in was 
dried off under a stream of nitrogen and the WLE was resuspended in 3ml of 
saline. It was then transferred to a glass syringe (Hamilton, Reno, NV, USA) and 
emulsified with 3ml of 0.5mg/ml CFA using a double hub needle. The resultant 
mixture was stored at 4°C overnight prior to use. Immunogens were created with 
incomplete Freund’s adjuvant (IFA) following the same protocol except that the 
CFA was replaced with IFA.  
The mice were bled prior to the beginning of the immunisation cycle as per the 
liposome immunisations. Each mouse was injected with 100µl of WLE/CFA 
subcutaneously so that they received approximately 2mg of WLE per injection. 
Each subsequent injection consisted of 100µl of WLE/IFA and was performed at 
week 2 and week 4.  
2.8 Production of Hybridomas  
 
Monoclonal antibodies were produced by fusing the splenocytes from the 
immunised mice with a myeloma cell line to create a hybridoma. This method 
employed the use of hypoxanthine/aminopterin/thymidine (HAT) media which 
blocks the de novo pathway of DNA synthesis forcing cells to use the salvage 
pathway. The myeloma cell line lacks the enzyme HGPRT and is unable to use 
the salvage pathway which results in the myeloma cells dying. The hybridoma 
cells will have regained this enzyme from the splenocytes and are able to 
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synthesise DNA and thus expand. This allows for the production of an immortal 
cell line that is capable of producing antibodies.  
Following an immunisation cycle, mice were culled with a rising concentration of 
CO2 as per UK Home Office guidelines. Cardiac puncture was then performed 
using a 26G needle and the blood retained for subsequent analysis as per section 
2.5.4.  
All tissue culture work was carried out in category 2 laminar flow hoods and 
followed good tissue culture practice. Unless otherwise stated, centrifugation 
was performed using a Sorvall biofuge primo centrifuge (Thermo Scientific, 
Waltham, MA, USA) and all cells were incubated in a Forma Series ii 3110 water 
jacketed CO2 incubator (Thermo Scientific, Waltham, MA, USA). Cells were 
counted using a haemocytometer (Hausser Scientific, Horsham, PA, USA) and 
employed the use of 0.4% trypan blue (Life Technologies, Carlsbad, CA, USA) as a 
method of dye exclusion.  
2.8.1 Spleen Harvest 
 
Mice selected for hybridoma fusion were euthanized, pinned out in the supine 
position and sprayed with 70% ethanol. The skin was removed from the thorax 
and the peritoneal cavity was opened to expose the abdominal organs. The 
stomach was pulled aside to access the spleen which was then removed with 
sterile dissection scissors. The spleen was placed in a 50ml tube containing 20ml 
of sterile 20% RPMI and moved to a laminar flow hood.  
A glass mortar and pestle were used to homogenise the spleen which was then 
filtered through a 70µm cell strainer (BD Falcon, Franklin Lakes, NJ, USA) into a 
new 50ml tube. 5ml of fresh 20% RPMI was washed through the strainer to 
maximise cell retention. The splenocytes were then centrifuged at x300g for 10 
minutes using a sorvall biofuge primo centrifuge (Thermo Scientific, Waltham, 
MA, USA). They were then resuspended in 10ml of RPMI and counted using a 
haemocytometer.  
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2.8.2 Hybridoma Fusion 
 
The mouse myeloma fusion partner, P3X63Ag8.653 (hereby referred to as 653s), 
were raised a week before the hybridoma fusion and were grown following the 
standard methods described in Section 2.9.1. They were expanded into several 
150cm2 vented flasks and were placed into the log phase of growth the day 
before the fusion to ensure that the cells were rapidly expanding. Following the 
preparation of the splenocytes, the 653s were loosened in their flasks by gentle 
agitation and centrifuged at 250xg for 10 minutes. They were then resuspended 
in 10ml of RPMI and counted using a haemocytometer.       
The splenocytes and 653s were mixed in a 10:1 ratio and centrifuged to a 
common pellet at 250xg for 10 minutes. All the supernatant was removed from 
the tube and the pellet was loosened by gentle agitation. In a water bath set to 
37°C, 1ml of polyethylene glycol (PEG) was added dropwise to the pellet over a 1 
minute period with constant agitation, to allow fusion of the cells to create the 
hybridoma. This was followed by a further 90 seconds of agitation after which 
2ml of RPMI was added dropwise over a period of 2 minutes. 20ml of RPMI was 
then added over a 5 minute period followed by centrifugation at x130g for 15 
minutes.  
The supernatant was removed and the pellet was resuspended in 60ml 20% RPMI 
+FS. 96 well plates were prepared by filling all the outer wells with 200µl of 
media without cells. The inner wells were then filled with 150µl of media 
containing the suspended cells and the plates were incubated at 37°C in 5% CO2. 
2.8.3 Maintenance and Screening of Hybridomas 
 
After two weeks of incubation, 110µl of supernatant was removed from each 
well and replaced with 120µl of 20% RPMI +FS. The supernatant was screened for 
monoclonal antibodies on ELISA or microarray as per sections 2.4.2 and 2.5.5 
respectively. Antibody positive wells were expanded by triturating the cells with 
200µl of media three times and applying the suspension to wells in a 24 well 
plate. These were then topped up with 500µl of 20% RPMI +FS. After three days 
of growth all the media was removed from each well and replaced with 1ml of 
20% RPMI +FS. The cells were incubated for a further 3 days after which the 
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supernatant was screened again for monoclonal antibodies following the method 
as above.  
2.8.4 Cloning by Serial Dilution 
 
Wells containing antibodies of interest were cloned by serial dilution to ensure 
that only one cell line was present. The cells were counted using a 
haemocytometer and the volume that contained 1200 cells was calculated. This 
was added to well A1 in a 96 well plate and topped up to 200µl with 20% RPMI 
+FS. The other wells were filled with 100µl of media and 100µl of the cell 
suspension in A1 was serially diluted 1:1 down column A. This was then topped 
up to 200µl with media and 100µl was then serially diluted 1:1 across all the 
columns. All the wells were then topped up to 200µl with 20% RPMI +FS. The 
plates were incubated at 37°C in 5% CO2 for two weeks until colonies began to 
appear and the media changed colour.   The wells were then screened using the 
ELISA method as per section 2.4.2. The smallest colony that was positive for 
antibodies was expanded into a 24 well plate as per section 2.8.3 and the 
cloning process was repeated for a total of three times.  
2.8.5 Freezing Cells 
 
At each stage of development the cells were frozen to ensure cell line retention. 
Following centrifugation the supernatant was removed and the pellet was 
resuspended at a density of 106 cells/ml in 20% RPMI + 10% dimethyl sulfoxide 
(DMSO) (Sigma Aldrich, St Louis, MO, USA). This suspension was added to several 
2ml freezer tubes which were then placed inside a Mr Frosty Freezer Container 
(ThermoScientific , Waltham, MA, USA) that contained isopropyl alcohol. This 
was frozen at -80°C for 24 hours and then moved to liquid nitrogen for long term 
storage.  
2.8.6 Growth Curves 
 
Once the hybridoma cloning process had been completed, growth curves were 
produced to determine the doubling time of each cell line (Figure 2.1). These 
were useful in establishing the growth rates of the cells, which would be 
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informative, in terms of cell health and viability, if they were raised again 
(Assanga, 2013). Any deviation from the normal growth curves could act as an 
indication of changes in the local environment and could be used to alter the 
growth conditions accordingly.  
To produce these growth curves, hybridoma cells were counted using a 
haemocytometer and the volume required to produce 104 cells/ml was 
calculated. This volume was then added to 5ml of 10% RPMI +FS in a vented 
25cm2 flask, which was then incubated at 37°C in 5% CO2. Every day, 20µl was 
taken from each flask and counted until the cell number plateaued. This data 
was plotted and the points on the steepest slope of the curve (log phase) were 
used to determine the cell doubling time (Figure 2.1).  
These were 20.60 hours, 31.61 hours, 30.52 hours, 23.38 hours, 64.85 hours, 
38.49 hours, 55.77 hours, 47.43 hours, 26.49 hours and 10.14 hours with the 
GAME-M1, GAME-M2, GAME-M3, GAME-M4, GAME-M5, GAME-M6, GAME-M7, GAME-
G1, GAME-G2 and GAME-G3 hybridomas respectively. 
Most of the hybridoma cells followed the standard shape of a growth curve; 
initially experienced a lag phase of growth, where the cell numbers either 
stalled or decreased, followed by the log phase where the cells grew at an 
exponential rate until they reached a plateau (Freshney, 2010). The only 
exception to this growth pattern was the hybridoma that produced GAME-M4. 
These cells experienced a rapid decrease in number after they reached their 
peak. During antibody production it was noted that this cell line was very 
sensitive to changes in the media, particularly the absence of feeder 
supplements. Unlike the other hybridoma cells that were successfully weaned 
off the supplement, this cell line died during each attempt. 
 This may help explain the rapid cell death experienced during the growth curve, 
as the cell line would most likely be sensitive to the increased levels of waste 
products produced by the growing cells. Despite these problems, the cell line 
was still able to produce antibodies although it was incapable of producing them 
long term. 
Aside from the shapes of the growth curves, there were also differences in their 
doubling times. This may have been related to the resources they invest in 
producing antibodies. GAME-M7, for example, was only able to maintain cell  
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 Figure 2.1 – Growth Curves of Anti-Glycolipid Antibodies 
Cells were counted every day and a growth curve was plotted for each 
hybridoma cell line. The doubling time was calculated from the steepest point 
on each curve. These were as follows: A: GAME-M1: 20.60 hours; B: GAME:M2: 
31.61 hours; C: GAME-M3: 30.52 hours; D: GAME-M4: 23.38 hours; E: GAME-M5: 
64.85 hours; F: GAME-M6: 38.49 hours; G: GAME-M7: 55.77 hours; H: GAME:G1: 
47.43 hours; I: GAME-G2: 26.49 hours; J: GAME-G3: 10.14 hours.  
 
growth up to a maximum 200000 cells. Antibody production in this cell line was 
particularly high, however, suggesting that the reduced cell growth was allowing 
the hybridoma cells to focus resources on antibody production (E. Suzuki & Ollis, 
1990).  
2.9 Production of Monoclonal Antibodies 
2.9.1 Production of Existing Hybridoma Cell Lines  
 
Existing hybridoma cell lines were thawed from storage in liquid nitrogen, and 
centrifuged at 250xg for 10 minutes. The supernatant was disposed and the 
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pellet resuspended in 20% RPMI and centrifuged again. This was repeated a total 
of three times. The cells were grown in 15ml of 20% RPMI in 25cm2 vented flasks 
until confluent after which they were expanded into bigger flasks containing 10% 
RPMI until there were eight 150cm2 flasks containing 100ml of media each.  
2.9.2 Collection of Antibody Supernatant 
 
As the cells became confluent, 50ml of media was removed from each flask and 
replaced with 50ml of 10% RPMI. The media that was removed was centrifuged 
at 525xg for 10 minutes and the supernatant was retained and frozen at -20°C. 
This process was repeated until approximately 1L of antibody containing media 
was collected after which all the media was thawed at 4°C for approximately 16 
hours. It was then pooled together and filtered through a 0.22µm sterile filter 
unit (Millipore, Billerica, MA, USA) under a constant vacuum.  
2.9.3 Purification of IgM Antibodies 
 
Attempts were made to purify the human IgM monoclonal antibodies using 
affinity purification columns (GE Healthcare, Little Chalfont, UK). The column 
operated on the principle of thiophilic adsorption to fractionate the IgM 
antibodies from the cell supernatant. The column was first washed through with 
5ml of binding buffer (20mM Na3PO4/0.8M (NH4)2SO4), elution buffer (20mM 
Na3PO4) and regeneration buffer (20mM Na3PO4 and 30% isopropanol) using a 
Watson Marlow 205S peristaltic pump (Watson Marlow Pumps, Falmout, UK). This 
was followed by equilibrating the column with another 5ml of binding buffer. 
The IgM antibody samples were prepared by slowly adding the same amount of 
ammonium sulphate that was in the binding buffer. This was followed by 
filtration through a 0.22µm sterile filter unit (Millipore, Billerica, MA, USA) using 
a vacuum pump.  
The sample was pumped through the column using a peristaltic pump at a speed 
of 1ml/min. When there was less than 5ml of sample remaining the pump was 
stopped and 15ml of binding buffer was run through the column to remove any 
unbound IgM antibody. To remove the bound IgM fractions, 12ml of elution 
buffer was run through the column, followed by 5ml of regeneration buffer to 
remove any remaining antibody. The column was then re-equilibrating with 5ml 
Chapter 2 – MATERIALS AND METHODS  54 
 
of binding buffer and was stored in 20% ethanol at 4°C to prevent bacterial 
growth. The elution was screened for antibody presence using a quantitative 
ELISA kit as per section 2.4.3. 
2.9.4 Concentration of IgM Antibodies 
 
The use of IgM purification columns proved unreliable in isolating antibodies 
from tissue culture media. A different method was therefore employed to allow 
for the production of sufficient stocks for analysis. This method involved running 
250ml of filtered media through a 100kDa filter inside a Vivacell bench top 
concentrator (Sartorius, Göttingen, Germany). The concentrator was sealed and 
a pressure of 3 bars was applied to the container which was then placed on a 
shaker at 100rpm. The media was topped up and the flow through removed as 
required until all of the media had been concentrated to a final volume of 
between 5 and 20ml. The concentrate was then screened using quantitative 
ELISA as per section 2.4.3 
2.9.5 Purification of IgG Antibodies 
 
IgG antibodies were purified using HiTrap protein G affinity purification columns 
(GE Healthcare, Little Chalfont, UK). The filtered media containing IgG 
antibodies was first dialysed against binding buffer (0.2M Na2HPO4/0.2M 
NaH2PO4) overnight at 4°C. The column was then prepared by running 5ml of 
binding buffer through it using a peristaltic pump set to 50rpm. The media was 
placed on ice and run through the column at a rate of 50rpm with the flow 
through being collected in a 1l Duran bottle. The pump was stopped when less 
than 10ml of media was remaining and binding buffer was then run through the 
column and 10x 1ml wash aliquots were collected.  Elution buffer (0.1M Glycine, 
pH 2.5) was subsequently run through the column followed by the collection of 
10x1ml elution aliquots which each contained 40µl of TRIS-HCl (pH 9.5). The 
column was capable of being reused so binding buffer was again run through it to 
remove any residual elution buffer followed by the addition of 20% ethanol 
which was used to store it at 4°C.  
The wash and elution aliquots were analysed using a Nanodrop 1000 
spectrophotometer (ThermoScientific, Waltham, MA, USA) that had been set up 
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to read absorbance at a wavelength of 280nm.  The software was capable of 
translating this absorbance into a protein concentration in mg/ml. The 
spectrophotometer was initialised using a sample of RNAse free water to act as a 
control. 2µl of each sample was then applied and each reading was noted.  
An example of the spectrophotometer read out is shown with the antibody, 
GAME-G3, in Figure 2.2. The initial wash fractions indicated that high 
concentrations of protein were present in the samples; however, this was due to 
the presence of FCS in the cell culture supernatant, which skewed the results. 
High concentrations of antibody were found in elution fractions 3-7 from the 
first run and 4-5 from the second run. These were subsequently pooled to create 
antibody stocks.  
 
Figure 2.2 –GAME-G3 Elution Fractions 
GAME-G3 supernatant was run through a commercial protein G column. The high 
protein concentration in the wash fractions was due to the presence of FCS. The 
highest antibody concentration was found in elution fractions 3-7 from the first 
run and 4-5 from the second run. 
 
Elution fractions that had high values were pooled together and desalted using 
PD-10 desalting columns (GE Healthcare, Little Chalfont, UK). 25ml of PBS was 
first run through the columns and disposed, followed by the samples which were 
topped up to 2.5ml with PBS. The flow through was retained to ensure that it 
was protein free and an additional 3.5ml of PBS was added to the column and 
collected in a bijou. Both of these elutions were analysed on the 
spectrophotometer for IgG concentration.  
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2.9.6 Isotyping 
 
Isotyping of the IgG sub-classes was performed by ELISA using secondary 
antibodies that were specific for the different antibody isotypes. The ELISAs 
were carried out as per Section 2.4.2 with some minor modifications. Briefly, 
the primary consisted of 100µl of the monoclonal antibody at 10µg/ml in 0.1% 
BSA/PBS, which was added to each well of the plate. The secondary consisted of 
IgG1, IgG2a, IgG2b and IgG3 antibodies at a 1:3000 dilution, which were added 
to rows A+B, C+D, E+F, and G+H respectively. These secondary antibodies were 
serially diluted 1:1 along the rows. The wash and development steps of the 
protocol were all performed as standard.  
Using this method GAME-G1, GAME-G2 and GAME-G3 were all determined to be 
of the IgG3 subclass.  
2.10 Isoelectric Focussing  
 
The monoclonality of the antibodies was determined by isoelectric focussing 
(IEF) which separates the antibodies according to their isoelectric points. This 
work was carried out in conjunction with laboratory staff at the Southern 
General Hospital, Glasgow, UK.  
A glass plate was cleaned with 70% ethanol and 5 drops of 50% methanol/dH2O 
was applied to the surface. The hybrophobic side of a pre cut sheet of GelBond 
film (Lonza, Basel, Switzerland) was then aligned with the edge of the glass 
plate and evenly pressed to remove air bubbles. A second plate containing a 
spacer was then placed on top and secured before a boiling glycerol sorbitol gel 
was applied. This was prepared by dissolving 24g of sorbitol in a mixture of 20ml 
of glycerol and 180ml of dH2O followed by the addition of 1ml of pharmalyte 3-
10 and 0.25ml of pharmalyte 8-10.5 (GE Healthcare, Little Chalfont, UK). The 
gel was left to set at room temperature for 1 hour before the glass was 
removed. It was then stored at 4°C in a humid chamber for up to 1 week.  
The multiphor ii electrophoresis system (GE Healthcare, Little Chalfont, UK) was 
used for the IEF portion of the experiment and was continually cooled through a 
constant flow of cold water. Five drops of 50% methanol/dH2O was applied to 
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the cooling plate and the gel was aligned with its edge to seal it in position. A 
strip of fixed Ilford Pan F Plus 50 dx 135-36 film (Calumet Photographic Ltd, 
Leith, UK) was applied 2.5cm from the anodic edge of the gel and was used to 
load 2.5µl of each sample. IgG and IgM antibodies were applied at 100µg/ml but 
IgM samples were first reduced by incubating them in 2% mecaptoethanol at 
room temperature for 30 minutes. The anode and cathode IEF electrode strips 
(Healthcare, Little Chalfont, UK) were soaked in 0.05M H2SO4 and 1M NaOH 
respectively and then applied to the gel to give an approximate interelectrode 
distance of 7cm. The glass plate containing the electrodes was then placed on 
top and the electrode wires were aligned with the IEF electrode strips. The 
voltage was set to 1200V at 20W and integrated over time to give a total run 
interval of 1000 volts/hour. The gel took 20 minutes to complete the IEF run 
after which it was removed from the plate using tweezers. 
The gel was placed on a plastic plate and blotted with HYBOND C nitrocellulose 
membrane (NCM) (GE Healthcare, Little Chalfont, UK) to remove excess 
moisture. A new sheet of NCM was then applied carefully onto the gel and 
covered with several sheets of filter paper and another plastic plate. This was 
weighed down by a 3kg weight for 30 minutes to ensure transference of the 
protein from the gel to the NCM.  
Once this had been completed the NCM was probed with secondary antibodies to 
detect the isoelectric points of the monoclonal antibodies. All the steps took 
part on a rocking platform shaker set to 30 rpm. The NCM was first blocked with 
2% Marvel (Premier Foods PLC, St Albans, UK) for 30 minutes followed by an 
incubation with 50ml of either goat anti-mouse IgM or goat anti-mouse IgG 
(1:1000) in 0.2% Marvel for 30 minutes. The NCM was then washed three times in 
saline for 5 minutes each. 50ml of HRP conjugated rabbit anti-goat Ig was then 
applied (1:1000) in 0.2% Marvel for 30 minutes followed by a repeat of the wash 
cycles. The membrane was developed by incubating it with a 3-amino-9-ethyl 
carbazole (AEC) solution in the dark for 15 minutes. Once bands appeared the 
NCM was washed with water several times and dried overnight by placing it 
between several sheets of blotting paper with a 3kg weight on top. 
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2.11 Thin layer chromatography  
 
The components of WLE were determined by thin layer chromatography (TLC) to 
establish what antigens were present in the immunisation bolus. Immuno-
overlays were also performed using TLC to screen the serum and the monoclonal 
antibodies to determine their targets.  
2.11.1 TLC Resorcinol Staining  
 
Lipids were prepared as per section 2.4.1 and WLE was prepared at 5mg/ml in 
methanol. Resorcinol was made 24 hours before use by first dissolving 200mg of 
resorcinol (Sigma Aldrich, St Louis, MO, USA) in 10ml dH2O and adding it to 80ml 
of 13M HCl containing 250µl of 0.1M CU2SO4. This was then topped up to 100ml 
with dH2O. 
A square of filter paper was attached to the back of a glass TLC tank (CAMAG, 
Muttenz, Switzerland) which was then filled with a solvent solution composed of 
50ml chloroform, 42ml methanol and 11ml 0.2% CaCl2.The rim of the tank was 
sealed with petroleum jelly and the lid was attached. The tank was then left to 
equilibrate at room temperature for 3 hours.  
HPTLC Silical gel 60 plates (Merck KGaA, Darmstadt, Germany) were loosely 
covered in foil and heated to 80-100°C for 1 hour prior to printing. The plates 
were then removed and placed in the TLC autosampler (CAMAG, Muttenz, 
Switzerland) which was fitted with a 100µl needle. The accompanying software 
was used to apply 30µl bands of each lipid (100ug/ml) or WLE (5mg/ml) to the 
plate. A maximum of 10 individual bands could be applied to each plate for 
standard TLC or 5 duplicate bands could be applied to each half for overlay TLC. 
Once printing was completed the plate was allowed to dry at room temperature 
for 15 minutes.  
When the tank was equilibrated, the plate was stood vertically against the filter 
paper inside the tank and the lid was replaced. The solvent solution moved up 
the plate and in doing so displaced the lipids according to their molecular 
weight. This was allowed to proceed for 45 minutes at room temperature.  
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The plate was then removed and dried flat for 10 minutes at room temperature 
until it no longer appeared transparent. It was then stood vertically against the 
outside of the tank and sprayed with resorcinol until the whole plate was 
covered. A second plate which had micro tube lids affixed to the corners was 
then laid on top of the plate and both were covered with foil and placed on the 
bottom shelf of an oven at approximately 90°C for 10 minutes. This allowed for 
the development of the lipid migration pattern. 
2.11.2 TLC Immuno-overlay 
 
Once the TLC had been performed, a diamond pen was used to split the plate 
into two halves. One half was sprayed with resorcinol and developed as 
described whilst the other half was dipped into a solution of 0.2% 
polyisobutlymethacrylate (PIBM) in n-hexane for 1 minute. It was then air dried 
inside a fume hood at room temperature for 30 minutes followed by a blocking 
step with 2% BSA/PBS for 16 hours. Subsequently, 3ml of a monoclonal antibody 
(10µg/ml) or serum (1:100) was applied to the plate, which was then covered 
with a sheet of parafilm (Pechiney Plastic Packaging Company, Chicago, IL, USA) 
and incubated at 4°C for 2 hours. The plate was washed three times in 100ml of 
1% BSA/PBS for 5 minutes on a shaker set to 100rpm. 3ml of HRP conjugated 
goat anti-mouse IgM (1:3000) was then applied to the plate, which was again 
covered with a sheet of parafilm and incubated at 4°C for 1 hour. The wash 
cycle was repeated as previously described and the plate was developed using 
the OPD method as per the ELISA protocol in Section 2.4.2. Stop solution was 
applied for 10 seconds and the plate was air dried for 20 minutes.  
2.12 Growth and Immunofluorescent Staining of Primary Cells  
2.12.1   Schwann Cell Culture 
 
Schwann cells were cultured based upon the protocol laid out by Honkanen et 
al., (Honkanen et al., 2007). The day before the culture, plates were prepared 
by placing sterile coverslips in each well of a flat bottomed 24 well plate. 500µl 
of 10µg/ml of poly-l-lysine (Sigma Aldrich, St Louis, MO, USA) in dH2O was 
applied to each well and the plate was incubated at 37°C in 5% CO2 for 1 hour. 
The wells were then washed twice in dH2O and allowed to dry overnight.  
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was removed and replaced with 700µl Schwann cell growth media. The cells 
were incubated for another 4 days until they had a morphology resembling an 
elongated spindle shape as those in Figure 2.3.  
2.12.2  Schwann Cell Immunofluorescence  
  
After eight days of growth the Schwann cells were probed with anti-sulfatide 
antibodies. Following each stage of the staining protocol, the wells were washed 
twice with PBS to remove excess reagents. The plates were incubated on ice and 
500µl of the appropriate antibody was added to each well at 10µg/ml for 1 hour. 
The cells were then fixed with 4% PFA for 20 minutes followed by a 5 minute 
incubation with 0.1% Triton X-100. 500µl of 5% heat inactivated normal goat 
serum (NGS) in PBS was then added to each well and the plates were incubated 
at room temperature for 30 minutes. 500µl of rabbit anti S-100 (Dako, Santa 
Clara, CA, USA) was then added in PBS at 40µg/ml and the plates were 
incubated overnight at 4°C.  
The following day, 500µl of an appropriate secondary antibody conjugated to 
FITC (3.33mg/ml) was added to each well alongside TRITC-conjugated anti 
rabbit IgG (3.33mg/ml). The plates were incubated at room temperature for 30 
minutes followed by 3x five minute washes in PBS. The coverslips were then 
removed from each well, mounted in DAPI (Life Technologies, Carslbad, CA, 
USA) and sealed with nail varnish onto a microscope slide. The slides were stored 
at 4°C prior to imaging.  
2.12.3  Oligodendrocyte Progenitor Cells 
 
Rat derived oigodendrocyte progenitor cells (OPCs) were grown by a colleague 
within the institute according to established methods (Lindsay et al., 2013). 
These were grown on poly-l-lysine coated coverslips for 10 days prior to 
immunofluorescent staining. 
2.12.3.1   Immunofluorescence   
 
The staining protocol for the OPCs was similar to that used for staining Schwann 
cells with a few changes. The primary antibody was applied with an immature 
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OPC marker, NG2 (Millipore, Billerica, MA, USA), at a concentration of 5µg/ml. 
After permeabilisation, anti-S100 was not added but instead an in-house 
monoclonal antibody (AA3), which binds proteolipid protein (PLP), was applied 
at a concentration of 10µg/ml. All other stages of the protocol remained the 
same.  
2.13 Muscle and Nerve Preparations 
 
The binding behaviours of the monoclonal antibodies in tissue were determined 
through application of the antibodies to muscles and nerves taken from naive 
mice. These tissues could be studied as either ex vivo preparations, where the 
tissue was kept alive in a physiological solution, or as frozen sections. All mice 
were culled by a rising concentration of CO2 as per Home Office guidelines. Upon 
cessation of breathing, death was confirmed by cervical dislocation.  
2.13.1 Triangularis Sterni 
 
The mouse was pinned in the supine position and the skin was retracted around 
the thoracic cavity. The lower abdominal organs were pulled away from the rib 
cage and the diaphragm was removed. The heart and lungs were carefully 
removed and the rib cage was detached from the spinal cord. It was then pinned 
pectoral side up in a Sylgard (Dow Corning, Midland, MI, USA) lined petri dish 
that contained oxygenated Ringer’s solution.  
The overlying muscles were removed using a dissecting microscope and the ribs 
were peeled back to reveal the triangularis sterni (TS). This was repeated to 
create four windows which contained the TS surrounded by ribs. These were 
then individually cut out and pinned under tension in separate wells of a Sylgard 
lined 24 well plate containing Ringer’s solution.  
Once all the TS sections were prepared, the solutions were removed and the 
antibodies were applied at a concentration of 100µg/ml with α-bungarotoxin 
(2µg/ml) for 1 hour at 4°C. This was followed by three washes in Ringer’s 
solution and fixation with 4% PFA for 20 minutes at room temperature. The 
tissues were then washed for 10 minutes in PBS, 10 minutes in 0.1M glycine (pH 
7.5), and 10 minutes in PBS. The appropriate secondary antibodies were then 
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applied overnight at 4°C. The following day, the tissues were washed 3 times in 
PBS for 5 minutes each. Finally, each TS was completely removed from the 
supporting ribs and tissue and mounted on adhesive slides (Tissue Tek, Sakura, 
Netherlands) with Citifluor AF1 (Citifluor, Fanshaw, UK) or DAPI (Life 
Technologies, Carslbad, CA, USA.) Coverslips were applied to slides and sealed 
with nail varnish followed by storage at 4°C, prior to imaging.  
2.13.1.1 Permeabilisation to Detect Uptake of Antibody 
 
Tissue was permeabilised to determine if any antibody had been internalised 
during the initial incubation. Once the original tissue has been imaged, the 
coverslip was removed and the TS was washed several times in PBS. It was then 
incubated in 0.5% Triton X-100 for 30 minutes at room temperature. This was 
followed by 3 washes in PBS and the application of the secondary antibody as 
previously described. The tissue was again mounted in the same manner as 
before.   
2.13.1.2 S100 Staining 
 
In mice that were not S100-GFP fluorescent an anti-S100 antibody was used to 
identify glia. After the permeabilisation step, rabbit anti- S100 was applied at 
20µg/ml for 1 hour at 4°C. The tissue was then washed three times and the 
secondary antibody was applied with an appropriate fluorophore conjugated 
goat-anti rabbit IgG as per the standard protocol.  
2.13.1.3 Neuraminidase Treatment  
 
The enzyme neuraminidase from Clostridium perfringens (Sigma Aldrich, St 
Louis, MO, USA), which cleaves the terminal sialic acid from gangliosides, was 
applied to tissue to examine how changing the ganglioside environment affected 
antibody binding behaviour. Once the TS preparations were pinned out in a 24 
well plate, 300µl of neuraminidase was applied at 10U/ml in Ringer’s solution to 
half the wells whilst the control wells received Ringer’s solution alone. The plate 
was incubated at 37°C for 2 hours followed by three washes in Ringer’s solution. 
Chapter 2 – MATERIALS AND METHODS  64 
 
The rest of the experiment followed the standard protocol as laid out in Section 
2.13.1.  
2.13.1.4 Complement Mediated Cell Injury 
 
To establish whether certain antibodies were pathogenic, it was necessary to 
apply normal human sera (NHS) to tissue, to determine if the antibodies were 
capable of activating the complement cascade. Mice with CFP positive axons 
were always used for these experiments and their TS were prepared as described 
previously. They were incubated with 100µg/ml of antibody and FITC 
conjugated-BTx for 2 hours at 32°C, followed by 30 minutes at 4°C and finally 10 
mins at room temperature. The control underwent the same protocol except 
that no antibody was added. Following incubation, the solutions were removed 
and the tissue was washed 3 times with Ringer’s solution. 40% NHS in Ringer’s 
solution was then applied for 1 hour at room temperature followed by three 
washes. Ethidium homodimer-1 (EthD-1) was then applied at a 1:500 dilution in 
Ringer’s solution for 1 hour at room temperature followed by 3 further washes. 
The TS was then fixed and an appropriate secondary antibody was applied as per 
Section 2.13.1. It was then mounted onto a microscope slide as standard.  
2.13.1.5 Terminal Myelinating Schwann Cell Characterisation 
 
Anti-sulfatide monoclonal antibodies were found to stain the terminal 
myelinating Schwann cells. As this staining was unique, it was thought that the 
cell may be different from the surrounding Schwann cells so it was characterised 
against a series of Schwann cell markers. 
Following incubation of anti-sulfatide antibodies with TS, the tissue was fixed as 
standard and then permeabilised with methanol for 10 minutes at -20°C. The 
tissue was then washed 3 times in PBS before a Schwann cell maker was added 
at an appropriate concentration. These were: anti-MBP (Millipore, Billerica, MA, 
USA) at 2µg/ml; anti-MAG (Millipore, Billerica, MA, USA) at 50µg/ml or anti-GFAP 
(Dako, Santa Clara, CA, USA) at 5.8µg/ml.  The tissues were incubated with 
these makers overnight followed by three further washes in PBS. The 
appropriate secondary antibodies were then applied to the tissue for six hours at 
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room temperature, after which it was mounted on adhesive slides with DAPI 
(Life Technologies, Carslbad, CA, USA) as per Section 2.13.1.  
2.13.2  Sciatic Nerve  
 
Adult mice were culled with a rising concentration of CO2 as per Home Office 
guidelines. The sciatic nerves were removed following the same procedure as for 
the Schwann cell culture discussed in Section 2.12.1. The nerves were frozen at     
-80°C until required for cryosectioning.   
2.13.2.1 Sciatic Nerve Sectioning 
 
The nerves were embedded transversely in optical cutting temperature cryostat 
sectioning medium (OCT) in preparation for cutting. 8µm sections were cut using 
a Bright OFT cryostat (Bright Instrument Co Ltd, Huntingdon, UK) and applied to 
24x70mm adhesive slides (Tissue Tek, Sakura, Netherlands). The slides were 
then stored at   -20°C prior to staining.  
2.13.2.2 Sciatic Nerve Immunofluorescence  
 
A hydrophobic pen (Vector Laboratories, Peterborough, UK) was first used to 
mark around the tissue sections on each slide to prevent dissemination of 
solutions prior to antibody application. The slides were then blocked in 3% NGS 
in PBS for 1 hour at 4°C followed by application of 300µl of the primary antibody 
(10µg/ml) for 2 hours at the same temperature. The slides were then washed 
three times in PBS followed by application of a suitable secondary antibody 
(3.33µg/ml) for 1 hour at 4°C. The slides were then washed three times with PBS 
and a myelin marker called  Fluoromyelin (Life Technologies, Carslbad, CA, USA) 
was applied at a 1:400 dilution for 12 minutes at room temperature. The slides 
were again washed three times in PBS and mounted in Citifluor AF1 as previously 
described.   
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2.14 Microscopy 
2.14.1  Zeiss AxioImager Z1 ApoTome Microscope 
 
Representative images were taken on an AxioImage Z1 ApoTome microscope 
(Carl Zeiss, Oberkochen,Germany) which employs the use of epifluorescence. As 
the microscope contained five different channels, it allowed for the imaging of 
up to five different secondary antibodies or dyes which could be compiled into 
one image. All images were taken at x63 magnification unless otherwise stated. 
2.14.1.1 Cell Counts 
 
Antibody binding to cells was quantified by manually counting the number of 
bound cells around each NMJ. The total number of bound cells was expressed as 
a percentage of the total number of NMJs.  
2.14.1.2 EthD-1 Positive Cell Counts  
 
EthD-1 stains the nuclei of dead cells and was used as an indication of 
complement activation by anti-sulfatide antibodies. Immunofluorescent studies 
using the new anti-sulfatide antibodies established that the terminal myelinating 
Schwann cell is present on a swelling of the CFP-positive axon at the terminal 
hemi node near the NMJ. This was used as a reference as to the location of the 
cell in the control tissue, which lacked antibody staining. 50 NMJs were imaged 
for each tissue and the number of EthD-1 positive cells in this location were 
counted.  The total number of EthD-1 positive cells was then expressed as a 
percentage of the total number of NMJs counted. 
2.14.2  Confocal Microscopy 
  
For quantitative purposes, images were taken upon a Zeiss LSM 5 Pascal confocal 
microscope or a Zeiss LSM 510 inverted confocal microscope (Carl Zeiss, 
Oberkochen, Germany). Confocal microscopes employ the use of lasers to excite 
the secondary antibodies at defined wavelengths of light. Fine optical z-slices 
through the tissue can be achieved due to the exclusion of all out of focus light. 
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All images were taken at a magnification of 40x with oil immersion and the same 
settings were used throughout the quantification of an antibodies binding.  
This was performed by first orientating the tissue by eye and then taking a snap 
image. Approximately one hundred and fifty NMJs were imaged for each tissue 
section which, once collected, were quantified using an in-house macro. This 
worked on the principal of identifying the BTx staining and any overlying 
secondary antibody staining. The intensity of antibody binding was then given as 
a value between 0 and 255 arbitrary units (AU). These values were used to 
create box and whisker plots but statistical analysis was only performed on the 
median intensity value of all the NMJs for each mouse.  
2.15 Statistical Analysis  
 
All graphs were generated using GraphPad Prism 6 (GraphPad Software Inc., San 
Diego, CA, USA) and statistical analysis, where appropriate, was performed using 
the same software with p values <0.05 deemed as significant. Array results were 
expressed as either individual values with the median marked by a line or as bar 
graphs displaying the mean ± standard error of mean (SEM). Immunofluorescence 
studies were graphed using either bar graphs or Tukey box and whisker plots. 
The statistical tests performed on individual experiments are given in their 
figure legends.  
2.15.1 Coefficient of Variation 
 
The intra-assay and inter-assay variation was calculated between runs using the 
mouse control serum. In large arrays every 12th combinatorial glycoarray slide 
was used as a control slide. The intra-assay variation for each lipid antigen was 
determined by comparing all the control slides within the one experiment. This 
was calculated by multiplying the mean of the SD by 100 and then dividing it by 
the total mean of the duplicates. The inter-assay variation was determined by 
comparing multiple control slides from different experiments using the same 
calculation.   
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2.15.2 Heat Map Analysis 
 
Raw intensity values from the human array studies were used to generate heat 
maps using MultiExperiment Viewer software (Dana-Farber Cancer Institute, 
Boston, MA, USA).. These maps underwent hierarchical clustering (HCL) and 
Pearson correlation with average linkage clustering. Raw values were displayed 
using a rainbow colour scheme, whereas complex signals that had individual 
values subtracted were displayed using a green-black-red colour scheme.  
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3 ARRAY SCREENING OF HUMAN MONOCLONAL ANTIBODIES 
 
3.1  Introduction 
 
As already discussed, the exact pathogenic mechanisms involved in MMN are still 
unclear. Evidence from clinical studies provide strong support that the condition 
is immune mediated, as it is commonly associated with anti-GM1 antibodies and 
responds well to immune modulating treatments (Lawson & Arnold, 2014);  
however, this has yet to be definitively proven.   
In an attempt to address whether the immune system was in fact responsible for 
disease pathogenesis, the Willison group cloned anti-GM1 antibodies from MMN 
and GBS patients over 20 years ago (Paterson et al., 1995; Willison et al., 1994). 
These antibodies were originally screened on ELISA against single ganglioside 
antigens and were found to bind GM1 and its structural analogues, GA1 and 
GD1b, to varying degrees. 
Subsequent studies attempted to establish the binding patterns of the antibodies 
in both human and mouse tissue (Greenshields et al., 2009; O’Hanlon et al., 
1996, 1998; Willison et al., 1997). They found that the antibodies were capable 
of binding to a wide range of neuronal structures, but were unable to adequately 
explain the specific injury experienced by MMN patients. The original conclusions 
drawn from these studies suggested that single antigen distribution alone could 
not account for disease pathogenesis. However, they did not address the effect 
of the lipid raft environment on ganglioside presentation or the 
pathophysiological vulnerability of different target sites to immunological 
attack.  
The recent advancements in neuropathy research regarding the roles of 
ganglioside complexes led to the desire to re-examine these antibodies and their 
target antigens. It was hypothesised that different antigen combinations may 
modify the binding abilities of these antibodies, which may better explain their 
binding patterns in tissue and their roles in the pathogenesis of the disease. This 
chapter therefore probed the human monoclonal antibodies against a series of 
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ganglioside complexes, printed using the combinatorial glycoarray, to better 
understand their significance in the pathogenesis of MMN.  
3.2 Results 
3.2.1  Human Monoclonal Antibodies 
 
The monoclonal antibodies were originally produced from the PBMCs of four MMN 
patients and one GBS patient. These were immortalised with EBV and then fused 
with a mouse myeloma cell line to allow for long term culture. As mentioned, 
the antibodies were screened upon ELISA and were found to bind to GM1, GA1 
and GD1b, with the exception of SM1 which did not bind the latter ganglioside. 
Table 3.1 indicates the names and original reactivities of the antibodies to the 
different target antigens.  
Table 3-1 – ELISA Binding Properties of Human Monoclonal Antibodies 
Reciprocal of Ab Conc that gave ½ max binding  
Antibody Isotype Disease GM1 GA1 GD1b 
BO1 IgMλ  MMN 1200 11500 250 
BO3 IgMλ  MMN 1500 7250 50 
BR1 IgMκ  MMN 1530 1680 680 
DO1 IgMλ  GBS (AMAN) 5500 4300 5700 
SM1 IgMλ  MMN 6500 50 0 
WO1 IgMλ  MMN 9100 14280 1700 
 
3.2.2  Antibody Production and Quality Screening 
 
The antibody producing cells were thawed from storage in liquid nitrogen and 
grown over a period of several weeks. Samples of supernatant from each cell 
line were tested periodically to determine if the cells were still producing 
antibody. Several different stocks of BO3, BR1 and SM1 were raised but all were 
poor antibody producers and eventually stopped producing antibody altogether. 
This resulted in the low availability of these three antibodies, particularly BO3 
and BR1.  
The original binding values of the human monoclonal antibodies as 
determined by ELISA. (Paterson et al., 1995) 
Chapter 3 – ARRAY SCREENING OF HUMAN MONOCLONAL ANTIBODIES 71 
 
Attempts were made to purify the antibodies following the collection of 
supernatant from the various hybridoma cell lines. Originally this was attempted 
by running the supernatant though a commercial IgM affinity purification 
column, which was expected to bind to and isolate the antibody. Starting 
material, wash and elution fractions were all tested using quantitative ELISA but 
it was found that none of the antibodies bound to the columns.  
This was somewhat expected as IgM antibodies are notoriously difficult to purify 
(Gautam & Loh, 2011). To overcome this problem, an alternative method was 
employed in which the supernatant was run through a 100kDa membrane to 
concentrate the antibodies. This method did not purify the antibodies but did 
allow for the production of sufficient stocks for subsequent characterisation 
studies.   
Some antibodies, particularly BO3, had very low concentrations even after this 
process. This resulted in the antibodies all being screened at 2µg/ml to allow for 
a fair comparison of the binding capabilities of all six antibodies. 
3.2.3   Combinatorial Glycoarray Screening  
 
Screening studies commonly use complexes in 1:1 w:w configurations; however, 
these do not take into consideration the differences in the molar ratios, which 
will vary substantially depending upon the molecular weights of the individual 
lipids. This may have a significant impact upon the comparability of the 
different complexes to one another but this effect has yet to be examined 
experimentally (Galban-Horcajo et al., 2013). To ensure that this was not being 
overlooked in this study, the antibodies were screened against lipids printed in 
both 1:1 w:w and 1:1 mol:mol arrangements. All experiments were performed 
using the combinatorial glycoarray as per Section 2.4.5. Signals were given in 
arbitrary units of fluorescence for both the single and complex epitopes. To best 
represent cis-enhancement and cis-inhibition the signals of the single 
constituent lipids were both subtracted from the dimer complex signal and then 
graphed. Negative values indicated cis-inhibition while positive values indicated 
cis-enhancement. Due to the non parametric nature of the data and the limited 
number of independent experiments, statistical analysis was not performed.   
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3.2.3.1 BO1 
 
Under these conditions, BO1 did not appear to bind particularly well to the 
single ganglioside species in either array configuration (Table 3.2 and Figure 
3.1). Signals could be detected to GM1 and associated complexes if the scanners 
PMT or the antibodies concentration was increased but the signals were still 
relatively weak (data not shown). 
 The only antigens that did produce strong signals were GA1:Chol, GA1:GalC and 
GA1:sulfatide. In the w:w configuration, they displayed respective values of 
7056, 14714 and 8501 FI units, whilst in the mol:mol configuration they 
displayed values of 35517, 631 and 4184 FI units.  
Comparisons of the different array configurations found that there were 
particularly large differences between the same complexes. This was most 
apparent with GA1:Chol, which in the mol:mol configuration had a signal that 
was approximately 28000 FI units higher than the w:w signal.  
These differences appeared to be related to the amount of Chol that was 
present in the complexes. GA1:Chol w:w was the equivalent of 1:3.23 mol:mol 
so the complex contained a lower proportion of Chol than the other 
configuration. This resulted in lower binding signals, suggesting that BO1 
preferentially binds to gangliosides in a Chol rich microenvironment.    
Similarly, when GA1 was in complex with GalC and sulfatide, it produced higher 
signals with the w:w lipids, which had the equivalent molar ratios of 1:1.5 and 
1:1.4 respectively. This suggested that increased number of accessory lipids, 
such as GalC or sulfatide, also improved antibody binding.  
3.2.3.2 BO3 
 
BO3 was derived from the same patient as BO1 but showed a stronger binding 
pattern to GM1 and GM1 complexes at the same concentration. It bound the 
single GM1 antigen with median signals of 13385 and 11777 FI units in the w:w 
and mol:mol arrays respectively.(Table 3.3 and Figure 3.2) Both configurations 
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Table 3-2 – Median Binding Values of BO1 to Ganglioside Complexes 
  GM1 GA1 Chol GalC Sulfatide GA1:Chol GA1:GalC GA1:Sulfatide 
w:w 989 1352 26 75 77 7056 14714 8501 
mol:mol 617 1708 0 51 0 35517 631 4184 
 
 
Figure 3.1 – BO1 Characterisation against Ganglioside Complexes 
BO1 (2µg/ml) was screened against a panel of lipids with complexes in a 1:1 w:w 
or 1:1 mol:mol ratio, with the exception of cholesterol which was in a 1:5 
mol:mol ratio. A: A representative blot indicates the binding pattern of the 
antibody. B: Graphs indicate the fluorescent intensity values produced by BO1 to 
different antigens in w:w (black) and mol:mol (red) configurations. Complex 
signals were calculated by subtraction of both constituent single lipid values 
from the dimer complex signal. Each dot indicates the mean of each repeat. BO1 
had weak signals to all single ganglioside antigens but was strongly enhanced 
with GA1:Chol, GA1:GalC and GA1:sulfatide in the w:w array and GA1:Chol and 
GA1:sulfatide in the mol:mol array.   
A
B
GM1 GD1a GD1b GT1b GA1 GD3 Chol GalC Sulfatide
X
GM1 X
GD1a X
GD1b X
GT1b X
GA1 X
GD3 X
Chol X
GalC X
Sulfatide X
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showed slight enhancement when GM1 was in complex with Chol, whilst all other 
GM1 complexes were neutral or inhibitory.  
BO3 also bound to the single GA1 antigen displaying median signals of 4077 and 
7115 FI units in the w:w and mol:mol arrays. GA1:sulfatide complexes enhanced 
antibody binding in both array configurations, displaying approximate median 
signals of 11000 FI units. Complexes containing Chol similarly enhanced BO3 
binding in the mol:mol array, whilst in the w:w array they had no effect. 
There was also binding to the single GD1b antigen, which displayed median 
signals of approximately 6000 FI units in both array configurations. Unlike GM1 
and GA1, however, there was no enhanced antibody binding with GD1b 
complexes.     
A common inhibitory signal was seen with GM1, GA1 and GD1b when the 
gangliosides were in complex with either GD1a or GT1b. Unlike other lipids, 
which attenuate binding when in complexes, GD1a and GT1b completely 
abolished the binding signals altogether, giving approximate raw readings of 0 FI 
units.  
Table 3-3 – Median Binding Values of BO3 to Ganglioside Complexes 
 
 
A comparison of both array configurations showed results similar to those seen 
with BO1 binding. The only major differences were with complexes containing 
Chol, which enhanced BO3 binding more in the mol:mol arrays. As described 
with BO1 binding, this could be attributed to the increased concentration of Chol 
producing an enhanced signal. 
 
 
- GM1 GD1a GD1b GT1b GA1 GD3 Chol GalC Sulfatide
w:w GM1 13385 - -12820 -14363 -13385 -13337 -12628 1560 -3295 883
mol:mol GM1 11777 - -10317 -13319 -11582 -11247 -10619 6146 -5330 -1642
w:w GA1 4077 -11247 -4066 -9456 -4077 - -1643 11485 -3044 11868
mol:mol GA1 7115 -13337 -5422 -7068 -6758 - -5920 -5872 -4812 11515
w:w GD1b 6262 -14363 -5545 - -6262 -7068 -5773 -5113 -4824 -1652
mol:mol GD1b 6121 -13319 -5535 - -6121 -9456 -6031 -4715 -3803 -1216
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Figure 3.2 - BO3 Characterisation against Ganglioside Complexes 
BO3 (2µg/ml) was screened against a panel of lipids with complexes in a 1:1 w:w 
or 1:1 mol:mol ratio, with the exception of cholesterol which was in a 1:5 
mol:mol ratio. A: A representative blot indicates the binding pattern of the 
antibody. B: Graphs indicate the fluorescent intensity values produced by BO3 to 
different antigens in w:w (black) and mol:mol (red) configurations. Complex 
signals were calculated by subtraction of both constituent single lipid values 
from the dimer complex signal. Each dot indicates the mean of each repeat. BO3 
bound to the single GM1, GA1 and GD1b antigens. It was enhanced by GM1:Chol, 
GA1:Chol and GA1:sulfatide complexes.   
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Figure 3.3 – BR1 Characterisation against Ganglioside Complexes 
BR1 (2µg/ml) was screened against a panel of lipids with complexes in a 1:1 w:w 
or 1:1 mol:mol ratio, with the exception of cholesterol which was in a 1:5 
mol:mol ratio. A: A representative blot indicates the binding pattern of the 
antibody.B: Graphs indicate the fluorescent intensity values produced by BR1 to 
different antigens in w:w (black) and mol:mol (red) configurations. Complex 
signals were calculated by subtraction of both constituent single lipid values 
from the dimer complex signal. Each dot indicates the mean of each repeat.  
BR1 showed a strong response to GM1 and GM1 in complex with Chol, GalC and 
sulfatide. It also bound GA1 and GA1 sulfatide in both array configurations and 
GA1-Chol in the mol:mol array. The antibody bound to GD1b but was inhibited by 
all associated complexes. 
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3.2.3.3 BR1 
 
BR1 showed a much stronger GM1 signal than either BO1 or BO3 under the same 
conditions (Table 3.4 and Figure 3.3). In the w:w array the single antigen 
displayed a median signal of 30931 FI units and showed enhancement when in 
complex with Chol and GalC. A similar result was shown in the mol:mol array, 
with the single GM1 antigen displaying a median signal of 22344 FI units, which 
was also enhanced by  Chol and GalC. As with BO3, the antibody binding signal 
was almost completely abolished when GM1 was in complex with GT1b and GD1a 
and to a lesser degree when it was in complex with GD3.  
Table 3-4 – Median Binding Values of BR1 to Ganglioside Complexes 
 
 
This was similarly found with GA1, where BR1 binding was inhibited in the 
presence of GD1a or GT1b. The antibody bound the single GA1 antigen in both 
arrays with low signals and was only enhanced in the w:w array when GA1 was in 
complex with sulfatide, whilst in the mol:mol array there was an enhancement 
with both sulfatide and Chol.  
The GD1b signals for both arrays were comparable to the signals found with GA1 
binding.  Unlike with GA1 though, all complexes with GD1b were inhibitory in 
both array configurations. 
The largest difference between arrays was again with GM1:Chol and GA1:Chol, 
which produced higher binding  signals in the mol:mol configuration. As 
previously stated, the higher amount of cholesterol present in the mol:mol array 
appeared to enhance the binding of the antibody to gangliosides.  
3.2.3.4 DO1 
 
DO1 was the only antibody derived from a GBS patient (Table 3.5 and Figure 
3.4). In the w:w array, it bound GM1 with a median signal of 9614 FI units, whilst  
- GM1 GD1a GD1b GT1b GA1 GD3 Chol GalC Sulfatide
w:w GM1 30931 - -24709 -21532 -29705 -15250 -20632 2042 1869 -8246
mol:mol GM1 22344 - -15756 -19534 -22223 -9918 -13483 11640 5186 631
w:w GA1 6627 -15250 -4706 -6421 -6434 - -3145 -2765 -3777 10387
mol:mol GA1 4114 -9918 -4114 -3782 -4114 - 1253 11348 -2491 13928
w:w GD1b 7429 -21532 -6374 - -7429 -6421 -6931 -3286 -5204 -5519
mol:mol GD1b 5105 -17794 -11733 - -17576 -21609 -13644 -12453 -3687 -18674
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in the mol:mol array it had a median signal of 15378 FI units. Unlike the other 
antibodies, DO1 was not enhanced when GM1 was in complex with either Chol or 
sulfatide.  
The antibody bound GA1 in the w:w array and mol:mol array with median signals 
of 17493 and 7629 FI units respectively. An enhancement was seen with 
GA1:sulfatide in the mol:mol array but this was not replicated in the w:w array. 
As with the other antibodies, there was a large enhancement when GA1 was in 
complex with cholesterol in the mol:mol array, displaying a median signal of 
34010 FI units. This was higher than both the single antigen and the other 
complexes including GA1-sulfatide. This same enhancement was not seen in the 
w:w array.  
Table 3-5 – Median Binding Values of DO1 to Ganglioside Complexes 
 
DO1 also bound GD1b displaying median signals of 25572 and 18731 FI units in 
the w:w and mol:mol arrays respectively. As with the other antibodies, this 
binding was inhibited when GD1b was in complex with any other lipid.   
Complexes containing GD1a or GT1b were again inhibitory with DO1 binding, as 
described with BO3 and BR1. A similar inhibition was shown with GD3 to a lesser 
degree in which complexes containing the ganglioside consistently displayed raw 
signals of 5000 FI units or less. 
Comparisons of the binding fingerprints of DO1 between arrays configurations 
showed higher binding to GA1:Chol and GA1:sulfatide in the mol:mol array 
compared to the w:w array. This again suggested that the higher cholesterol 
content in the GA1-Chol complex enhanced the binding capability of the 
antibody. The increased binding to GA1:sulfatide was unexpected as the mol:mol 
array contained a smaller amount of sulfatide than the w:w array. It was 
possible that DO1 preferentially bound to the complex with less sulfatide but, as 
the differences between the arrays were small, no definitive conclusions could 
be drawn from this data. 
- GM1 GD1a GD1b GT1b GA1 GD3 Chol GalC Sulfatide
w:w GM1 9614 - -7577 -12499 -8923 -8260 -5425 -7469 -5512 -11284
mol:mol GM1 15378 - -8991 -17794 -14946 -12033 -6060 -6118 -11755 -9859
w:w GA1 17493 -8260 -8521 -28428 -17006 - -9102 -3668 -11580 -515
mol:mol GA1 7269 -12033 -7269 -21609 -7269 - -3169 31717 -5368 8258
w:w GD1b 25572 -12498.5 -19057 - -23984 -28428 -19794 -11445 -16216 -13344
mol:mol GD1b 18731 -17794 -11733 - -17576 -21609 -13644 -12453 -3686.5 -18674
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Figure 3.4 - DO1 Characterisation against Ganglioside Complexes  
DO1 (2µg/ml) was screened against a panel of lipids with complexes in a 1:1 w:w 
or 1:1 mol:mol ratio, with the exception of cholesterol which was in a 1:5 
mol:mol ratio. A: A representative blot indicates the binding pattern of the 
antibody. B: Graphs indicate the fluorescent intensity values produced by DO1 to 
different antigens in w:w (black) and mol:mol (red) configurations. Complex 
signals were calculated by subtraction of both constituent single lipid values 
from the dimer complex signal. Each dot indicates the mean of each repeat.  
DO1 bound to GM1 but was not enhanced by any GM1 complexes. It also bound 
GA1 and GA1 sulfatide in both array types and GA1-Chol in the mol:mol array. 
The antibody bound to GD1b but was inhibited associated complexes. 
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Table 3-6 - Median Binding Values of SM1 to Ganglioside Complexes 
 
 
Figure 3.5 - SM1 Characterisation against Ganglioside Complexes  
SM1 (2µg/ml) was screened against a panel of lipids with complexes in a 1:1 w:w 
or 1:1 mol:mol ratio, with the exception of cholesterol which was in a 1:5 
mol:mol ratio. A: A representative blot indicates the binding pattern of the 
antibody. B: Graphs indicate the fluorescent intensity values produced by SM1 to 
different antigens in w:w (black) and mol:mol (red) configurations. Complex 
signals were calculated by subtraction of both constituent single lipid values 
from the dimer complex signal. Each dot indicates the mean of each repeat.   
SM1 bound to GM1 in both array configurations but was not enhanced by GM1 
complexes. The antibody similarly bound the single GA1 antigen but was not 
enhanced by any GA1 complexes.  
 
- GM1 GD1a GD1b GT1b GA1 GD3 Chol GalC Sulfatide
w:w GM1 17421 - -15479 -13582 -15957 -17705 -11201 -2096 -4780 -1877
mol:mol GM1 24372 - -20470 -22665 -23328 -15468 -19067 -1186 -5859 -6009
w:w GA1 20884 -17705 -20745 -20559 -20764 - -20717 -16845 -24809 -9292
mol:mol GA1 12829 -15468 -12659 -5374 -12741 - -10277 -2501 -15632 -1735
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3.2.3.5 SM1 
 
SM1 bound well to GM1 in both array configurations displaying median signals of 
17421 and 24372 FI units in the w:w and mol:mol arrays respectively (Table 3.6 
and Figure 3.5). Neither array showed a median cis-enhancement with GM1 
complexes, although both had at least one repeat where a complex containing 
Chol, GalC or sulfatide was enhanced.  
A similar result was seen with GA1, where the single antigen produced a high 
signal in both arrays that was not enhanced by any GA1-complexes. SM1 also 
differed from BO3, BR1 and DO1 as it did not bind the single GD1b epitope at all.  
A comparison between array configurations did not show any clear differences. It 
should be noted, however, that although GA1:Chol did not produce an 
enhancement, it did have a higher signal in the mol:mol array compared to the 
w:w array, which is similar to the results seen with the other antibodies. 
3.2.3.6 WO1 
 
Under these conditions, WO1 showed a poor response to GM1, displaying FI 
medians of 925 and 6235 in the w:w and mol:mol arrays respectively (Table 3.7 
and Figure 3.6). Little enhancement was seen in either array configuration, with 
most complexes showing similarly low signals as those of the single antigen. The 
only enhanced signal was found with GM1:Chol in the mol:mol array, which was 
higher than the single antigen and the other complexes. 
Table 3-7 - Median Binding Values of WO1 to Ganglioside Complexes 
 
The antibody produced a much stronger response to GA1 than GM1, displaying FI 
medians of 25543 and 19925 in the w:w and mol:mol array respectively. In the 
w:w arrays this signal was enhanced when GA1 was in complex with Chol and 
GalC. In the mol:mol array, the only enhancement was with GA1:Chol. 
- GM1 GD1a GD1b GT1b GA1 GD3 Chol GalC Sulfatide
w:w GM1 925 - 430 1391 -365 -18103 981 915 578 3212
mol:mol GM1 6235 - -3198 -4605 -5245 -19863 -3434 12070 -2601 -398
w:w GA1 25543 -18103 -19814 -20118 -25423 - -21925 17421 28150 -12839
mol:mol GA1 19925 -19863 -19914 -11094 -19925 - -16848 40803 -1105 -1657
w:w GD1b 1961 1390.5 -1961 - -1961 -20118 -1961 11998 -3136 -1059
mol:mol GD1b 1566 -4605 -1424 - -1566 -11094 -1307 7542 -1605 -865
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Figure 3.6 – WO1 Characterisation against Ganglioside Complexes 
WO1 (2µg/ml) was screened against a panel of lipids with complexes in a 1:1 
w:w or 1:1 mol:mol ratio, with the exception of cholesterol which was in a 1:5 
mol:mol ratio. A: A representative blot indicates the binding pattern of the 
antibody. B: Graphs indicate the fluorescent intensity values produced by WO1 
to different antigens in w:w (black) and mol:mol (red) configurations. Complex 
signals were calculated by subtraction of both constituent single lipid values 
from the dimer complex signal. Each dot indicates the mean of each repeat.   
WO1 bound poorly to GM1 but showed a good signal to the single GA1 epitope 
and GA1-Chol in both array configurations. It also had poor GD1b reactivity but 
shown enhancement with the GD1b-Chol complex. 
GA1 & ComplexesGM1 & ComplexesB
GD1b & Complexes
A GM1 GD1a GD1b GT1b GA1 GD3 Chol GalC Sulfatide
X
GM1 X
GD1a X
GD1b X
GT1b X
GA1 X
GD3 X
Chol X
GalC X
Sulfatide X
Chapter 3 – ARRAY SCREENING OF HUMAN MONOCLONAL ANTIBODIES 83 
 
There was little binding to the single GD1b epitope but unlike the other 
antibodies, WO1 was enhanced when GD1b was in complex with Chol in both the 
w:w and mol:mol arrays. 
A comparison between the two array configurations showed a larger 
enhancement to GM1:Chol and GA1:Chol in the mol:mol array compared to the 
w:w array, which was consistent with the results of the other antibodies. In 
contrast, the w:w array showed a larger enhancement with GA1:GalC and 
GD1b:Chol which was unique to WO1 alone.  
3.2.3.7 Galactocerebroside and Sulfatide Binding 
 
GalC and sulfatide are closely associated with lipid rafts and are major 
components of the myelin sheath. Many anti-carbohydrate antibodies have been 
found to cross react to these lipids due to the presence of specific binding sub 
domains (Alving, 1986). 
The single species and complexes composed of both glycolipids are also targets 
of auto-antibodies in their own right and were included in the array to 
determine if the human monoclonal antibodies were cross reactive with their 
structures (Table 3.8 and Figure 3.7).   
At 2µg/ml  BO1 and CTx showed little or no binding to either GalC, sulfatide or 
GalC:sulfatide complexes, whilst WO1 showed a small signal to the single GalC 
species in both array configurations. BO3 did not bind the single species in either 
array but showed enhancement to the GalC:sulfatide complex in the w:w array 
displaying a median signal of 8937 FI units. This enhancement was not replicated 
in the mol:mol array. A similar result was seen with BR1 which shown little 
reactivity to the single antigens but was enhanced with the GalC:sulfatide 
complex displaying values of 5733 and 13831 FI units in the mol:mol and w:w 
arrays respectively. 
DO1 did not show any binding to the single GalC epitope but did bind to sulfatide 
displaying an approximate median signal of 11000 FI units in both array 
configurations. This signal was enhanced with the GalC:sulfatide complex 
displaying median signals of 15791 and 6910 FI units in the mol:mol array and 
w:w arrays respectively.  
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Table 3-8 – Median Binding Values of Human Monoclonal Antibodies to Sulfatide and 
GalC Complexes 
 
 
Figure 3.7 – GalC:sulfatide Complexes 
All 6 human monoclonals and CTx were screened against GalC (black), sulfatide 
(blue) and GalC:sulfatide complexes (red) which were printed in either 1:1 w:w 
or 1:1 mol:mol configurations. Each spot represents the mean of each repeat 
and the complex value represents the complex signal minus both the single 
constituent values. In the w:w array BR1 and DO1 bound to the single sulfatide 
antigen,  whilst SM1, BR1 and DO1 bound to the single GalC antigen. The binding 
signals of BO3, BR1, and DO1 were enhanced with GalC:sulfatide complexes but 
SM1 was attenuated by GalC:sulfatide complexes. In the mol:mol array SM1 and 
WO1 bound to GalC, DO1 bound to sulfatide and BR1 and DO1 bound to 
GalC:sulfatide complexes. The SM1 binding signal was attenuated by 
GalC:sulfatide complexes. 
 
SM1 differed from the other antibodies as it bound to the single GalC species in 
both array configurations, while showing little or no binding to the single 
sulfatide antigen. The GalC binding signal was completely attenuated in the 
presence of sulfatide (GalC:sulfatide complex).  
BO1 BO3 BR1 DO1 SM1 WO1 CTx
w:w GalC 75 134 1204 91 6407 1975 0
mol:mol GalC 51 67 306 7 6598 1547 147
w:w Sulfatide 77 4 1865 11245 10 42 428
mol:mol Sulfatide 0 25 113 11739 0 5 749
w:w GalC:Sulfatide 121 8937 13831 6910 -6252 -1742 -163
mol:mol GalC:Sulfatide -34 290 5733 15791 -6598 -1393 -700
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3.2.3.8 Cholera Toxin 
 
Cholera toxin (CTx) is commonly used as a marker of GM1 but is known to bind to 
other gangliosides including GA1, GD1a, GM2, GD1b and GT1b (Kuziemko et al., 
1996).  When these antibodies were first cloned they were screened against 
human tissue and characterised as either being CTx like or CTx unlike in their 
binding behaviour (O’Hanlon et al., 1998).  
Cholera toxin conjugated to Alexa-fluor 647 was therefore screened on the 
combinatorial glycoarray at 2µg/ml to establish its binding pattern and 
determine any similarities between it and the human monoclonal antibodies 
(Table 3.9 and Figure 3.8). As a result of the intense signals seen with CTx, the 
slides were scanned at a lower PMT (reduced amplification of the fluorescent 
signal) to allow for the full binding fingerprint to be elucidated.  
In both the array configurations CTx bound GM1 and GA1 with similar median 
values of approximately 10000 FI units. In the w:w array, GD1b also displayed a 
similar value whereas in the mol:mol array there was very little binding to the 
single GD1b antigen, which contained a higher proportion of ganglioside. This 
reduction in the binding signal may be attributed to a change in density, which 
affects the ability of CTx to bind.   
There was little or no inhibition of the binding signals with complexes except 
with GD1b, which was inhibited when in complex with any of the other lipids. 
The only enhancing complex was GA1:Chol,  which was higher than the single 
antigens in the mol:mol array. This enhancement was not seen in the w:w array. 
Cholera toxin differed from the human monoclonal antibodies as it bound to 
complexes containing GD1a as well as the single GD1a antigen displaying 
medians of approximately 10000 FI units. Under these conditions it did not bind 
GT1b even though this had previously been reported (Kuziemko et al., 1996). To 
ensure the validity of the stock of GT1b, it was tested against an in house mouse 
antibody targeting the ganglioside and was shown to bind successfully. The 
absence of CTx binding on the combinatorial glycoarray was therefore surprising 
but may have been related to differences in lipid concentration or density in the 
array format.   
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Table 3-9 - Median Binding Values of Cholera Toxin to Ganglioside Complexes 
 
 
Figure 3.8 – Cholera Toxin Binding Profile 
CTx (2µg/ml) ) was screened against a panel of lipids with complexes in a 1:1 
w:w or 1:1 mol:mol ratio, with the exception of cholesterol which was in a 1:5 
mol:mol ratio. A: A representative blot indicates the binding pattern of the 
antibody. B: Graphs indicate the fluorescent intensity values produced by CTx to 
different antigens in w:w (black) and mol:mol (red) configurations. Complex 
signals were calculated by subtraction of both constituent single lipid values 
from the dimer complex signal. Each dot indicates the mean of each repeat.   In 
the w:w array CTx bound with similar values to GM1, GD1a, GD1b and GA1 with 
little or no complex enhancement or inhibition. In the mol:mol array CTx 
similarly bound to GM1, GD1a and GA1 but not GD1b. There was little complex 
enhancement except for GA1-Chol. 
GM1 GD1a GD1b GA1 GA1:Chol
w:w 8836 9238 7290 14076 -1803
mol:mol 11511 8503 1003 13425 16203
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GT1b X
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Overall, there was no apparent difference between the CTx like (BO3, SM1, 
WO1) and the CTx unlike (BO1, BR1, DO1) antibodies, nor was there anything 
unusual about the CTx binding fingerprint. The differences between the tissue 
binding properties of the two groups must therefore be related to the presence 
of other lipids or proteins in the natural lipid raft environment, which were not 
examined in this study. 
3.3 Discussion 
 
The use of the combinatorial glycoarray allowed for a more robust screening of 
the human monoclonal antibodies than had previously been performed. By 
incorporating different ganglioside and glycolipid complexes, it was possible to 
establish how the presence of different lipids could influence the binding 
behaviour of antibodies, which is more akin to the lipid membrane environment.  
As reported previously, the presence of GD1a in complexes inhibits the binding 
of GM1 antibodies in mouse peripheral nerve (Greenshields et al., 2009).This was 
also found to be true with all six human monoclonal antibodies which had FI 
values of 0 when screened against any complexes containing GD1a. Greenshields 
et al hypothesised that this could be caused by the interaction between the 
glycosphingolipid hydroxyl groups in the gangliosides, which would act as 
hydrogen donors between the molecules. This interaction would result in a 
change in the conformation of GM1 which would become cryptically hidden from 
the immune system. 
A similar inhibitory effect was seen in this experiment, when antibodies were 
probed against complexes that contained GD1a and GT1b. Both GD1a and GT1b 
differ from the other gangliosides screened as they share a sialic acid on their 
terminal galactose. As sialic acids contain several hydroxyl groups it is plausible 
that these interact with the GM1/GA1/GD1b molecules to mask their antibody 
binding epitope through steric hindrance.  
In contrast, the presence of non ganglioside accessory lipids appeared to 
enhance the binding signals of the various antibodies. This was shown through 
the comparisons between the mol:mol and w:w arrays, which indicated that 
antibody binding improved in varying degrees when higher amounts of Chol, GalC 
or sulfatide were present in complexes. As these are all found in lipid rafts it 
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could be assumed that their presence more closely imitates the natural cellular 
environment, which improves the ability of the antibodies to bind.  
Recent work has shown that the presence of these lipids can modify the 
ganglioside head group orientation and thus enhance or inhibit their 
presentation to the immune system. This has been shown in particular with 
cholesterol, which is almost entirely buried in the plasma membrane except for 
a hydroxyl group which protrudes into the exoplasm. This hydroxyl group can 
interact with glycosphingolipids to form complexes, which have been shown to 
enhance the binding of certain toxins, proteins and recently anti-ganglioside 
antibodies (Fantini & Yaho, 2013; Galban-Horcajo et al., 2014; Mahfoud et al., 
2010).  
Alternatively, it is possible that the presence of greater number of accessory 
lipids improves the spacing between the gangliosides. When screened as single 
antigens, it is often assumed that the gangliosides exist as single standalone 
epitopes that are free to interact with antibodies. The different hydroxyl groups 
within the various molecules, however, are likely to interact with one another 
and thus change the presentation of the head groups. This has been explored 
previously in work that suggested that the presence of different lipids such as 
DPPC alters the phase behaviour of GM1 to form condensed domains which 
modifies molecular packing (Frey et al., 2008). Other work has also suggested 
that cholesterol can interfere with interactions between headgroups of other 
lipids by acting as a spacer molecule (Kucerka et al., 2007). With respect to this 
work, it is possible that the presence of accessory lipids may interfere with 
interactions between ganglioside head groups and thus open up them up to 
interactions with antibodies.  
Aside from gangliosides, it was also noted that many of the antibodies cross 
reacted to sulfatide and GalC. Previous research has shown that anti-ganglioside 
antibodies commonly bind to these glycolipids in solid phase assays, due to the 
presence of specific binding domains (Alving & Richards, 1977; Townson, 
Greenshields, et al., 2007). This phenomenon may not be relevant in disease, 
however, as the antibodies are unable to bind these glycolipids if they have been 
incorporated into plasma membranes.  
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Examination of the glycoarray blots from this experiment may offer an 
explanation for this behaviour, as the antibodies were unable to bind either GalC 
or sulfatide when they were in complex with most other lipids. It would 
therefore be highly improbable that the antibodies would bind to these antigens 
in vivo, as the glycolipids would be unlikely to be found naturally in standalone 
formations.  
Although this chapter provided a fresh insight into the binding behaviours of the 
human monoclonal antibodies, it also raised questions about a previously 
unexplored aspect of neuroimmunology research. It was noted, through the use 
of the two different array configurations, that the concentration of lipids in 
complexes could drastically alter the binding signals of the antibodies. 
Current screening methods, however, only employ complexes in 1:1 w:w 
configurations, raising the possibility that they are unable to detect low levels of 
particular antibodies. To address this issue, the binding behaviours of the 
antibodies would need to be assessed against complexes containing a range of 
different lipid concentrations, which is a concept that is further explored in 
Chapter 4.    
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4 ACCESSORY LIPID COMPLEXES 
 
4.1 Introduction 
 
Clinical assays acts as supportive tools in the diagnosis of inflammatory 
neuropathies with ELISA acting as the current gold standard. The established 
method for ELISA involves coating plates with single gangliosides to identify 
specific anti-ganglioside antibodies (Willison et al., 1999). The drawback of this 
method is that gangliosides would not be naturally found in standalone 
formations in the plasma membrane. They would be clustered with other lipids 
and proteins in liquid ordered (lipid rafts) and liquid disordered domains, which 
would alter their presentation and thus their ability to bind antibodies 
(Hammond et al., 2005; Sonnino et al., 2007).  
Although the exact mechanism of disease has not been elucidated in GBS or 
MMN, research has suggested that antibodies are able to exert pathogenic 
effects via specific binding to lipid rafts (Ueda et al., 2010). These rafts contain 
higher proportions of certain lipid containing molecules such as gangliosides, 
Chol and SM compared to the liquid disordered phase, which contain high 
amounts of other lipids such as PC (Brown & Rose, 1992; Pike et al., 2002). 
There are also other lipids that are enriched in rafts but their presence is 
dependent upon the function and state of the cells in which they are contained. 
GalC and sulfatide for example, are enriched within the lipid rafts of myelin 
where they aid in the transportation of myelin proteins, whereas PS is enriched 
in the rafts of apoptotic or necrotic cells, which aids in their clearance by 
macrophages (DeBruin et al., 2005; Simons et al., 2000). 
The cis-interactions of these raft lipids with gangliosides have been explored 
from an immunological viewpoint by autoimmune neuropathy researchers 
(Galban-Horcajo et al., 2013; Rinaldi et al., 2013). They identified a subset of 
antibodies in patient sera, which were either enhanced in the presence of these 
ganglioside:lipid complexes or were only capable of binding in their presence. 
This led to the hypothesis that the antibodies were binding to a neo-epitope, 
which is a unique structural epitope formed by components of both lipids.  
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These neo-epitopes would possibly account for the discrepancy between the 
presence of gangliosides in a large number of tissues and the limited injury 
experienced in autoimmune neuropathies (Gong et al., 2002; Svennerholm et al., 
1992, 1994). For example in MMN, in which patients frequently have anti-GM1 
antibodies, it could be postulated that pathogenic antibodies would bind 
exclusively to complexes consisting of GM1 and those lipids that are enriched 
within myelin such as GalC or sulfatide (Norton & Cammer, 1984).This would 
explain why other GM1 enriched tissues remain unaffected in the disease as the 
absence of the other lipids would prevent formation of the complex.  
Whilst this hypothesis is valid, it is reliant upon the formation of neo-epitopes, 
which is a concept that has never been demonstrated at a molecular level 
(Harschnitz et al., 2014). In contrast, the concept of conformational modulation, 
in which lipids in the microenvironment influence the presentation of the 
ganglioside, has much more compelling evidence, having been demonstrated 
both experimentally as well as in modelling studies (Fantini & Yaho, 2013; 
Lingwood et al., 2011). The distinguishing feature in this theory is that the lipids 
are not incorporated into the binding epitope themselves but are merely 
responsible for its exposure on the gangliosides. As such, the lipids in this 
process are referred to as accessory lipids.  
By altering the orientation of the ganglioside, these accessory lipids would 
directly influence the concealment or exposure of different binding epitopes, 
which would affect the binding capabilities of different anti-ganglioside 
antibodies (P. Lopez et al., 2006). This suggests that the composition of the 
ganglioside microenvironment, not only influences which antibodies can bind, 
but also which tissues are vulnerable to immune mediated injury.  
A prime example of this was shown in Chapter 3 where the human monoclonal 
antibodies were shown to bind preferentially to ganglioside complexes 
containing Chol, GalC or sulfatide. These lipids are enriched in myelinating cells, 
which would suggest that the antibodies arose to preferentially target 
ganglioside epitopes that are uniquely presented in myelin rich tissues. This 
suggestion corresponded well with the known source of the antibodies, which 
were MMN patients. As MMN is a demyelinating condition, it is cogent to assume 
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that patient antibodies would bind and injure the myelin sheath, whilst leaving 
other tissues unaffected (Krämer et al., 1999; Lee, 2001).  
In addition to their presence, another aspect relating to accessory lipids was 
found during the experiments in Chapter 3. Comparisons of the different array 
configurations indicated that the antibodies appeared to bind preferentially to 
complexes containing higher proportions of accessory lipids. 
 This was an interesting finding as our previous research has tended to focus on 
screening antibodies against complexes in uniform ratios (Galban-Horcajo et al., 
2013; Rinaldi et al., 2013). The drawback of screening sera in this fashion is that 
it does not take into account that the concentrations of lipids will presumably 
differ in rafts in relation to their function and location. This will likely have an 
impact upon how they interact with gangliosides and thus how certain epitopes 
will be presented for antibody binding. This would also have ramifications in the 
effectiveness of sera studies, which may be overlooking the detection of certain 
antibodies that can only bind to complexes containing higher proportions of 
accessory lipids.  
To further address the roles that these lipids have in complexes, an experiment 
was devised to examine the binding of the human monoclonal antibodies to 
ganglioside complexes containing a variety of raft and non raft lipids in 
increasing proportions. These included Chol, GalC, sulfatide, PS, SM, and PC. It 
was hypothesised that increased binding signals would be detected against 
complexes containing higher proportions of raft rich lipids common to the myelin 
sheath, whereas non raft lipids would be expected to have only a minimal 
effect.  
4.2 Results  
4.2.1 Accessory Lipid Arrays 
 
All experiments were performed using the combinatorial glycoarray as per 
Section 2.4.5. Each array consisted of single lipid targets and complexes 
composed of the gangliosides and lipids in molar ratios. These were all prepared 
as per Section 2.3.1. The number of moles of ganglioside remained constant 
throughout the experiment and were 6.39x10-12, 7.96x10-12 and 5.47x10-12 for 
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GM1, GA1 and GD1b respectively. The 1:1 complexes consisted of the same 
number of moles of accessory lipids as the gangliosides and these doubled in 
each corresponding complex to produce ratios of 1:2. 1:4, 1:8, 1:16 and 1:32. 
Complexes were not printed at higher ratios as the excess lipid was found to 
interfere with the ability of the TLC printer to accurately dispense the lipid 
solution.  
To best represent cis-enhancement and cis-inhibition the signals of the single 
constituent lipids were both subtracted from the dimer complex signal and then 
graphed. Negative values indicated cis-inhibition while positive values indicated 
cis-enhancement. The experiments were performed five times and analysed 
using a Kruskal-Wallis test followed by Dunn’s multiple comparisons. 
4.2.1.1 Chol Complexes 
 
The different array configurations in Chapter 3 indicated that the human 
monoclonal antibodies bound better to ganglioside complexes that contained a 
higher proportion of Chol. As Chol is the most abundant lipid in mammalian cell 
membranes (Bloch, 1991), it was hypothesised that further increasing its 
proportion in complexes would lead to the detection of even higher binding 
signals.  
This was confirmed to varying degrees within this experiment; with some 
antibodies producing substantially higher binding signals, whilst others showed 
more subdued increases (Figure 4.1). In general, the largest binding signal 
enhancements of each antibody were found to be against their main target 
antigen as originally established by ELISA (Table 3.1). 
An example of this was the antibody BO1, which had previously been shown by 
ELISA and combinatorial glycoarray to primarily target GA1 and GA1 complexes 
(Willison et al., 1994). In this experiment, BO1 followed a similar pattern and 
produced considerably higher binding signals against GA1:Chol complexes 
compared to those composed of GM1 or GD1b.  
Based upon their target antigens, the antibodies were found to follow a general 
pattern, where increasing the proportion of Chol in complexes led to an increase 
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Figure 4.1 – Binding of Human Monoclonal Antibodies to Chol Complexes 
The human monoclonal antibodies were screened against ganglioside:Chol 
complexes at various molar ratios. Representative blots indicate examples of 
concentration dependent (A) and concentration independent binding (B). 
Fluorescent intensity values for ganglioside complex enhancement or inhibition 
were calculated by subtraction of both constituent single lipid mean values from 
the mean complex signal. Each spot represents the mean of the repeat 
experiments. Positive signals indicate enhancement whilst negative signals 
denote inhibition (C). The relative binding signals were compared between each 
antibody and analysed using a Kruskal-Wallis test with Dunn’s multiple 
comparisons (n=5) (D). The binding signals of all the antibodies tended to 
increase as the proportion of Chol increased. At a 1:32 ratio, BO1, SM1 and WO1 
produced the highest binding signals and were significantly higher than both BO3 
and BR1 against different ganglioside:Chol complexes. DO1 was slightly 
enhanced with Chol ratios but to a lesser degree than the other antibodies 
(*=p<0.05), (**=p<0.01), (***=p<0.001). 
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in binding signal. For the majority of antibodies, this resulted in a 
ganglioside:Chol ratio of 1:32 being deemed optimal for antibody detection. The 
only exception to this was BR1, which was found to produce a peak binding 
signal for GM1:Chol complexes at a ratio of 1:8 that decreased in each 
subsequent complex.  
Examination of the binding signals at a 1:32 ratio indicated that the antibodies 
fell into two broad categories: those that were greatly enhanced and those that 
were to a lesser degree. Comparisons between the antibodies respective binding 
signals indicated that BO1, SM1 and WO1 showed the largest levels of 
enhancement, which were found to be significantly higher than those signals 
produced by BO3 and BR1 (Kruskal-Wallis test, Dunn’s multiple comparisons, 
P<0.05). These differences varied between complexes depending upon which 
ganglioside was present, but the BO3 and BR1 signals tended to remain low 
regardless of the composition of the complex. Other differences between 
antibodies, such as the statistically higher difference between WO1 and DO1 
compared to SM1 in the GD1b complexes, were attributed to the variability in 
ganglioside target antigens between antibodies.  
The only exception to this broad categorisation was DO1, which showed 
intermediate levels of enhancement with most complexes. The differences in 
the derivation of the antibodies may have accounted for this as DO1 was derived 
from an AMAN patient, whereas the other antibodies were derived from patients 
suffering from MMN.  Differences in epitope specificity would therefore be 
expected but there is not enough evidence from this data to draw any solid 
conclusions in regards to its binding behaviour.  
4.2.1.2 GalC Complexes 
 
As with Chol, the data in Chapter 3 showed that higher binding signals were 
detected against complexes containing higher proportions of GalC. As GalC is the 
most abundant glycolipid in the myelin sheath (Coetzee et al., 1996), it was 
hypothesised that further increasing its proportion in complexes would lead to  
the detection of even higher binding signals.  
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This hypothesis appeared to correlate well with the results from this 
experiment; however, the variation between antibodies was particularly high 
(Figure 4.2). In general, the binding signals followed the same pattern produced 
by the Chol complexes, with increased proportions of GalC producing increased 
binding signals. Again, the only exception to this was BR1, which produced an 
optimal signal with GM1:Chol complexes at a ratio of 1:8 that decreased in each 
subsequent complex.   
Unlike Chol complexes however, the increases in binding signals were not solely 
focussed on the main target antigen. Similar levels of enhancement were 
detected with all ganglioside:GalC complexes although the target antigen 
tended to produce the highest overall signal.    
The two broad categories described with the Chol complexes were similarly 
produced in this experiment; however the differences between the two groups 
were much more distinctive with GalC. A ratio of 1:32 was again optimal for 
producing the largest enhancements for the majority of antibodies. Statistical 
analysis between the antibodies at this ratio showed that the binding signals of 
BO1, SM1 and WO1 were significantly higher than BO3, BR1 and DO1 against a 
variety of complex compositions (Kruskal-Wallis test, Dunn’s multiple 
comparisons, P<0.05). The latter group of antibodies were found to produce 
consistently low binding signals regardless of the ratio of GalC present in the 
complex, which suggested that they bind to their targets independent of the 
modulating effect of GalC.  
4.2.1.3 Sulfatide Complexes 
  
In Chapter 3, sulfatide followed the same pattern as both Chol and GalC with 
complexes containing higher proportions producing higher binding signals. 
sulfatide is closely related to GalC and is similarly found in abundance in the 
myelin sheath (Coetzee et al., 1996). It was therefore hypothesised that it would 
produce a similar pattern to that seen with the GalC ratios, in that complexes 
containing increased proportions would result in increased binding signals.  
The data, however, did not fully support this hypothesis (Figure 4.3). Most 
antibodies did show an initial increase in their binding signals as the proportion 
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Figure 4.2 - Binding of Human Monoclonal Antibodies to GalC Complexes 
The human monoclonal antibodies were screened against ganglioside:GalC 
complexes at various molar ratios. Representative blots indicate examples of 
concentration dependent (A) and concentration independent binding (B). 
Fluorescent intensity values for ganglioside complex enhancement or inhibition 
were calculated by subtraction of both constituent single lipid mean values from 
the mean complex signal. Each spot represents the mean of the repeat 
experiments. Positive signals indicate enhancement whilst negative signals 
denote inhibition (C). The relative binding signals were compared between each 
antibody and analysed using a Kruskal-Wallis test with Dunn’s multiple 
comparisons (n=5) (D). The binding signals of all the antibodies tended to 
increase as the proportion of GalC increased. At a 1:32 ratio, BO1, SM1 and WO1 
produced the highest binding signals and were significantly higher than BO3, BR1 
and DO1 against different ganglioside:GalC complexes (*=p<0.05), (**=p<0.01), 
(***=p<0.001). 
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of sulfatide increased; however, this appeared to peak at a ratio of 1:4 for GA1 
complexes and 1:16 for GM1 and GD1b complexes, where the majority of the 
signals began to decrease again. Certain antibodies, such as BR1 and DO1, also 
bound to the single sulfatide antigens at higher concentrations, which further 
reduced their net binding signals. 
The optimal ratios were used to compare the binding signals of the different 
antibodies. The two categories, which had been described previously for both 
Chol and GalC, were not replicated with the sulfatide complexes. The antibodies 
instead tended to have similar binding signals, which only varied in regards to 
their target antigens. The only exception to this was DO1 which did not appear 
to be enhanced by sulfatide at any ratio.  
As mentioned previously, DO1 was derived from an AMAN patient whilst the 
other antibodies were derived from MMN patients. This may account for the 
differences in binding signal as AMAN is not a demyelinating disease and would, 
therefore, be unlikely to generate antibodies that would target gangliosides in 
environments enriched with myelin lipids.  
4.2.1.4  PS Complexes  
 
Ganglioside:PS complexes were not part of the original characterisation of the 
human monoclonal antibodies in Chapter 3, but were included within this 
experiment due to their previous association with antibodies in GBS (Rinaldi et 
al., 2013). As these complexes would be expressed on the membranes of 
necrotic or apoptotic cells (Hoffmann et al., 2001), it was hypothesised that 
they may be potential targets during ongoing neuropathy. Assuming that PS 
would be abundantly expressed on these cells due to pathological changes, it 
was also proposed that increasing the proportion of PS in the complex may lead 
to the detection of higher binding signals, due to increased interactions between 
the lipids and ganglioside headgroups.  
The data appeared to correspond well with this hypothesis, as complexes 
containing higher amount of PS were found to produce higher binding signals 
(Figure 4.4). For the majority of antibodies, similar signals were produced for  
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Figure 4.3 – Binding of Human Monoclonal Antibodies to Sulfatide Complexes 
The human monoclonal antibodies were screened against ganglioside:sulfatide 
complexes at various molar ratios. Representative blots indicate examples of 
concentration dependent (A) and concentration independent binding (B). 
Fluorescent intensity values for ganglioside complex enhancement or inhibition 
were calculated by subtraction of both constituent single lipid mean values from 
the mean complex signal. Each spot represents the mean of the repeat 
experiments. Positive signals indicate enhancement whilst negative signals 
denote inhibition (C). The relative binding signals were compared between each 
antibody and analysed using a Kruskal-Wallis test with Dunn’s multiple 
comparisons (n=5) (D). The binding signals of all the antibodies except DO1 
tended to increase as the proportion of sulfatide increased up to a point where 
binding began to decrease again. At high ratios some binding was detected to 
the single sulfatide. At a 1:16 ratio, SM1 was found to be significantly higher 
than DO1 in GM1:sulfatide complexes. In GA1:sulfatide complexes at a ratio of 
1:4 BO1 was found to be significantly higher than DO1 and SM1 (*=p<0.05), 
(**=p<0.01), (***=p<0.001). 
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Figure 4.4 - Binding of Human Monoclonal Antibodies to PS Complexes 
The human monoclonal antibodies were screened against ganglioside:PS 
complexes at various molar ratios. Representative blots indicate examples of 
concentration dependent (A) and concentration independent binding (B). 
Fluorescent intensity values for ganglioside complex enhancement or inhibition 
were calculated by subtraction of both constituent single lipid mean values from 
the mean complex signal. Each spot represents the mean of the repeat 
experiments. Positive signals indicate enhancement whilst negative signals 
denote inhibition (C). The relative binding signals were compared between each 
antibody and analysed using a Kruskal-Wallis test with Dunn’s multiple 
comparisons (n=5) (D). The binding signals of all the antibodies tended to 
increase as the proportion of PS increased up to an optimal ratio of between 
1:16 and 1:32. No discernible differences were detected between the antibodies 
except with BR1 which indicated very little enhancement. The only significant 
difference was between SM1 and BR1 in the GM1:PS complexes.  (*=p<0.05), 
(**=p<0.01), (***=p<0.001). 
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both GM1 and GA1 complexes; however, BO1 and DO1 were found to only 
produce high signals against one type of ganglioside complex.  
The optimal ratio for binding varied between antibodies with some preferring a 
ratio of 1:16, whilst others preferred a ratio of 1:32. For comparison purposes, 
the latter was selected as it was found to produce the highest signals for the 
most antibodies. Unfortunately, the variation between experimental repeats was 
found to be particularly high with PS complexes, which resulted in the detection 
of few statistically significant differences between antibodies.  
Regardless of these limitations, BO1, SM1 and WO1 were still found to produce 
the highest binding signals, although there was less of a clear definition between 
these antibodies and the others. BO3 and DO1 produced reasonably high signals, 
particularly against complexes containing higher proportions of PS, whilst BR1 
was found to produce minimal increases in binding signals that, again, peaked at 
a ratio of 1:8.  
4.2.1.5 SM Complexes  
 
Alongside Chol, SM is one of the most abundant raft lipids in mammalian cell 
membranes (Brown & Rose, 1992). It is found in particularly high quantities in 
the myelin sheath of the PNS (Morell & Quarles, 1999), which suggested that it 
may have roles in influencing the presentation of gangliosides within these 
tissues. This led to the hypothesis that the human monoclonal antibodies would 
produce higher binding signals against ganglioside:SM complexes compared to 
those produced against the single glycolipids. As SM is highly enriched within 
myelinating cells, it was also hypothesised that complexes containing a higher 
proportion would produce higher binding signals compared to those containing a 
lower proportion.    
This was confirmed with half the antibodies; however, the other half had a 
drastically different response (Figure 4.5). The binding signals of BO1, SM1 and 
WO1, as hypothesised, increased as the proportion of SM in the ganglioside 
complexes increased. BO1 and WO1 were only enhanced by complexes 
containing GA1 whilst SM1 was enhanced by complexes containing either GA1 or 
GM1. In contrast, the binding signals of BO3, BR1 and DO1 were inhibited by all  
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Figure 4.5 - Binding of Human Monoclonal Antibodies to SM Complexes 
The human monoclonal antibodies were screened against ganglioside:SM 
complexes at various molar ratios. Representative blots indicate examples of 
concentration dependent (A) and concentration independent binding (B). 
Fluorescent intensity values for ganglioside complex enhancement or inhibition 
were calculated by subtraction of both constituent single lipid mean values from 
the mean complex signal. Each spot represents the mean of the repeat 
experiments. Positive signals indicate enhancement whilst negative signals 
denote inhibition (C). The relative binding signals were compared between each 
antibody and analysed using a Kruskal-Wallis test with Dunn’s multiple 
comparisons (n=5) (D). The binding signals of BO1, SM1 and WO1 increased as the 
proportion of SM increased up to an optimal ratio of 1:32. At this ratio they were 
significantly higher than BO3, BR1 and DO1. SM was found to inhibit the binding 
of these antibodies and was found to completely abolish the binding altogether 
(*=p<0.05), (**=p<0.01), (***=p<0.001).  
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complexes containing SM in low proportions and were completely abolished by 
complexes containing high proportions.   
For those antibodies that were enhanced, the optimal ratio for binding was 1:32. 
This was used for comparisons between the antibody groups to establish any 
significant differences. As expected BO1, SM1 and WO1 were found to be 
significantly higher than BO3, BR1 and DO1 (Kruskal-Wallis test, Dunn’s multiple 
comparisons, P<0.05). These differences varied depending upon the target 
antigens but, as stated, the binding signals for the latter group were always 
substantially lower.  
4.2.1.6 PC Complexes  
 
Phosphatidylcholine is the most common phospholipid in mammalian cell 
membranes (Ohvo-rekila et al., 2002). Unlike the other lipids used in this 
experiment, however, it is not commonly associated with lipid rafts but is 
instead found primarily in the liquid disordered partition of the plasma 
membrane (Pike et al., 2002). Based upon this information, it was hypothesised 
that ganglioside:PC complexes would have little influence on the binding 
capabilities of the human monoclonal antibodies, which would produce the same 
binding signals as seen with the single glycolipids.  
Surprisingly, this was not found to be the case (Figure 4.6). All the antibodies 
showed enhanced binding signals against these complexes to varying degrees, 
with the usual group of BO1, SM1 and WO1 showing the most enhancements as 
described previously. Unlike the other ganglioside:accessory lipid complexes 
though, binding was somewhat restricted against PC. An example of this was BO1 
and SM1, which produced strong enhancements against complexes containing 
their respective target antigens but no enhancements whatsoever against 
complexes containing other gangliosides.  
In respect to their target antigens, the binding signals of the antibodies were 
found to increase as the proportion of PC increased. However, these 
enhancements tended to peak at a ratio of 1:8 where the majority of the 
antibody signals dropped off again. The antibodies fell into their previously 
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Figure 4.6 - Binding of Human Monoclonal Antibodies to PC Complexes 
The human monoclonal antibodies were screened against ganglioside:PC 
complexes at various molar ratios. Representative blots indicate examples of 
concentration dependent (A) and concentration independent binding (B). 
Fluorescent intensity values for ganglioside complex enhancement or inhibition 
were calculated by subtraction of both constituent single lipid mean values from 
the mean complex signal. Each spot represents the mean of the repeat 
experiments. Positive signals indicate enhancement whilst negative signals 
denote inhibition (C). The relative binding signals were compared between each 
antibody and analysed using a Kruskal-Wallis test with Dunn’s multiple 
comparisons (n=5) (D). The binding signals of most antibodies increased up to a 
ratio of 1:8 where they dropped off again. Comparisons at this ratio indicated 
that SM1 and WO1 produced significantly higher binding signals compared to BO3 
and DO1. Binding to the single PC antigen was weakly detected in high ratios for 
all antibodies. (*=p<0.05), (**=p<0.01), (***=p<0.001).  
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described categories with statistical analysis between them indicating that the 
binding signals of SM1 and WO1 were significantly higher than both BO3 and BR1 
(Kruskal-Wallis test, Dunn’s multiple comparisons, P<0.05). DO1, as shown 
previously with Chol, produced an intermediate level of binding and did not fall 
strictly into either category. 
4.2.2 Summary  
 
The data from these experiments demonstrated that ganglioside:accessory lipid 
complexes were capable of enhancing the binding signals of monoclonal 
antibodies. Furthermore, they also established that by increasing the proportions 
of accessory lipids in these complexes, substantially higher binding signals could 
be achieved by certain antibodies, whilst others only obtained marginal 
improvements or inhibitions.  
Examination of the individual antibodies found that they tended to fall into the 
same categories, regardless of which accessory lipid was present. Although it 
was not ideal to compare different antibodies to one another, previous research 
and in-house work had established that the antibodies had similar binding 
affinities and avidities (O’Hanlon et al., 1996; Willison et al., 1997). The 
differences between them in this experiment could therefore be assumed to be 
caused by the influence of the accessory lipids.  
Based upon this assumption, it could be postulated that the antibodies that were 
enhanced (concentration dependent) preferentially bound to gangliosides that 
had undergone significant headgroup modification. In contrast, those antibodies 
which bound poorly to complexes containing high proportions of accessory lipids 
(concentration independent) could be assumed to bind preferentially to 
ganglioside headgroups in their relatively unmodified state.  
4.3 Discussion 
 
The roles of accessory lipids in neuroimmunology research are only now 
beginning to be appreciated. Even though they were first examined as far back 
as 1997 (Pestronk et al., 1997), it is only in the past few years that researchers 
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have begun to intensify their use in clinical assays (Galban-Horcajo et al., 2013; 
Nobile-Orazio et al., 2010).  
Most of this work has focussed on GM1:GalC complexes, which several studies 
have indicated enhance the detection of antibodies in the sera of MMN patients 
(Nobile-Orazio & Gallia, 2013). The exact mechanism by which the complex 
achieves this is disputed; with some researchers believing that the antibodies 
are binding to a neo-epitope, formed by the combination of the lipids (Galban-
Horcajo et al., 2013; Willison & Goodyear, 2013), whilst others believe that GalC 
is modulating the conformation of the GM1 headgroup, to reveal a hidden 
epitope (Harschnitz et al., 2014; Nobile-Orazio et al., 2013).  
Evidence appears to favour the latter theory, with several different studies 
indicating that accessory lipids such as Chol can modify the orientation of GM1, 
to improve or impede the binding of proteins or toxins (Fantini & Yaho, 2013; 
Lingwood et al., 2011). Assuming that the same principle applies to antibody-
epitope presentation, it could be proposed that different accessory lipids could 
alter the binding abilities of anti-ganglioside antibodies.   
This was explored within this chapter by probing human monoclonal antibodies 
against a series of ganglioside:accessory lipid complexes. In line with the original 
hypothesis, all complexes containing low proportions of accessory lipids were 
found to enhance the binding signals of the antibodies. The levels of 
enhancement varied between accessory lipids, however, with complexes 
containing those found enriched in the rafts of the myelin sheath producing the 
highest binding signals, whilst those found in the liquid disordered partition of 
the membrane produced the lowest. In general, GalC was found to produce the 
most enhancement, followed by SM, sulfatide, Chol, PS and PC.   
The exact mechanism by which the accessory lipids improved antibody binding 
was not established in these experiments; however, evidence from other fields 
supports the theory that the lipids interact with ganglioside headgroups to 
modify macromolecular access to binding sites. This has been shown most 
prominently by Alzheimer’s researchers, who have investigated the interactions 
between GM1 and Chol and the effects that they have upon ligand binding  (Lin 
et al., 2008; Lingwood & Simons, 2010; Lingwood et al., 2011). The research 
found that the hydroxyl group of Chol forms hydrogen bonds with the glycosidic 
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linkage between the galactose and ceramide molecules of GM1 (Fantini & Yaho, 
2013; Manna & Mukhopadhyay, 2013). This produces a change in the orientation 
of the GM1 headgroup so that it shifts from perpendicular to parallel to the 
plasma membrane, resulting in the attenuation of the cytotoxicity of β-amyloid 
plaques. 
As this glycosidic linkage is common to all three of the gangliosides screened 
within this experiment (GM1, GA1 and GD1b), it could be assumed that Chol 
would similarly modify their orientations to lie parallel to the membrane as well. 
This cannot be stated for certain however, as the influence of the gangliosides 
sialic acid group on its orientation is unknown.  
Whilst this research has focussed on Chol, it would be reasonable to assume that 
other accessory lipids would also be able to interact with gangliosides in a 
similar manner. The structure of Chol is unique, however, as it is almost entirely 
buried within the plasma membrane, except for the hydroxyl group which 
protrudes into the exoplasm (Lodish et al., 2000). As such, this group is the only 
part of Chol that is able to form hydrogen bonds with GM1.  
By contrast, only the ceramide or glycerol portions of the other accessory lipids 
are embedded in the plasma membrane, leaving their headgroups free to 
interact with gangliosides on the extracellular surface (Lee, 2001). These 
headgroups contain a variety of different functional groups that form a hydrogen 
bonding network with gangliosides (Mombelli et al., 2003; Stoffel & Bosio, 1997). 
The extent of these networks is dependent upon which accessory lipids are 
present. For example, GalC is capable of forming a large number of hydrogen 
bonds with gangliosides, due to the increased presence of a series of acceptor 
oxygen groups and donator hydroxyl and amine groups (Hall et al., 2010). 
Conversely, SM only has two donor groups, whilst PC has none.  
It is unknown to what extent these hydrogen bonding networks influence the 
orientation of the gangliosides; however, as the accessory lipids are 
comparatively smaller, it could be assumed that they act to pull the ganglioside 
headgroups into an orientation parallel to the membrane, in a similar manner as 
Chol. The degree of this pull will presumably be determined by the functional 
groups of the accessory lipids and may explain the variation in the binding 
signals observed with the human monoclonal antibodies.  
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As GalC contains a large number of hydrogen bond donors and acceptors, it 
would presumably have a larger influence on the tilt of the ganglioside 
headgroup, leading to the preferential exposure of certain epitopes. This may 
explain why the binding signals of the human monoclonal antibodies were 
particularly high to ganglioside:GalC complexes. 
 In comparison, PC has only a limited ability to form hydrogen bonds with 
gangliosides, which may result in the reduced tilt of its headgroup. This may 
have led to a less optimal exposure of certain epitopes, which explains the 
reduced biding signals detected to complexes containing PC compared to those 
containing other accessory lipids. 
In addition to conformational modulation, it is also possible that the accessory 
lipids act to disrupt the intra- and inter-molecular bonds that form between 
different gangliosides (Frey & Lee, 2013). This has been established in modelling 
studies, which have shown that lipids such as DPPC can act as spacer molecules 
to reduce electrostatic repulsion between the sialic acid groups of gangliosides 
(Patel & Balaji, 2008). As a result, the lipids reduce the influence that the 
gangliosides have upon one another’s orientation, which may improve the 
presentation of certain epitopes.  
Alongside 1:1 mol:mol complexes, this chapter also explored the impact that 
complexes containing different proportions of accessory lipids had upon the 
binding signals of the human monoclonal antibodies. As lipid rafts contain high 
concentrations of accessory lipids (Pike, 2003; Sezgin et al., 2012), it was 
hypothesised that complexes containing higher proportions would be more 
representative of the endogenous rafts and would, therefore, produce higher 
binding signals.  
The results correlated well with this hypothesis; however, there were distinct 
differences in the levels of enhancement between antibodies. The binding 
signals of BO1, SM1 and WO1increased substantially as the proportion of 
accessory lipids increased, whilst the others only experienced marginal 
improvements or inhibitions depending upon the accessory lipid present.  
The antibodies were therefore categorised as being either concentration 
dependent (BO1, SM1, WO1) or concentration independent (BO3 and BR1) in 
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their ability to bind to complexes containing high concentrations of accessory 
lipids. The only exception to this broad classification was DO1, which tended to 
have low or intermediate binding signals. This may be attributed to the 
derivation of DO1, which was created from an AMAN patient. As AMAN is not a 
demyelinating condition (J. W. Griffin et al., 1995), it would be unlikely that 
antibodies would bind to the same epitopes as those derived from patients 
suffering from MMN. This may explain the differences in the binding pattern 
between DO1 and the other antibodies but there is not enough evidence from 
these experiments to draw any solid conclusions.  
In terms of the conformational modulation theory, it could be proposed that the 
concentration dependent and concentration independent antibodies bound to 
different epitopes on the ganglioside headgroups. Increasing the number of 
accessory lipids in complexes would presumably lead to the formation of larger 
hydrogen bonding networks. This would result in a more pronounced tilt in the 
headgroups so that they were lying almost completely parallel to the plasma 
membrane. As the concentration dependent antibodies had higher binding 
signals to these complexes, it could be surmised that they bound to epitopes 
that were optimally presented when the gangliosides were in this configuration.  
In contrast, the concentration independent antibodies may bind to an epitope 
that is preferentially presented when the ganglioside headgroup is lying 
perpendicular to the membrane. The initial binding enhancements experienced 
by these antibodies to complexes containing low proportions of accessory lipids, 
may be the result of the gangliosides condensing into organised domains (Hall et 
al., 2010). This leads to an initial increase in the binding signals due to improved 
epitope presentation; however, with certain accessory lipids, such as SM, this 
improvement is lost when the concentration increases further and the 
gangliosides orientation is changed. The epitope will then become inaccessible 
leading to a reduction in the binding signal.  
For the majority of the accessory lipids (Chol, GalC, PS and SM), the binding 
signals of the concentration dependent antibodies increased as the proportion of 
lipids in the complexes increased. These signals eventually reached a plateau, 
where the epitope was presumably as optimally presented as possible. PC and 
sulfatide did not follow the same pattern as these lipids but were instead found 
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to produce an increase up to a point, followed by a drop off in the binding 
signal.    
With regards to PC, it was hypothesised that the decrease in binding was due to 
the presentation of the gangliosides within the lipid environment. Previous 
studies have established that gangliosides suspended in artificial POPC 
containing membrane bilayers are scattered; whereas those contained within 
Chol/SM bilayers are condensed into highly organised domains (Mori et al., 
2012). Assuming that this same effect occurs with PC complexes, it could be 
proposed that the increased concentration of the lipid results in a larger degree 
of scattering of the ganglioside. In terms of antibody binding, this may lead to a 
reduction in the availability of certain epitopes on the headgroup, reducing the 
binding ability of the human monoclonal antibodies.     
The decreases in the binding signals associated with sulfatide enriched 
complexes were more difficult to explain. Sulfatide is almost identical to GalC 
except that it contains a sulfate group attached to the 3rd carbon of its galactose 
ring (Coet et al., 1998). It was therefore expected to form similar hydrogen 
bonding networks as GalC, which would result in similar levels of antibody 
enhancement.  
This was not found experimentally, however, as the complexes were only 
capable of producing an increase in enhancement up to a ratio of 1:4, followed 
by a rapid decrease in binding in each subsequent complex. This decrease was 
unexpected but may have been related to the sulfate group, which gives the 
molecule a negative charge.  
When the concentration of sulfatide is high, the sulfate group may have a 
detrimental effect on epitope presentation; however, little is known about the 
molecular interactions between sulfatide and gangliosides. Modelling studies 
would need to be performed to substantiate whether this group was responsible 
for the relative decrease in antibody binding or if it was another aspect of the 
molecule that was producing this result.  
Aside from the effect of the lipids concentration, sulfatide was also unique in its 
ability to elicit antibody enhancement. Unlike the other accessory lipids, which 
only produced enhancements with concentration dependent antibodies, sulfatide 
Chapter 4 – ACCESSORY LIPID COMPLEXES  111 
 
complexes were able to produce them with all 5 antibodies derived from MMN 
patients. In comparison, DO1, which was derived from an AMAN patient showed 
no enhancement with sulfatide complexes whatsoever.  
This suggests that the interactions between gangliosides and sulfatide may 
expose an epitope, which is specifically targeted in MMN. As such, it may be of 
interest in future studies to examine this complex further and to ascertain 
whether it is also a target in the serum.  
Whilst the array data was useful in determining the effects that different 
accessory lipid concentrations had upon antibody binding, it did not establish 
whether these findings translated into differences in their tissue binding ability. 
To address this, the original paper, in which the antibodies were first screened 
against human tissue, was re-examined (O’Hanlon et al., 1998).  
The concentration dependent and concentration independent antibodies were 
directly compared to ascertain whether they bound to different tissues. The only 
difference between the two groups appeared to be with cross-striations of the 
diaphragm to which the concentration independent antibodies were solely 
capable of binding. Unfortunately, this was not particularly informative as little 
is known about the lipid composition of these cross-striations or their relevance 
in disease.  
Examination of the other tissues was inconclusive in establishing distinct 
differences between the two antibody groups; however, the nature by which the 
tissue was collected may have affected the ganglioside distribution within these 
tissues, which would impact the validity of the binding data. As the tissue was 
collected from amputated limbs, it was immediately snap-frozen or fixed in 
either an ethanol solution or 4% PFA. Both these fixation methods have 
previously been shown to drastically alter the distribution of gangliosides within 
plasma membranes (Schwarz & Futerman, 1997), to the extent that gangliosides 
appear on cells that do not express them endogenously.   
As such, the human monoclonal antibodies may not bind to these tissues as they 
would in vivo, which may affect the interpretation of the results. To overcome 
these problems, it would be ideal to screen the antibodies against unfixed 
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tissue; however the logistics of collecting live human tissue may make this an 
unrealistic possibility.  
Examination of the binding capabilities of the antibodies in mouse tissue is 
similarly difficult, as they are all incapable of binding gangliosides in the 
presence of GD1a (Chapter 3). Binding studies in these tissues would therefore 
be impractical, as GD1a is widely distributed throughout the mouse nervous 
system (Gong et al., 2002), and can only be removed by converting it to GM1 
through neuraminidase treatment. Whilst this would allow binding to take place 
(Greenshields et al., 2009), it would also be counterintuitive for the intentions 
of this study, which require the membrane to resemble its natural state.  
Despite the difficulties in correlating the array data with the tissue binding 
studies, the experiments still provided a novel insight into how the composition 
of ganglioside complexes affects the binding abilities of monoclonal antibodies. 
The emergence of two distinct antibody groups was particularly interesting, as it 
suggested that the complexes used in standard assays may be insufficiently 
designed for the optimal detection of all anti-ganglioside antibodies.  
To determine if this was true, a new clinical array was created consisting of 
complexes that contained high concentrations of accessory lipids.  These arrays 
were probed with MMN patient sera to determine whether the new complexes 
increased antibody detection compared to those in current use. The results of 
this study are discussed in the subsequent chapter.  
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5 SCREENING MMN PATIENT SERA AGAINST ACCESSORY 
LIPID COMPLEXES 
 
5.1 Introduction 
 
The work carried out using the human monoclonal antibodies in the previous 
chapters demonstrated the important roles that a ganglioside’s 
microenvironment plays in the presentation of different binding epitopes. 
Through the use of different ganglioside complexes, it was shown that it was not 
just the content of the microenvironment that influenced the presentation of 
epitopes but the concentration of the lipids that were contained within it.   
Whilst some antibodies were found to bind avidly to complexes containing high 
concentrations of accessory lipids, others were found to experience no change in 
their binding behaviour. It was therefore hypothesised that certain antibodies 
were concentration dependent and bound to ganglioside epitopes that were 
optimally presented in lipid rich environments. In contrast, the other antibodies 
were considered to be concentration independent as they were unaffected by 
changes in the lipids concentration and presumably bound to epitopes that were 
already optimally presented.   
The suggestion that two classes of anti-ganglioside antibodies existed, raised 
questions about the effectiveness of current screening methods, which employ 
complexes in 1:1 w:w formations. Whilst these may effectively detect low levels 
of the concentration independent antibodies, they may not be able to detect 
low levels of the concentration dependent antibodies that preferentially bind 
gangliosides in lipid rich microenvironments. 
To address this possibility, a new array was designed that incorporated the 
ganglioside:accessory lipid ratios that gave the highest binding signals for the 
concentration dependent antibodies. These were: 1:32; 1:32; 1:4; 1:32; 1:32: 
and 1:8 for Chol, GalC, sulfatide, PS, SM, and PC respectively. Alongside these 
new complexes, the new arrays also included the normal 1:1 complexes as well 
as the single constituent lipids of both.  
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Table 5-1 - Example of Array Layout for Screening Human Sera against 
Accessory Lipid Complexes 
 
As a consequence of the inclusion of these extra complexes, duplicate spots had 
to be removed from the arrays, due to space restrictions (Table 5.1). All other 
settings remained the same and the arrays were printed using the combinatorial 
glycoarray following the standard protocol.  
5.2 Results  
 
The arrays were probed with sera collected from a clinical centre in Marseille, 
France. These consisted of samples from MMN patients (n=20), other 
neurological diseases (OND) (n=40) and healthy controls (n=20). The ONDs 
comprised of samples from amyotrophic lateral sclerosis (ALS, n=20) and 
Charcot-Marie-Tooth (CMT, n=20) patients, which acted as controls for acquired 
and hereditary diseases respectively.    
Following screening, the array data for all the MMN and control samples 
underwent cluster analysis and were plotted in a heatmap using a rainbow scale 
of intensity (Figure 5.1). At first glance, there was no immediate indication of an 
antigen that was specifically targeted by the MMN sera compared to the 
controls. However, a minority of sera were found to have noticeably higher 
values against GM1 and GA1 with a variety of complexes.   
The 95th percentile for the controls (n=60) was calculated for each glycolipid 
target and was used for the threshold of positivity. These results were then 
applied to the MMN sera data, with values above this threshold being considered 
as true positives.  
Having established the cut off values for the array data, the sensitivities of each 
antigen could be calculated, assuming a specificity of 95% (Table 5.2). From this 
data, it could be seen that complexes which contained higher proportions of 
accessory lipids had higher sensitivities. In general, they increased the sensitivity 
by 10% compared to the standard complexes, but some increased it even 
GM1 GA1 GD1b M GM1 GA1 GD1b
Chol A GM1:Chol 1:1 Chol B GA1:Chol 1:1 Chol C GD1b:Chol 1:1 M PS A GM1:PS 1:1 PS B GA1:PS 1:1 PS C GD1b:PS 1:1
Chol 32 A GM1:Chol 1:32 Chol 32 B GA1:Chol 1:32 Chol 32 C GD1b:Chol 1:32 M PS 32 A GM1:PS 1:32 PS 32 B GA1:PS 1:32 PS 32 C GD1b:PS 1:32
GalC A GM1:GalC 1:1 GalC B GA1:GalC 1:1 GalC C GD1b:GalC 1:1 M SM A GM1:SM 1:1 SM B GA1:SM 1:1 SM C GD1b:SM 1:1
GalC 32 A GM1:GalC 1:32 GalC 32 B GA1:GalC 1:32 GalC 32 C GD1b:GalC 1:32 M SM 32 A GM1:SM 1:32 SM 32 B GA1:SM 1:32 SM 32 C GD1b:SM 1:32
Sulf A GM1:Sulf 1:1 Sulf B GA1:Sulf 1:1 Sulf C GD1b:Sulf 1:1 M PC A GM1:PC 1:1 PC B GA1:PC 1:1 PC C GD1b:PC 1:1
Sulf 4 A GM1:Sulf 1:4 Sulf 4 B GA1:Sulf 1:4 Sulf 4 C GD1b:Sulf 1:4 M PC 8 A GM1:PC 1:8 PC 8 B GA1:PC 1:8 PC 8 C GD1b:PC 1:8
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Figure 5.1 - Heat Map of Patient Antibody Binding 
Sera from MMN, ALS, CMT patients and healthy controls (HC) were screened 
against an different lipids and complexes. The relative binding intensities of the 
IgM antibodies to the various gangliosides and complexes are indicated by the 
colours of the bands. These follow a rainbow scale, with red indicating the 
strongest binding, blue indicating low binding and black indicating a negative 
signal. The signals have been sorted by disease and have been ordered by 
hierarchical clustering with Pearson correlation.  
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further, with GA1:sulfatide 1:4; GA1:PS 1:32 and GM1:SM 1:32 displaying 
sensitivities that were 15-25% higher.  
Further analysis was performed upon the array data to ensure that the increased 
sensitivities were not a result of increased binding to the single constituent 
lipids. As such, a second heat map was created that consisted of the complex 
binding signals with the individual constituents subtracted (Figure 5.2). This 
indicated whether the antibodies were enhanced or inhibited, which allowed for 
more accurate comparisons between the different groups. 
Examination of these results indicated that most of the complexes were 
inhibitory for antibody binding. The only exceptions to this were GM1:GalC 1:1 
and ganglioside:GalC 1:32 complexes. These were enhanced with all the sera but 
GM1:GalC 1:1, GM1:GalC 1:32 and GA1:GalC 1:32 were found to be significantly 
higher in the MMN sera compared to the both the ALS samples and the healthy  
 
Table 5-2 – Sensitivity Values for GM1 and GA1 Complexes 
  Sensitivity 1:1 Ratios Sensitivity Inc Ratios Sensitivity 
GM1 30% GM1:Chol 30% 
GM1:Chol 
1:32 40% 
GA1 25% GA1:Chol 35% GA1:Chol 1:32 35% 
GD1b 15% GM1:GalC 30% 
GM1:GalC 
1:32 40% 
GA1:GalC 30% GA1:GalC 1:32 40% 
GM1:sulfatide 35% 
GM1:sulfatide 
1:4 35% 
GA1:sulfatide 30% 
GA1:sulfatide 
1:4 45% 
GM1:PS 35% GM1:PS 1:32 35% 
GA1:PS 30% GA1:PS 1:32 45% 
GM1:SM 35% GM1:SM 1:32 60% 
GA1:SM 25% GA1:SM 1:32 40% 
GM1:PC 35% GM1:PC 1:8 30% 
GA1:PC 35% GA1:PC 1:8 45% 
 
The sensitivity values for GM1, GA1, GD1b, GM1 and GA1 complexes were 
calculated assuming a specificity of 95%. This was determined for each spot 
using the binding signals from the combined controls (n=60). Green indicates 
those lipids which had sensitivities higher than both the single lipid and the 
standard 1:1 mol:mol complex.  
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Figure 5.2 - Comparison of the Enhancements and Inhibitions of Human Sera 
A heatmap was created of the human sera data following subtraction of single 
constituent lipids from complexes. Red indicates enhancements whilst green 
indicates inhibition. The data showed that GM1:GalC 1:1, GM1:GalC 1:32, and 
GA1:GalC 1:32 enhance the binding signals of the different sera. This 
enhancement is significantly higher in the MMN patients compared to the ALS 
and HC samples and was found to be higher than the enhancement with GM1 
alone (Kruskal-Wallis Test, Dunn’s Multiple Comparisons, *=p<0.05, **=p<0.01, 
***=p<0.001). 
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controls (Kruskal Wallis, Dunn’s multiple comparisons, P<0.05). There was no 
significant difference, however, between the MMN and CMT samples, although 
the MMN samples did have a higher median signal. 
To determine if GalC was enhancing the binding signals of the antibodies beyond 
the single GM1 species, a side by side comparison was performed between the 
different antigens. This data indicated that, with GM1, the MMN sera were 
significantly higher than the healthy controls (Kruskal Wallis, Dunn’s multiple 
comparisons, P<0.05). In comparison, with GM1:GalC, the MMN sera were 
significantly higher than both the healthy controls and ALS (P<0.05), which 
suggested that the presence of GalC enhanced antibody detection. However, 
there was no difference between the GM1:GalC 1:1 and GM1:GalC 1:32 ratios, 
which suggested that the increased proportion of GalC in the complex was not 
producing any additional enhancement. 
Taken together, this data suggested that complexes containing increased 
proportions of accessory lipids do not improve antibody detection in MMN sera. 
Although the sensitivity of these complexes was increased compared to the 
standard configurations, this was offset by the increased sensitivities of the 
single accessory lipid antigens. As such, only complexes containing GalC were 
found to improve antibody detection compared to the single ganglioside target. 
This was in line with previous research, suggesting that the new array design did 
not provide any benefit compared to the standard assays that are already in use.    
5.3 Discussion 
 
The emergence of concentration dependent and concentration independent 
antibodies in the previous chapter raised questions about the effectiveness of 
current clinical assays. As these assays employ complexes in 1:1 w:w ratios, they 
may be inadvertently omitting the detection of antibodies that preferentially 
bind to complexes containing higher proportions of accessory lipids, giving the 
impression that they are not present.  
To address this possibility, an experiment was performed in which a cohort of 
patient sera was screened against a newly designed array. This array was 
composed of the ganglioside:accessory lipid complexes that produced the most 
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enhancement for the concentration dependent antibodies, alongside the normal 
1:1 mol:mol complexes and the single constituents of both.    
In line with previous research, complexes containing GalC were found to 
enhance antibody detection compared to the single ganglioside antigens 
(Galban-Horcajo et al., 2013; Nobile-Orazio & Gallia, 2013). This was true for 
both the GM1:GalC 1:1 complexes as well as those composed of GalC in higher 
proportions. There was no difference between these complexes, however, 
suggesting that increasing the proportion of GalC had no additional benefit in 
detecting serum antibodies compared to those complexes in the standard 
configuration.  
All other ganglioside:accessory lipid complexes were found to be ineffective in 
enhancing the detection of antibodies compared to the single antigens. The new 
complexes did have higher sensitivities; however, this was attributed to an 
increase in non-specific antibody binding rather than the increased detection of 
anti-ganglioside antibodies. 
Overall, these results suggested that the performance of the new array was 
relatively poor, as the new complexes were not found to provide any additional 
enhancements compared to those complexes in the standard configuration. 
Whilst this was possibly due to the absence of concentration dependent 
antibodies in the serum, it was also possible that the lack of binding was due to 
issues with the samples or the array configuration itself.  
In regards to the serum samples, it was reasonable to assume that their 
polyclonal nature may have occluded the detection of certain complex 
enhancements (Mahon et al., 2014; Wine et al., 2013). The presence of 
antibodies targeting the single accessory lipids would lead to the attenuation of 
the complex signal giving the impression that it was absent. This was most 
prominent in this experiment with anti-Chol antibodies, which were present in 
almost every patient in both the disease and control groups. Although the 
monoclonal antibodies were significantly enhanced with ganglioside:Chol 
complexes, in the serum study the complexes appeared to have no effect due to 
these anti-Chol antibodies. Unfortunately, as these are commonly found in the 
general population (Alving et al., 1989), it would be unlikely that complexes 
containing Chol would be useful in detecting anti-ganglioside antibodies.  
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The quality of the samples may also have affected the experimental results, due 
to degradation following freeze-thaw cycles. The effect of these cycles on anti-
glycolipid antibodies is unclear, as some studies suggest that they have no 
effect, whilst others have shown degradation after as few as three cycles (Brey 
et al., 1994; Siebert et al., 2013). Unfortunately, these samples were taken from 
another study so their quality could not be guaranteed. It would therefore be 
ideal to repeat this experiment using freshly collected samples.    
The relatively low levels of anti-GM1 antibodies in these samples may also be 
another reason to repeat the experiments. In most studies these antibodies are 
detected in up to 80% of MMN patients but in this cohort they were only 
detected in 30% of patients, which is substantially lower (Cats, Jacobs, et al., 
2010; Nobile-Orazio & Gallia, 2013; Nobile-Orazio, 2001). This may be a valid 
result; however, it would be worthwhile to repeat this experiment on a different 
cohort of sera in the future to definitively determine whether different ratios of 
accessory lipid complexes are able to enhance antibody detection in MMN.  
Aside from the serum samples, it was also possible that the configuration of the 
complexes was preventing the accurate detection of anti-ganglioside antibodies. 
Recent work within the Willison laboratory has established that GM1:GalC 
complexes between the ratios of 1:1 and 1:5 w:w are optimal for detecting anti-
GM1 antibodies (Delmont et al., 2015). Complexes that contain higher 
proportions of GalC experience a reduction in specificity, which makes them less 
suitable for detecting antibodies and rules out their use in clinical assays.  
This same problem may have occurred with the complexes used in this study. 
Although they were optimal for enhancing the binding signals of monoclonal 
antibodies, they may not be as well suited to detecting serum antibodies due to 
the aforementioned issues with polyclonality. Future work may therefore wish to 
analyse these complexes at the ranges used in the original monoclonal antibody 
characterisation, to fully establish their optimal configuration for use in clinical 
assays.  
Overall, the results from the accessory lipid studies have indicated that the 
composition of ganglioside complexes, in terms of both the presence and 
concentration of accessory lipids, has a large influence on the presentation of 
different epitopes, which by extension affects antibody binding. These findings 
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also suggest that antibodies may be much more diverse than they appear when 
screened on a standard assay such as ELISA. When probed in a more biologically 
relevant manner, the differences become clearer and the antibodies appear to 
fall into different classes. This may translated into differences in pathogenicity; 
however, this study was unable to verify this hypothesis.  
Although the findings of the previous chapter were not replicated in the 
serological studies performed here, future work may wish to more closely 
examine the effect that the local microenvironment has upon ganglioside 
presentation. Utilising assays that are more biologically representative will lead 
to vast improvements in the accuracy of antibody detection, which will 
ultimately increase their usefulness in diagnosing autoimmune neuropathies.  
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6 IMMUNISATIONS WITH GANGLIOSIDE COMPLEXES 
 
6.1 Introduction 
 
The presence of high titres of anti-ganglioside antibodies in patients are a 
distinguishable feature in autoimmune neuropathies, but little is known about 
their pathogenic effects. Research into the roles of these antibodies is limited in 
humans because the production of human monoclonal antibodies is fraught with 
difficulties. Those which have been produced have been shown to have poor 
binding qualities in tissue, which is problematic in establishing their roles and 
whether they are in fact responsible for causing the disease (O’Hanlon et al., 
1998). 
The use of animal research has partially addressed this problem by utilising 
hybridoma technology. This technique involves immunising animals with an 
antigen conjugated to an adjuvant, which produces an immune response. After 
several immunisations, the spleen of the animal is removed and fused with a 
myeloma cell line to create an immortal antibody producing cell called a 
hybridoma. This is considerably cheaper and easier to produce than human 
monoclonal antibodies and allows for the production of high numbers of diverse 
antibodies.  
In recent years these hybridoma cell lines have been used to generate 
monoclonal antibodies targeting gangliosides and other lipid components. 
Various lower mammals including rabbits, rats and mice have been used to 
produce these antibodies, which have then been investigated in vivo to establish 
their pathogenic roles (O’Hanlon et al., 2001; Rupp et al., 2012). This research 
has subsequently led to the identification of new therapeutic targets and 
treatments, which demonstrates the importance that these antibodies have in 
investigating neuropathies (Halstead, Humphreys, et al., 2005).   
The Willison laboratory employs the use of mice in research as they are the 
lowest mammals that synthesise gangliosides and are cheap to maintain and 
breed. Various different genotypes of these mice have been used to produce 
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approximately 100 monoclonal antibodies through active immunisations with 
ganglioside liposomes or lipopolysaccharides derived from C. jejuni.  
These antibodies are diverse in their targets, isotypes and specificity. Some are 
cross reactive and are capable of binding multiple gangliosides, whereas others 
are only capable of binding one. They also differ widely in their abilities to bind 
to tissue, with some antibodies requiring very specific environments for binding 
to take place (Greenshields et al., 2009).   
There has been recent interest in the importance of anti-ganglioside complex 
antibodies in patients in which antibodies bind specifically to a complex epitope 
composed of two different glycolipids, without binding to the single 
components. These antibodies could be key to identifying why certain tissues are 
targeted by antibodies whilst others remain unaffected, which could explain the 
mechanism of disease of certain autoimmune neuropathies. This chapter 
explores the attempts to produce these antibodies in mice through 
immunisations with liposomes composed of various ganglioside complexes.    
6.2 Results 
6.2.1 Technique Development 
 
Antibodies were produced by immunising mice with ganglioside liposomes over a 
period of four weeks (Table 6.1). The spleens were then collected and fused 
with a myeloma cell line to create a hybridoma that produced the antibodies 
indefinitely. During the immunisation process, blood was collected at regular 
intervals and was screened using the combinatorial glycoarray to establish the 
development of the immune response.  
6.2.1.1 Mouse Control Sera  
  
The variability between print runs on the glycoarray could occasionally be high 
depending upon a number of factors related to the normal operation of the 
equipment. To ensure that this variation was not skewing the sample results, a 
control sera was created, which was applied during each experiment and used to 
normalise the data.  
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Table 6-1 – Immunisation Protocols for the Production of various Complex-
Dependent Antibodies  
   Desired Antigen Liposome Components 
Liposome 
Ratio 
Mouse 
Genotype 
Immunisation 
Protocol 
Section 
GM1:GalC GM1:Chol:SM:DCP:GalC 1:5:4:1:1 
GalNAc T 
B6CGTGN 
x DBA  
IP: Day 0, 7, 14, 21 
IV: 25, 26, 27 
6.2.2.1 
GM1:GalC GM1:Chol:DCP:GalC 1:5:1:1 GalNAc T 
IP: Day 0, 7, 14, 21 
IV: 25, 26, 27 
6.2.2.2 
GM1:GalC GM1:Chol:DCP:GalC 1:5:1:2 GalNAc T 
IP: Day 0, 7, 14, 21 
IV: 25, 26, 27 
6.2.2.3 
GM1:GalC GM1:Chol:DCP:GalC 1:5:1:20 GalNAc T 
IP: Day 0, 7, 14, 21 
IV: 25, 26, 27 
6.2.2.4 
GM1:GD1a GM1:Chol:DCP:GD1a 1:5:1:1 GalNAc T 
IP: Day -112, -98,  
-84, 7, 14 
IV: 19, 20 
6.2.3.1 
GM1:GD1a GM1:Chol:DCP:GD1a 1:5:1:1 GalNAc T 
IP: Day 0, 7, 14, 21 
IV: 25, 26, 27 
6.2.3.2 
GM1:Sulf GM1:Chol:SM:DCP:Sulf 1:5:4:1:1 GalNAc T 
IP: Day 0, 7, 14, 21 
IV: 25, 26, 27 
6.2.4 
GM1:Sulf GM1:Chol:SM:DCP:Sulf 1:5:4:1:1 
    CST-/- x 
GalNAc T-/-
  x Thy 1 
IP: Day 0, 7, 14, 21 
IV: 25, 26, 27 
6.2.4.2 
Gang Complexes 
5mg of WLE in  
Chol:SM:DCP 
5:4:1   GalNAc T 
IP: Day 0, 7, 14, 21 
IV: 25, 26, 27 
6.2.5 
 
 
Three B6CGTGNxDBA mice were immunised with GM1 liposomes created as per 
Section 2.4. These mice were selected as they had previously been shown to 
respond well to immunisation and were readily available. The mice were 
injected IP with liposomes three times a week. After six immunisations the mice 
were killed and their serum was collected and pooled. 
The sera were screened against a standard grid of lipids and were found to have 
good IgM responses to GM1 and the other lipids which were included in the 
liposomes. 
A serial dilution was created to establish the optimal concentration for use in 
screening (Figure 6.1). At an exposure time of 16ms the GM1 response was 20525 
FI units at a 1 in 100 dilution. As a linear relationship existed between exposure 
time and GM1 response, this dilution was found to be acceptable for comparisons 
between experiments. 
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Figure 6.1 - Mouse Control Serum 
 
IgM response in mice immunised with GM1 liposomes. A: Binding fingerprint at a 
1 in 100 dilution and scanned at 16ms exposure. B: Binding signals to the single 
lipids at the different dilutions. C: Semi-log graphs of GM1 binding at different 
dilution factors at different exposure times with and without the subtraction of 
the background signal. A linear relationship existed between the dilution of 
serum and fluorescent intensity. 
 
6.2.1.2 IgG Control Antibody 
 
Unfortunately, for some unknown reason, the IgM antibodies in the mouse 
control sera did not class switch to IgG, so a different control was required for 
this isotype. An in-house IgG monoclonal antibody, DG2, was selected as this had 
previously been well characterised within the laboratory (Townson et al., 2007). 
An initial DG2 concentration of 400µg/ml was serially diluted 1:1 with 1% BSA to 
a final concentration of 49ng/ml and screened using the combinatorial 
glycoarray. The values for the median signal and the median signal minus 
background of GM1 binding were plotted to create a semi-log graph (Figure 6.2). 
The background signal was particularly high at increased concentrations of DG2 
which is reflected in the graph where there is a decreased binding signal at 
Mouse Control Serum – 1 in 100 Dilution
A B
C
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these concentrations. The steepest point on both graphs, which was not 
negatively affected by background binding, was therefore selected as the 
antibody concentration for control slides. This was 3µg/ml.   
 
Figure 6.2 - IgG Control Antibody 
The in-house antibody DG2 was characterised to create an IgG isotype control. 
A: A representative blot of DG2 at 3µg/ml. The antibody was serially diluted 1:1 
from 400µg/ml to 49ng/ml and plotted with (B) and without the background 
subtracted (C). The optimal concentration where background was not influencing 
the signal was found to be 3µg/ml which was selected for use in the control 
slides of future experiments.  
 
6.2.1.3 Control Slides  
 
To accommodate these controls, the twelfth slide of each print was designated a 
control slide. These slides contained the same lipids as the other slides, but 
were instead probed with either the mouse control sera of DG2 at the 
predetermined concentrations. The results of these slides were then compared 
with the original slides and used to normalise the data.   
DG2 – Monoclonal IgG Control – 3μg/mlA
B C
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6.2.1.4 Coefficient of Variation  
 
The control slides were also used to calculate the coefficient of variation (CV) 
for each experiment, which could be used to determine the intra and inter assay 
variability. The data was first manipulated by truncating and setting values 
below 200 to 200 units as data at the lower end of the intensity scale was highly 
variable. The mean and SD of each spot was used to determine the overall CV of 
the experiment which was an indication of the intra-assay variability. This was 
found to be in the range of 17.8-23.4%. The inter-assay variability was calculated 
using the overall mean and SD of each assay across several experiments and was 
determined to be 15%. Although these values were high in comparison to 
different types of assay, they were deemed acceptable for a carbohydrate assay 
based upon the current literature (Oyelaran et al., 2010). 
6.2.2 Immunisations with GM1:GalC Liposomes 
  
As mentioned in Chapter 1, complexes composed of GM1 and GalC are potential 
targets for antibodies in MMN. In order to study the possible pathogenic effects 
of these antibodies, mice were immunised with GM1:GalC complexes to try and 
trigger a specific immune response. The sera was analysed using slides printed 
upon the combinatorial glycoarray to determine if complex specific antibodies 
had been generated.  
6.2.2.1 GM1:GalC Liposomes with Sphingomyelin 
 
Three different genotypes of mice (GalNAc T-/-, GalNAc T+/+ and 
B6CGTGNxDBA) were immunised with liposomes composed of cholesterol, DCP, 
SM, GM1 and GalC to establish which genotype was best suited for immunisations 
(Figure 6.3). It was hypothesised that the GalNAc T-/- mice would produce the 
highest responses as they do not express complex gangliosides and are therefore 
antigen naïve. In contrast, the GalNAc T+/+ mice are exposed endogenously and 
would therefore be expected to have a reduced immune response  (Bowes et al., 
2002). In-house studies also indicated that B6CGTGNxDBA mice responded well 
to gangliosides immunisations so these mice were included to establish if they 
were suitable for these experiments (unpublished data).  
Chapter 6 – IMMUNISATIONS WITH GANGLIOSIDE COMPLEXES 128 
 
 
GM1 GD1a GalC Sulf Chol DCP GA1 SM
X
GM1 X
GD1a X
GalC X
Sulf X
Chol X
DCP X
GA1 X
SM X
GM1 GD1a GalC Sulf Chol DCP GA1 SM
X
GM1 X
GD1a X
GalC X
Sulf X
Chol X
DCP X
GA1 X
SM X
GalNAc T-/- GalNAc T+/+ B6CGTGNxDBA
GalNAc T-/- GalNAc T+/+ B6CGTGNxDBA
A
B
GM1 GD1a GalC Sulf Chol DCP GA1 SM
X
GM1 X
GD1a X
GalC X
Sulf X
Chol X
DCP X
GA1 X
SM X
GM1 GD1a GalC Sulf Chol DCP GA1 SM
X
GM1 X
GD1a X
GalC X
Sulf X
Chol X
DCP X
GA1 X
SM X
GM1 GD1a GalC Sulf Chol DCP GA1 SM
X
GM1 X
GD1a X
GalC X
Sulf X
Chol X
DCP X
GA1 X
SM X
GM1 GD1a GalC Sulf Chol DCP GA1 SM
X
GM1 X
GD1a X
GalC X
Sulf X
Chol X
DCP X
GA1 X
SM X
Figure 6.3 - GM1:GalC:SM Liposome Immunisations 
The sera were screened against a panel of lipids and complexes using the 
combinatorial glycoarray. A representative blot of the terminal bleed antibody 
binding behaviour is displayed for each genotype and the binding signal to GM1 and 
GM1:GalC were plotted over time. A: IgM responses. All genotypes of mice 
responded to immunisations, with the GalNAc T-/- mice producing the earliest and 
largest intensity signals over time. B:IgG responses. Only the GalNAc T-/- mouse 
responded to GM1 and GM1 complexes. Both the GalNAc T-/- and GalNAc T+/+ 
mice showed high responses against GA1 and GA1 complexes. The B6CGTGNxDBA 
mice showed no IgG response to any gangliosides under these conditions. GalNAc 
T-/- (n=2), GalNAc T+/+ (n=3), B6CGTGNxDBA (n=3) 
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As predicted, the GalNAc T-/- mice were found to have the highest levels of 
anti-ganglioside IgM antibodies over the immunisation period. This immune 
response rose steadily to a peak at day 21, where it was assumed that the 
antibodies began class switching, as the signals decreased again at day 28. 
Neither the GalNAc T+/+ or the B6CGTGNxDBA mice produced a response until 
day 28, with the latter producing a much higher signal. There was little 
difference between the signals to GM1 and GM1:GalC except in the  
B6CGTGNxDBA mice, which showed a slightly higher response to GM1:GalC.  
The IgG responses remained relatively weak for all the mice throughout the 
immunisation period. The B6CGTGNxDBA had higher background binding with IgG 
antibodies, which resulted in higher baseline levels at all timepoints. The mice 
therefore did not show any net change in IgG intensity over the immunisation 
period. The GalNAc T+/+ mice displayed no response to GM1 or GM1 complexes 
at any timepoint, whilst the GalNAc T-/- mice produced a peak response against 
GM1 and GM1:GalC at day 28. This correlated with the IgM results that showed a 
drop between day 21 and day 28, which can be attributed to antibody class 
switching.  
Unexpectedly, both the GalNAc T-/- and GalNAc T+/+ mice had high IgG 
responses to GA1 and GA1 complexes. This suggested that the immune system of 
the mice preferred the oligosaccharide portion common to GA1 and GM1 over 
the sialic acid residue unique to GM1 alone. This, alongside the lack of a specifc 
anti-GM1:GalC complex antibody, led to a reconfiguration of the liposomes.  
6.2.2.2 GM1:GalC 1:1 mol:mol Liposomes without SM 
 
Examination of the literature suggested that phospholipids with long fatty acid 
chains such as SM may inhibit antibody binding to smaller lipids due to steric 
hindrance (Alving & Richards, 1977). Sphingomyelin was therefore eliminated 
from the liposome composition to establish if a specific GM1:GalC response could 
be generated. Only the GalNAc T-/- and GalNAc T+/+ mice were used for these 
immunisations as the delayed immune response of the B6CGTGNxDBA mice made 
them an undesirable candidate for monoclonal antibody production. 
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Figure 6.4 –GM1:GalC Liposome Immunisation 
The sera were screened against a panel of lipids and complexes using the 
combinatorial glycoarray. A representative blot of the terminal bleed antibody 
binding behaviour is displayed for each genotype. The antibody binding signals to 
GM1 and GM1:GalC were plotted over time for each genotype and a comparison of 
the GM1 complexes with the single components subtracted is plotted. A: GalNAc T   
-/- mice had significantly higher IgM antibody intensity to GM1 at day 14, 21 and 28 
and  to GM1:GalC at day 14 and 21 compared to GalNAc T+/+ mice. GM1 complexes 
were compared to one another and showed no enhanced binding. B: GalNAc T-/- 
mice had significantly higher binding to GM1 and GM1:GalC at day 28 compared to 
GalNAc T+/+ mice. An analysis of the complexes showed enhancement with DCP and 
Chol but not GalC. (Mann Whitney, P<0.05) (n=5) 
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The sera were analysed from the mice following the same protocol as before 
(Figure 6.4). The GalNAc T-/- mice had significantly higher IgM intensity values 
for GM1 and GM1:GalC at day 14 and day 21 compared to the GalNAc T+/+ mice 
(Mann Whitney Test, P<0.05). The GM1 values were also significantly higher at 
day 28 but this was not reflected by the GM1:GalC complex. A comparison of the 
complexes with the single components subtracted showed no enhancements.  
The IgG intensity values for GM1 and GM1:GalC were only significantly higher at 
day 28 in the GalNAc T -/- mice compared to the GalNAc T+/+ mice. This was 
consistent with the reduction in signal in the IgM intensity values, which 
suggested that class switching had taken place. The removal of SM from the 
liposomes appeared to allow for the production of a GM1 and GM1 complex 
specific IgG response, but the only enhanced signals were showed with 
complexes containing Chol and DCP, not GalC.  
6.2.2.3 GM1:GalC 1:2 mol:mol Liposomes 
 
A GM1:GalC specific response was still not generated in-vivo using the new 
liposome configuration, so the proportion of GalC was doubled to try and induce 
a specific antibody. This resulted in liposomes composed of GM1:GalC in a 1:2 
mol:mol ratio instead of the previously used 1:1 mol:mol ratio.  
The sera were screened against the same array of lipids as the GM1:GalC 1:1 
mol:mol immunised mice except that an additional row and column of GalC was 
added to the grid at double the proportion previously used. The corresponding 
complexes consisted of ganglioside:GalC in a 1:2 mol:mol ratio instead of the 
previously used 1:1 ratio (Figure 6.5).  
The IgM antibody response was higher in the GalNAc T-/- mice than the GalNAc 
T+/+ mice as previously shown. This was only significantly higher in the 
GM1:GalC 1:2 complex at day 21 (Mann Whitney Test, P<0.05). There was no 
apparent difference between GM1 and either configuration of the GM1:GalC 
complex and no GM1 complexes appeared to enhance antibody binding.   
The IgG antibody binding intensity was significantly higher in the GalNAc T-/- 
mice with GM1, GM1:GalC 1:1, and GM1:GalC 1:2 at day 28 compared to the 
GalNAc T+/+ mice. It was also significantly higher in the GM1:GalC 1:2  
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Figure 6.5 – GM1:GalC 1:2 Liposome Immunisation 
The sera were screened against a panel of lipids and complexes using the 
combinatorial glycoarray. A representative blot of the terminal bleed antibody 
binding behaviour is displayed for each genotype. The antibody binding signals to 
GM1, GM1:GalC 1:1 and GM1:GalC 1:2 were plotted over time for each genotype 
and a comparison of the complexes with the single components subtracted is 
plotted. A: GalNAc T-/- mice showed higher IgM antibody binding signals than the 
GalNAc T+/+ but this was only significant on day 21 against the GM1:GalC 1:2 
complex. There were no enhancing complexes. B: IgG binding intensity in GalNAc 
T-/- mice was significantly higher compared to the GalNAc T+/+ mice at day 28 
when screened against GM1, GM1:GalC 1:1 and GM1:GalC 1:2. No complexes 
showed enhancement of IgG antibody binding. (Mann Whitney, P<0.05) (n=5) 
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immunised mice at day 21 (Mann Whitney Test, P<0.05). As with the IgM results 
there was no enhancement of antibody binding with GM1 complexes. 
6.2.2.4 GM1:GalC 1:20 Liposomes 
 
A distinguishable GM1:GalC specific response was still not detected in the sera 
using the 1:2 liposome configuration. It was plausible that the antibody was 
present but was being masked by the polyclonality of the sera; however, this 
would remain unclear until a hybridoma fusion was performed. This was an 
undesirable option as the fusion was labour intensive and required expensive 
reagents. To overcome this problem, the liposome composition was reconfigured 
again but for this experiment the number of moles of GalC was increased 20 
fold.  
As per the previous protocol, an additional row and column of GalC was added to 
the lipid array used for screening. This was 20x the original GalC proportion, 
with the corresponding complexes configured to give a molar ratio of ganglioside 
to GalC of 1:20.  
The GalNAc T-/- mice responded better to immunisation than the GalNAc T+/+ 
mice as shown with the other immunisations (Figure 6.6). The IgM response to 
GM1:GalC 1:20 was much higher than the response to either GM1 or GM1:GalC 
1:1 throughout the immunisation period. This was most apparent at day 28, 
where the GM1:GalC 1:20 signal was found to be approximately 12000 FI units 
higher than both the GM1 and GM1:GalC 1:1 signals. The IgG response reflected 
these results with the GM1:GalC 1:20 complex producing a binding signal that 
was approximately 6000 FI units higher than either GM1 or GM1:GalC 1:1 at day 
28.  
This suggested that a distinguishable GM1:GalC response had been generated in-
vivo, which led to a number of these mice being used for hybridoma fusions. 
After two weeks of incubation, the supernatant was screened for specific 
GM1:GalC antibodies and, whilst many wells were found to produce GM1 
antibodies, none were found to produce antibodies that were capable of binding 
specifically to GM1:GalC in a 1:1 or 1:20 ratio.  
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Figure 6.6 - GM1:GalC 1:20 Liposome Immunisation 
The sera was screened against a panel of lipids and complexes using the 
combinatorial glycoarray. A representative blot of the terminal bleed antibody 
binding behaviour is displayed for each genotype. The antibody binding signals 
to GM1, GM1:GalC 1:1 and GM1:GalC 1:20 were plotted over time for each 
genotype. A: GalNAc T-/- mice showed higher IgM antibody binding signals than 
the GalNAc T+/+. GM1:GalC 1:20 appeared to have a much higher binding signal 
than GM1 or GM1:GalC 1:1 B: IgG binding intensity in GalNAc T-/- mice were 
higher compared to the GalNAc T+/+ mice at day 21 and day 28 when screened 
against GM1, GM1:GalC 1:1 and GM1:GalC 1:20. The binding signal against 
GM1:GalC 1:20 was higher than both GM1 and GM1:GalC 1:1 however this signal 
was highly variable. There was a high baseline IgG  antibodyto GalC but this 
remained steady throughout the immunisation period. (n=2) 
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6.2.2.5 Screening of Sera Against Complexes containing different Ratios 
  of GalC  
 
The lack of a GM1:GalC specific antibody was unexpected but it was 
hypothesised that the presence of increased GalC in the array may have resulted 
in the formation of a complex that enhanced anti-GM1 antibody binding. This 
enhanced binding may have given the illusion that a separate GM1:GalC antibody 
was present. It would also explain why no GM1:GalC specific antibodies were 
detected from the hybridoma fusion as the arrays were only detecting GM1 
antibodies. 
To test this hypothesis, the terminal sera from all the immunised mice were 
screened against a panel of different ratios of GalC. This array followed the 
same configuration as that used in Section 4.2.1 except that GM1 was the only 
ganglioside screened.  
The best IgM response was found in the GM1:GalC:SM 1:1:1 immunised mice, 
which all showed a clear trend of enhancement as the ratio of GM1:GalC 
increased (Figure 6.7). This was found to be strongest in the GalNAc T+/+ mice 
but was also found in both the GalNAc T-/- and B6CGTGNxDBA mice. The signal 
to the GalNAc T-/- sera was lower than the other genotypes as there was binding 
to the single GalC epitope, which increased as the ratio increased. Due to the 
polyclonal nature of sera it was not possible to determine if this was the result 
of the GM1 antibody cross reacting or a separate GalC antibody.    
In contrast to these results, the GM1:GalC 1:1 immunised mice showed a neutral 
response overall and were not enhanced by increasing concentrations of 
GM1:GalC complexes. Examination of the individual mouse serum showed that 
two mice did have weakly enhancing signals; however, three other mice did not 
produce an enhancement, as they contained antibodies that also bound to the 
individual GalC epitope. This attenuated the binding signal to the GM1:GalC 
complexes, which resulted in a neutral signal. 
The GM1:GalC 1:2 immunised mice had similar issues; however, they produced 
weakly positive enhancements at high ratios. The binding signals were found to 
be higher in the GalNAc T+/+ mice as the sera did not tend to cross react to the 
single GalC epitopes as it did in the GalNAc T-/- mice.   
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Figure 6.7 - IgM responses to different ratios of GM1:GalC 
The sera from the different immunisations were screened against GM1:GalC 
complexes that contained differing proportions of GalC. Representative blots 
indicated the antibody reactivities against complexes following subtraction of 
single components and were plotted on semi log graphs for each genotype. 
GM1:GalC:SM 1:1:1 immunised mice responded well to different ratios of 
GM1:GalC complexes. The highest peak in all three genotypes was found with a 
ratio of 1:32. GM1:GalC 1:1 immunised mice shown a poor IgM response at any 
ratio. GM1:GalC 1:2 immunised mice showed an enhanced but low response in 
both genotypes at higher ratios. This was also shown with GM1:GalC 1:20 
immunised mice. Some antibodies in the sera also bound to the single GalC 
epitopes.  
 
Mice immunised with GM1:GalC 1:20 showed a higher level of enhancement as 
the proportion of GalC increased in the complexes. This was found with both the 
GalNAc T-/- and the GalNAc T+/+ mice particularly between the ratios of 1:16 
and 1:32. As before, the GalNAc T-/- sera tended to bind to the single GalC 
epitope; however, this appeared to have less of an impact on the overall binding 
signal compared to the other immunised mice. 
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Figure 6.8 - IgG responses to different ratios of GM1:GalC 
The sera from the different immunisations were screened against GM1:GalC 
complexes that contained differing proportions of GalC. Representative blots 
indicated the antibody reactivities against complexes following subtraction of 
single components and were plotted on semi log graphs for each genotype. All 
the GalNAc T-/- mice showed similar levels of enhancement against complexes 
containing higher ratios of GalC except for the GM1:GalC:SM immunised mice 
which had a much higher enhancement. The B6CGTGNxDBA mice had a similar 
binding pattern as these mice. The GalNAc T+/+ mice tended to have low 
responses even at higher GM1:GalC ratios except in the GM1:GalC 1:1 immunised 
mice which showed an enhancement at the higher ratios. Some antibodies in the 
sera also bound to the single GalC epitopes but this had little effect on the 
binding signals.  
 
The IgG responses to increasing ratios of GM1:GalC complexes were more 
consistent than the results seen with IgM antibodies (Figure 6.8). Generally, the 
GalNAc T-/- mice, which had the highest levels of GM1 antibodies, appeared to 
show the most enhancement with increasing concentrations of GalC. This 
enhancement was highest in the GM1:GalC:SM immunised mice, which displayed 
a binding signal of 15932 FI units at a ratio of 1:32. This was substantially higher 
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than the signals achieved by the GM1:GalC 1:1; 1:2, and 1:20 immunised mice, 
which all displayed similar signals between 4000 and 6000 FI units at the same 
ratio.   
Very little binding was observed in the GalNAc T+/+ mice regardless of their 
antigen. Signals were only detected at high ratios of GM1:GalC, where binding 
was also detected to the single GalC epitope. This resulted in neutral levels 
overall. The only exception was the GM1:GalC 1:1 immunised mice, which 
showed an improvement in binding as the ratio of GalC increased in the 
complexes. This resulted in an enhanced signal; however, it was still lower than 
the signals detected in the GalNAc T-/- mice.  
The GM1:GalC:SM immunised B6CGTGNxDBA mice also showed an increase in 
binding signal as the ratio of GM1:GalC increased, although this was lower than 
the signal seen with the GalNAc T-/- mice. This binding was unexpected as the 
original characterisation suggested that no GM1 IgG antibodies were present 
(Figure 6.3).  
6.2.2.6 Summary 
 
There was no clear trend found with the IgM sera results in regards to increasing 
GalC ratios, except in the GM1:GalC:SM immunised mice. The initial screening 
indicated that these mice produced a larger response to GM1, so it is possible 
that the increased number of antibodies led to higher levels of enhancement. 
The low enhancement in the other immunised mice was impacted by the 
presence of antibodies that bound to GalC, which resulted in the attenuation of 
the GM1:GalC complex signal relative to the signals of the single component 
lipids. The polyclonality of the serum made it difficult to determine if anti-GalC 
antibody reactivity was caused by the anti-GM1 antibody cross reacting with this 
lipid, or a separate GalC antibody that had arisen during the immunisation 
period.  
Another issue was the effect that class switching had upon the IgM antibody 
repetoire. The number of anti-GM1 IgM antibodies was reduced during class 
switching, whilst the number of antibodies targetting other antigens appeared to 
be unaffected. This resulted in a lower raw signals against GM1 complexes, 
whilst the signals against GalC remained high. This would have impacted the 
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complex binding signals following subtraction of the single components, which 
may have given a false impression that the complexes were not enhancing anti-
GM1 antibody binding.  Screening the sera at an earlier timepoint would have 
addressed this issue and may have indicated a more clear trend.  
The IgG data was much more supportive of the hypothesis that increased 
concentrations of GalC in GM1:GalC complexes enhanced GM1 binding. The 
GalNAc T-/- mice from all the immunisations showed a similar trend with the 
enhancement increasing as the ratio of GalC in the complex increased. This was 
also found in the B6CGTGNxDBA mice, which had shown no GM1 binding in the 
original characterisation.    
This data added credence to the hypothesis that a GM1:GalC complex dependent 
antibody was not responsible for the enhanced signals and that they were in fact 
produced by a GM1 antibody that bound better to different configurations of the 
complex .  
This enhancing behaviour was not a phenomenon unique to sera alone and was 
also found with monoclonal antibodies. Two in-house anti-GM1 antibodies, DG1 
and DG2, were also screened using the same grid and demonstrated the same 
binding behaviour (data not shown). This data alongside that in Chapters 3 and 4 
suggested that a GM1:GalC response in serum was unlikely to be a GM1:GalC 
complex-dependent antibody.  
These antibodies may still exist in patients; however, the major drawback of 
producing them in mice is the uncertainty in the configuration and presentation 
of the liposome antigen. The interaction between GM1 and GalC in liposomes is 
unclear as it is not known if the molecules are even in close proximity to one 
another, let alone forming a neo-epitope complex. To produce a specific 
antibody the lipids would have to be fused into a true dimer with a known 
structure as shown in other studies (Mauri et al., 2012). This technique is 
relatively new however, and was not attempted within these studies. It was for 
these reasons that attempts to produce GM1:GalC dependent antibodies were 
abandoned and instead the focus shifted to other ganglioside complexes.  
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6.2.3 Immunisation with GM1:GD1a Liposomes 
 
The inhibitory effects of GM1:GD1a complexes on antibody binding have been 
well described in both humans and mice (Greenshields et al., 2009; Kusunoki & 
Kaida, 2011). An antibody which could specifically target this complex would 
prove beneficial in establishing its location in tissue and could explain why some 
tissues are targeted in disease whilst others are not. GalNAc T-/- and GalNAc 
T+/+ mice were immunised against liposomes that contained GM1, GD1a, Chol 
and DCP to try and produce one of these antibodies. They were bled at regular 
intervals and their sera was analysed using the combinatorial glycoarray.  
6.2.3.1 Immunisation of GM1:GD1a Pre-Immunised Mice 
 
A colleague immunised mice with GM1:GD1a liposomes three times over a 6 
week period and then discontinued the experiment for three months (Galban 
Horcajo, Unpublished data). The mice then received two IP and two IV 
immunisations over a three week period followed by a hybridoma fusion. Only 
the sera collected from the second immunisation cycle were analysed. For 
clarity, the timepoints for serum collection were reset to reflect the second 
immunisation cycle only.  
As shown with the GM1:GalC immunisations, the GalNAc T-/- mice produced a 
higher level of anti-ganglioisde antibody than the GalNAc T+/+ mice (Figure 6.9). 
The day 0 results indicated that the mice still had low levels of circulating anti-
ganglioside IgM antibodies prior to the commencement of the new immunisation 
cycle. Anti-GM1 IgM antibodies increased modestly throughout the immunisation 
period, whilst anti-GD1a and anti-GD1a complex antibodies showed a more 
substantial increase. There were no enhancements or inhibitions by GD1a 
complexes.  
An analysis of the IgG data demonstrated that there were no circulating anti-
ganglioside antibodies in the sera of the mice prior to the second round of 
immunisations. There was also no detection of an IgG response in the GalNAc 
T+/+ mice throughout the immunisation cycle. In the GalNAc T-/- mice, the anti-
GM1 antibodies increased slightly at day 14, whilst anti-GD1a and anti-GD1a 
complex antibodies increased substantially at both day 7 and day 14.  
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Figure 6.9 – GM1:GD1a Pre-Immunised Mice 
The sera were screened against a panel of lipids and complexes using the 
combinatorial glycoarray. A representative blot of the terminal bleed antibody 
binding behaviour is displayed for each genotype. As shown previously the 
GalNAc T-/- mice responded better to immunisation than the GalNAc T+/+ mice. 
A: The mice had residual IgM antibody reactivity from the initial immunisation 
cycle. GM1 antibody increased modestly over the immunisation period whilst 
GD1a and GM1:GD1a increased to a substantially higher level. There appeared to 
be no GD1a complex enhancements. B: There was no IgG response in the GalNAc 
T+/+ mice. The GalNAc T-/- mice had no IgG antibody reactivity at day 0 but this 
increased substantially at each subsequent immunisation. At day 14 the GD1a 
and GD1a complex response was approximately 40000 FI units. There was no 
GD1a complex enhancement or inhibition. (n=2) 
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6.2.3.2 Hybridoma Screening by ELISA 
 
A specific GM1:GD1a antibody was not identified in the serum using the defined 
protocol; however, a hybridoma fusion was performed to determine if B cells 
were present that had been raised against this target. The spleens from both 
GalNAc T-/- mice were harvested and fused with a myeloma cell line and the 
supernatant was screened after two weeks of incubation.  Due to the limited 
volumes of supernatant available, only one lipid and one antibody isotype were 
able to be screened using the standard ELISA protocol. As a result, the 
supernatant was only analysed for IgM reactivity against GM1:GD1a complexes. 
Several wells had ODs above the threshold of 0.1 but only the well with the 
highest OD of 2.1 was expanded and rescreened against the single lipids, GM1 
and GD1a alone. Further analysis of supernatant on the combinatorial glycoarray 
indicated that it was an antibody that bound GD1a in its single form and when in 
heteromeric complexes. This was cloned further and antibody stocks were 
produced for characterisation as shown in Chapter 7. This antibody was dubbed 
GAME-M1 
6.2.3.3 Immunisation of Naive Mice with GM1:GD1a Liposomes  
 
Following on from this experiment, another immunisation was performed with 
GM1:GD1a liposomes using naive mice. These were immunised following the 
standard protocol as per Section 2.7. 
An analysis of the sera indicated that the IgM response targeted GM1 and its 
structural analogues GA1 and GD1b (Figure 6.10). In the GalNAc T-/- mice, the 
signle GM1 response developed at day 14 and became significantly higher than 
the GalNAc T+/+ mice at day 21 and day 28 (Mann Whintey, P<0.05). This was 
also found with the GM1:GD1a complex except that the overall binding signal 
was much lower than the GM1 signal. A response to GD1a also developed; 
however, it was much lower than that found with GM1 and was similar between 
genotypes.  
An IgG response did not develop in the GalNAc T+/+ mice but in the GalNAc T-/- 
mice a response to GM1 and GM1 complexes developed at day 21. This was 
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Figure 6.10 - GM1:GD1a Immunised Mice 
The sera were screened against a panel of lipids and complexes using the 
combinatorial glycoarray. A representative blot of the terminal bleed antibody 
binding behaviour is displayed for each genotype. As shown previously the 
GalNAc T-/- mice responded better to immunisation than the GalNAc T+/+ mice. 
A: The IgM results indicated a larger response to GM1 and GA1 than GD1a. The 
GM1 and GM1 complex responses rose steadily during the immunisation period. 
They became significantly higher in the GalNAc T-/- mice in at day 21 and 28 but 
showed a higher response to GM1 than to GM1:GD1a. There was little GM1 
complex enhancement. B: The GalNAc T+/+ mice did not have any IgG antibodies 
in the sera except to cholesterol. The GalNAc T-/- mice had a response develop 
at day 21 that targeted GM1 and GM1 complexes. This was significantly higher 
than the GalNAc T+/+ mice at day 28. The antibody response to single GM1 was 
again higher than the response to GM1:GD1a. (Mann Whitney, P<0.05)  
GalNAc T-/- (n=3) GalNAc T+/+ (n=5) 
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significantly higher at day 28 (Mann Whitney, P<0.05). A very low response 
developed to GD1a but this was again much lower than the binding signals found 
with GM1.  
6.2.3.4 Hybridoma Screening by Lipid Microarray 
 
Although a response specifically targeting the GM1:GD1a complex was not 
established in the serum, the mice were still fused to determine if any anti-
complex antibodies had developed. One GalNAc T+/+ mouse and three of the 
GalNAc T-/- mice were culled and their spleens harvested for the hybridoma 
fusion. The original PCR indicated that the GalNAc T+/+ mouse was a knock out; 
however, analysis of the serum and resampling of the DNA proved that it was 
actually a GalNAc T+/+ mouse. This was discovered after the hybridoma fusion 
had been performed.  
The previous experiment showed the limitations of using an ELISA as the 
screening method for anti-ganglioside complex antibodies. The volume of 
supernatant available for sampling was only 100µl and half of this had to be used 
as a negative control.  
In addition to these issues, only one lipid could realistically be probed at one 
time and only one isotype of antibody could be analysed. The number of assays 
that had to be performed was also detrimental to the screening process, so a 
new method was developed using the lipid microarray. 
The microarray was capable of printing grids that resembled those used for 
screening the sera. Different single lipids and combinations of various complexes 
could be analysed in the one assay, which would permit quick identification of 
complex dependent antibodies. The major advantage of the microarray was that 
it could print 20 slides in one cycle which consisted of 16 arrays each. The slides 
could then be sampled using just 50µl of undiluted supernatant and probed for 
both IgM and IgG reactivity simultaneously (Figure 6.11). 
The initial screening of the supernatant from the GM1:GD1a immunised mice 
indicated several different targets that were both IgM and IgG (Figure 6.11). The  
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Figure 6.11 – Initial Supernatant Screen of GM1:GD1a Immunised Mice 
Hybridoma Cells 
Hybridoma supernatant was screened to determine antibody positive wells. 
Screen 1 was performed two weeks after the initial hybridoma fusion. Wells 
were found containing IgM and IgG antibodies that targeted GM1, GD1b, and 
GA1. Wells were also found containing some antibodies that cross reacted to 
various different gangliosides. Screen 2 was performed on the expanded cells. 
Overall, fewer antibody positive wells were detected. Wells were found 
containing IgM antibodies that bound to GM1, GD1a and cross reacted to 
different gangliosides. The only IgG positive wells found were those that 
contained antibodies targeting GM1.  
 
most frequent IgM target was GD1a followed by GM1, which was surprising 
considering that anti-GM1 antibodies were the predominant response in the sera. 
There were a higher number of anti-GM1 IgG antibodies, which is an indication 
that the GM1 antibodies were undergoing class switching. This was an example 
of the discrepancy between B2 cells in the spleen and what antibodies were 
being produced by the long lived plasma cells in the serum. As the B2 cells had 
recently undergone class switching, they were producing IgG antibodies but the 
plasma cells in the serum were still producing IgM antibodies. This led to a 
difference between the antibody repertoires in the hybridoma supernatant 
versus those in the sera.  
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Asides from GM1 and GD1a, IgM and IgG antibodies also targeted GA1 and several 
were present that cross reacted to several different gangliosides. No antibodies 
were detected that were complex dependent.  
The positive wells were expanded into 24 well plates and after three days, all 
the media was removed and replaced. This addressed the possibility that the 
positive results detected during the first screen were due to unfused splenocytes 
or unstable hybridoma cells. The process of fusing two nuclei together often 
results in unstable cells, which experience chromosome loss. This leads to short 
lived hybridoma cells that produce antibody for a few days and then die.  The 
supernatant was therefore tested again after a further three days of growth.  
The number of positive wells dropped substantially. Several IgM antibodies were 
detected that still bound GM1, GD1a and cross reacted to several different 
gangliosides. IgG antibodies were detected in several wells but these only bound 
to GM1. A selection of cells were taken forward and expanded further for 
cloning.  
Some cell lines were lost during the cloning process but a GM1 IgG antibody 
dubbed GAME-G2 was developed. This was characterised in Chapter 7.  
6.2.4 Immunisation with GM1:Sulfatide Liposomes 
 
Although there was little success in producing complex antibodies against 
GM1:GalC and GM1:GD1a, an attempt was made to produce GM1:sulfatide 
dependent antibodies. These have been associated with AMAN, with a recent 
study finding that patients who had no detectable anti-GM1 antibodies, 
commonly produced antibodies targeting the GM1:sulfatide complex (Rinaldi et 
al., 2013). There was also an association between MMN and GM1:sulfatide 
antibodies, which raised the possibility that they were targeting a specific 
structure common to both conditions (Galban-Horcajo et al., 2013).  
To produce these antibodies, mice were immunised against liposomes containing 
GM1, sulfatide, SM, DCP and Chol following the standard immunisation protocol.   
Blood was collected regularly and the serum was screened using slides printed on 
the combinatorial glycoarray (Figure 6.12). 
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Figure 6.12 - GM1:Sulfatide Immunised Mice 
The sera were screened against a panel of lipids and complexes using the 
combinatorial glycoarray. A representative blot of the terminal bleed antibody 
binding behaviour is displayed for each genotype and a comparison of the GM1 
complexes with the single components subtracted is plotted. As shown 
previously the GalNAc T-/- mice responded better to immunisation than the 
GalNAc T+/+ mice. A: The IgM results indicated a similar response to GM1 and 
GM1:sulfatide. This was only significantly higher with GM1 in the GalNAc T-/- on 
day 14. There were no enhancements with GM1 complexes at day 28. B: The 
GalNAc T+/+ mice had a minimal IgG response to any target.  The GalNAc T-/- 
mice had a response that was significantly higher on day 28 that targeted GM1. 
There was also an enhanced signal to GM1:sulfatide that was also significantly 
higher than the GalNAc T+/+ mice on day 28. There was enhancement with 
GM1:DCP and GM1:sulfatide complexes.  (Mann Whitney, P<0.05) (n=4) 
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The GalNAc T-/- mice had the largest response showing a steady increase in IgM 
antibodies targeting both GM1 and GM1:sulfatide. This was consistently higher 
than the response of the GalNAc T+/+ mice but was only significantly higher 
against GM1 on day 14 (Mann Whitney, P<0.05). There was no enhancement with 
any GM1 complexes.  
The IgG response was mostly absent at all timepoints in the GalNAc T+/+ mice. 
In the GalNAc T-/- mice the GM1 response developed at day 21 and became 
significantly higher than the GalNAcT +/+ mice at day 28. This was also found 
with the GM1:sulfatide responses except that the signal was much higher than 
that found against the single GM1. Enhancements were found against both 
GM1:DCP and GM1:sulfatide at day 28.  
6.2.4.1 Hybridoma Screening by Lipid Microarray 
 
The spleens from all the GalNAc T-/- mice were harvested and fused with the 
myeloma cells to create hybridomas. After two weeks of incubation, the 
supernatant was screened for antibodies following the method established with 
the lipid microarray. The data from the first screen indicated that a large 
number of IgM antibodies were found that cross reacted to GM1 and GA1 (Figure 
6.13). There were also antibodies that bound to the single GM1, sulfatide and 
SM. IgG antibodies were detected that bound to the single GM1 and other 
antibodies were found that cross reacted to GM1 and GA1. No complex 
dependent antibodies were detected in either isotype. The positive wells were 
expanded into 24 well plates and grown for a further 3 days before the 
supernatant was removed and replaced. The cells were incubated for a further 3 
days and rescreened.  
Screen 2 showed a large drop in the number of GM1/GA1 cross reacting 
antibodies as well as the loss of those targeting sulfatide. There was also a drop 
in the number of both IgG and IgM GM1 antibodies. This was again associated 
with unfused splenocytes and unstable hybridoma cells as described with the 
GM1:GD1a supernatant screening.  
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Figure 6.13 - Initial Supernatant Screen of GM1:Sulfatide Immunised Mice 
Hybridoma Cells 
Hybridoma supernatant was screened to determine antibody positive wells. 
Screen 1 was performed two weeks after the initial hybridoma fusion. Wells 
were detected containing IgM and IgG antibodies that cross reacted to GM1 and 
GA1 and antibodies were also found that bound to the single GM1. Other wells 
contained IgM antibodies that bound to sulfatide and SM. Screen 2 was 
performed on the expanded cells. Overall, fewer antibody positive wells were 
detected particularly those containing antibodies that bound GM1/GA1. The 
anti-sulfatide antibody positive wells were lost completely.    
A selection of the antibody producing cells were expanded further and tested 
routinely to determine if they were still producing antibody. As with the 
GM1:GD1a hybridomas, some cells were lost during expansion but an anti-GM1 
IgM and an anti-SM IgM were successfully cloned. These antibodies were dubbed 
GAME-M3 and GAME-M4 respectively and were characterised in Chapter 7.     
6.2.4.2 GM1:Sulfatide Immunisation with Transgenic Rescue Mouse 
 
A transgenic mouse was created to try and address the potential issues with 
tolerance that may have been hindering the ability to produce a complex 
specific antibody. A mouse has recently been created in the Willison laboratory 
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that lacks all complex gangliosides except in places where the Thy 1 promoter is 
active. This restricts ganglioside expression to the axons in these mice, which 
makes them useful for studying autoimmune neuropathies.  
An immunisation study, performed by a former colleague, indicated that these 
mice lacked the tolerance to gangliosides seen in normal WT mice but not to the 
same degree as GalNAc T-/- mice (Rupp, Unpublished Observations). The 
suitability of the mice for immunisation studies led to the desire to try and 
produce a mouse that lacked tolerance to both GM1 and sulfatide.  
This was achieved by crossing the Thy1 mice with the CST-/- mice to create a 
new mouse – CST-/- x GalNAc T-/- Thy 1 - dubbed the double KO axonal rescue. 
These mice lacked sulfatide entirely and had only restricted complex ganglioside 
expression. They suffered from a reduced muscle mass and developed a tremor 
and ataxia as they aged which resembled the normal CST-/- mice. As a result of 
these features, the mice were immunised at 4 weeks to reduce any excess 
suffering.  
A pilot study was performed using one mouse, which was immunised with 
GM1:Sulfatide liposomes that were created as per Section 2.6. The mouse was 
bled regularly but smaller volumes than normal were collected due to its 
reduced size. The serology indicated that no anti-GM1 antibodies were created 
throughout the immunisation cycle (Figure 6.14). Antibody responses were 
detected to other components of the liposomes particularly sulfatide and 
sulfatide complexes such as sulfatide:SM and sulfatide:Chol. There were also 
antibodies that targeted Chol complexes, which were enhanced beyond the 
signal detected to the single epitope. 
A hybridoma fusion was performed using the spleen from the mouse, with the 
first screening indicating that several cells were producing antibodies. As 
expected most cells were producing sulfatide antibodies but there were also 
several cells producing anti-GM1 IgM and IgG antibodies. The blots indicated that 
these had high intensity values which supported the theory that the signals were 
not artefacts. 
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Figure 6.14 – Double KO Axonal Rescue Immunisation with GM1:Sulfatide 
Liposomes 
Double KO axonal rescue mice were immunised with GM1:sulfatide liposomes 
and their sera were screened by combinatorial glycoarray. A: The IgM and IgG 
blots from the terminal bleed indicate a high sulfatide antibody response that is 
enhanced with SM and Chol. There is also minor responses to Chol complexes 
which are enhanced compared to the single Chol. No anti-ganglioside antibodies 
were detected. B: The spleens from these mice were used to create hybridoma 
cell lines. A high number of sulfatide antibodies were detected in the 
supernatant but there were also a high number of GM1 antibodies which were 
both IgM and IgG. The spot colour indicated that these were strong signals. 
 
A selection of cells, which produced the highest signals, were expanded and 
attempts were made to clone them further but unfortunately the cells were 
outgrown and ceased antibody production.  
6.2.5 Immunisations with WLE Liposomes 
 
The lack of success in producing complex-dependent antibodies raised questions 
about the effectiveness of the liposome configurations. The simplistic 
composition, whilst useful for producing antibodies against single antigens, is not 
representative of the endogenous membrane and, as such, may be unable to 
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induce the same complex-dependent antibody responses that are observed in 
certain patient’s sera.  
In an attempt to address this issue, an immunogen was sought that more closely 
resembled the lipid composition of a nerve membrane. This resulted in the 
selection of whole lipid extract (WLE), which is derived from homogenised cauda 
equina. As this nerve is enriched in a variety of gangliosides (Ogawa-Goto et al., 
1992), it was a particularly good candidate for inducing the generation of 
complex-dependent antibodies.  
Initially, attempts were made to immunise mice with WLE suspended in CFA/IFA; 
however, this was found to be ineffective in inducing an immune response (data 
not shown). Instead, an alternative approach was taken, in which WLE was 
incorporated into liposomes in place of the glycolipids. Both GalNAc T-/- and  
 
Figure 6.15 – WLE Immunised Mice 
GalNAc T-/- and GalNAc T+/+ mice were immunised with liposomes containing 
WLE over a 4 week peiod. A: An ELISA was performed to analyse the 
development of the immune response over the immunisation cycle. The response 
rose steadily in both genotypes to a peak OD of approximately 0.3 at day 21. 
There was no difference between genotypes. B: TLC was performed on the WLE 
alongside ganglioside markers to determine its composition. An immuno-overlay 
was performed with the serum of the immunised mice, which determined that 
the antibody was not binding to one of the gangliosides screened.  
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GalNAc T+/+ mice were immunised with these liposomes over a 4 week period as 
per Section 2.7.1. 
During the immunisation cycle, thin layer chromatography (TLC) was performed 
on the WLE and a series of ganglioside markers, to establish its composition and 
determine which antigens to include in the serum screening (Figure 6.15). As 
predicted from the literature, WLE contained GM3, GD3, GD1a, GD1b, and 
GM1/LM1 (Ogawa-Goto et al., 1992). Unfortunately, due to their identical 
molecular weights, it was not possible to distinguish between GM1 and LM1 using 
this method, so both lipids were included in the serum screening. 
After 4 immunisations, the serum from the mice was screened against the panel 
of aforementioned gangliosides, Chol, DCP, SM, WLE and associated complexes. 
Unusually, neither genotype had a detectable antibody response against the 
ganglioside antigens; however, IgM antibodies were detected to WLE, suggesting 
that the mice were producing an antibody that was targeting a lipid not included 
in the initial screening.  
Analysis of the serum responses over the immunisation period appeared to 
correlate well with this theory, as there was no distinguishable difference 
between the mouse genotypes suggesting that the mice were not generating  
 
Figure 6.16 – GAME-M6 and GAME-M7 TLC immuo-overlay 
A TLC immuno-overlay was performed with both GAME-M6 and GAME-M7. The 
antibodies appeared to bind to a lipid that had a smaller molecular weight that 
all of the ganglioside markers.  
GD1a – 1849.55
GD1b – 1829.41
GQ1b – 2488.7
GM3 – 1268.66
WLEGAME-M6
GD1a – 1849.55
GD1b – 1829.41
GQ1b – 2488.7
GM3 – 1268.66
WLEGAME-M7
A B
Chapter 6 – IMMUNISATIONS WITH GANGLIOSIDE COMPLEXES 154 
 
antibodies against a complex ganglioside (Figure 6.16). Further analysis by TLC 
immuno-overlay proved that the serum antibodies were in fact binding to 
another lipid that had a smaller molecular weight than the ganglioside markers.   
As the investigations into the antigens continued, the four mice with the highest 
antibody responses were fused with a myeloma cell line to produce a hybridoma 
as per the standard protocol. Following two weeks of incubation, the cell 
supernatant was screened by ELISA against WLE instead of a specific antigen. A 
series of wells with ODs above 0.5 were expanded and rescreened after a further 
two weeks, resulting in the production of two stable hybridoma cell lines, 
dubbed GAME-M6 and GAME-M7. 
In an attempt to establish which antigen the monoclonal antibodies were 
binding, a further TLC immuno-overlay experiment was performed (Figure 6.16). 
The results from this experiment correlated with those from the serum TLC 
immuno-overlay, confirming that the antibodies were not binding to a 
ganglioside. Rather than screen the antibodies against a series of non-
gangliosides lipids, the decision was taken to perform mass spectrometry on the 
lipid band to determine its composition. A colleague carried out this experiment 
and found that the antibodies were binding to sulfatide, which was confirmed 
through ELISA and combinatorial glycoarray. Further characterisation of these 
antibodies was carried out in both Chapters 8 and 9.  
6.3 Discussion 
 
Antibodies raised against neo-epitopes composed of ganglioside complexes are a 
relatively new concept in autoimmune neuropathies. They were first speculated 
to exist when antibodies from GBS patients were found to preferentially bind to 
dimers composed of different gangliosides (Kaida et al., 2004). Since this initial 
discovery, a vast amount of research has been performed to try and identify 
potential targets of these antibodies, their pathogenic roles and their tissue 
binding capabilities (Créange et al., 2014; Kaida et al., 2007; Notturno et al., 
2009). 
Little research has been performed, however, to clone these antibodies, which is 
essential to establish what roles, if any, they have in disease. This chapter 
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explored the attempts to produce one of these antibodies in mice though 
immunisations with ganglioside and WLE liposomes.  
This method is well established and has been used in the past to induce antibody 
production in vivo (Bowes et al., 2002). In this experiment it was possible to 
produce a variety of anti-ganglioside antibodies in serum, but no antibodies were 
detected, under these conditions, which were purely complex dependent.  
The data from the GM1:GalC immunisations suggested that an anti-complex 
antibody had been created but further analysis, using an array of GM1:GalC 
complexes with differing ratios of GalC, implied that this response was most 
likely due to preferential presentation of the epitope. This was confirmed by the 
use of mouse monoclonal antibodies, which displayed the same behaviour, and 
was further supported by the data in Chapter 4.  
It is still possible that a GM1:GalC specific antibody exists; however, induction of 
such an antibody would require a precisely designed epitope. Other researchers 
have shown that dimers can be produced by fusing the oligosaccharide tails of 
two different gangliosides (Mauri et al., 2012). These dimers represent a true 
complex; however, by artificially changing the way they interact the researchers 
may have inadvertently modified their natural behaviour. The combination of 
the oligosaccharide tails may have added a level of rigidity to the complex, 
which would prevent the normal flexibility of the headgroups and thus modify 
the ability of the gangliosides to interact with other lipids.   
Aside from the potential issues with the structure of these complexes, they did 
consist of a guaranteed 1:1 dimer, which is a feature that cannot be attributed 
with those created through liposomes. The method of creating the liposomes 
involved mixing the components together simultaneously, which may result in 
any combination of lipids. There is no evidence to support that the desired 
complex has formed or that the constituent lipids are even in proximity to one 
another. This may explain why no complex dependent antibodies were 
identified.  
The immunisations themselves yielded new information in regards to the 
development of the antibody response. The differences between the GalNAc 
T+/+ and GalNAc T-/- mice have often been attributed to tolerance (Lunn et al., 
2000). The GalNAc T-/- mice are antigen naive as they have never been exposed 
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to gangliosides whereas the GalNAc T+/+ are exposed endogenously. This is 
often purported as the reason that the GalNAc T-/- mice have such a high 
antibody response as they do not recognise the antigen.  
The double KO axonal rescue raised questions about this assumption as the 
hybridoma fusion indicated that anti-GM1 antibodies were being generated. 
There was no response in the serum, however, which may suggest that the 
antibodies were being degraded or absorbed. There could be a similar response 
in the GalNAc T+/+ mice where antibodies were being produced at similar levels 
to the GalNAc T-/- mice but were being removed from the serum. This would 
result in lower levels of circulating antibodies giving the impression that there 
was a lower immune response.  
This hypothesis has been strongly supported by the work of a colleague who has 
shown that antibody internalisation is one of the main mechanisms for the 
removal of antibodies from serum (M Cunningham, Unpublished Data). The 
consequences of this work suggest that the antibody repertoire in the serum may 
not be representative of the immune response, which may have impacts on 
further immunisation studies.   
Although the desired outcome of anti-complex antibodies did not come to 
fruition, the development of the hybridoma supernatant screening technique 
proved beneficial for future studies. The lipid microarray was an optimal tool in 
establishing a high throughput screening method that could quickly identify a 
large variety of different reactivities. It was also essential for determining the 
presence of complex dependent antibodies and was vastly superior to ELISA in 
achieving this goal.  
The benefits of this technique included: the identification of antibodies with 
different targets; the ability to screen for different antibody isotypes 
simultaneously; reduced false positives as the background signal was subtracted; 
and the characterisation of an antibody and its potential targets. 
Although no anti-complex antibodies were identified, the technique did prove 
useful in identifying complex independent antibodies. In the GM1:sulfatide  
immunised mice, it allowed for the selection of two monoclonal antibodies that 
had different lipid targets. This would not have been possible using ELISA as the 
growth rate of the cells would not have permitted the supernatant to be 
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screened twice. The resultant monoclonal antibodies produced from these 
experiments are characterised in Chapter 7.
Chapter 7 – CHARACTERISATION OF ANTI-GANGLIOSIDE ANTIBODIES  158 
 
7 CHARACTERISATION OF ANTI-GANGLIOISDE ANTIBODIES 
 
7.1 Introduction 
 
The liposome immunisations performed in Chapter 6 yielded several monoclonal 
antibodies.  These were dubbed GAME-M1, GAME-M3, GAME-M4, and GAME-G2 
and were found to predominantly bind to GD1a, GM1, SM, and GM1 respectively. 
Although an initial screening was performed by ELISA and microarray, the 
antibodies required a more robust characterisation to determine their 
pathogenicity and whether they would be useful in future studies. This chapter 
explores this characterisation through analysis of the antibodies binding 
behaviours to solid phase assays and live tissue preparations.   
7.2 Results  
7.2.1 Combinatorial Glycoarray 
 
Although the main targets of the antibodies had been ascertained through the 
initial screening process, a more thorough characterisation was required to 
identify their fine specificities. This was carried out by probing the antibodies 
against various ganglioside and glycolipid targets printed using the combinatorial 
glycoarray.  
7.2.1.1 GAME-M1 
 
GAME-M1 was derived from a GalNAc T-/- mouse that was immunised with 
GM1:GD1a liposomes. On ELISA, the antibody had been shown to bind to GD1a 
and GD1a:GM1 complexes but on the combinatorial glycoarray it was found to 
bind to other glycolipid targets (Figure 7.1).  
These included GT1b, sulfatide and associated complexes. As per the original 
screening, the antibody bound primarily to GD1a and produced equivalent signals 
with all complexes containing the ganglioside. GT1b binding remained stable 
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Figure 7.1 - GAME-M1 Characterisation on Combinatorial Glycoarray 
A: A representative blot indicates the binding pattern of the antibody to various 
lipids and complexes. GAME-M1 was found to bind predominantly to GD1a, GT1b, 
sulfatide and associated complexes. B: Hypothetical binding of the antibody to 
the different gangliosides based upon its relative binding intensities. The 
antibody is likely to bind to the terminal sialic acid, common to GD1a and GT1b. 
C: Graphs of the raw data indicated the antibody’s binding signals. GAME-M1 
binds predominantly to GD1a with equivalent signals found against GD1a 
complexes. It also weakly binds to GT1b and most GT1b complexes, although it 
is slightly inhibited by GM1 and GD1b. Very weak binding was detected against 
sulfatide. All sulfatide complex binding was inhibited by gangliosides except 
those to which the antibody bound in their own right (GD1a and GT1b).   
 
with most complexes except GM1 and GD1b, which slightly inhibited the signals. 
Sulfatide binding was inhibited by all gangliosides except those to which the 
antibody bound in their own right, e.g. GD1a and GT1b.  
From this data it was concluded that the antibody preferentially bound to the 
terminal sialic acid, common to both GD1a and GT1b, that is absent from the 
other gangliosides screened. The weak sulfatide binding was attributed to the 
sulfatide specific binding domain that is common to many anti-carbohydrate 
antibodies (Alving, 1986; Townson, Greenshields, et al., 2007).   
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7.2.1.2 GAME-M3 
 
GAME-M3 was derived from a GalNAc T-/- mouse that was immunised with 
GM1:sulfatide liposomes. It was partially characterised during the hybridoma 
supernatant screening but a more thorough characterisation was performed on 
the combinatorial glycoarray, to further establish its binding pattern (Figure 
7.2).   
 
 
Figure 7.2 - GAME-M3 Characterisation on Combinatorial Glycoarray 
A: A representative blot indicates the binding pattern of the antibody to various 
lipids and complexes. Strong binding was detected to both single targets and 
complexes composed of GM1, GA1 and GD1b with smaller signals detected 
against GD1a and sulfatide. B: Hypothetical binding of the antibody to the 
different gangliosides based upon its relative binding intensities. The antibody is 
likely to bind to the terminal galactose of the ganglioside headgroup. C: Graphs 
of the raw data indicating the antibody’s binding signals. GAME-M3 binds to the 
single GM1, GA1, and GD1b epitopes and weakly to GD1a and sulfatide. GM1, 
GA1 and GD1b display similar binding signals and are all slightly enhanced with 
complexes containing accessory lipids. GD1a binding is weak and is inhibited in 
the presence of SM. All sulfatide complex binding was inhibited by gangliosides 
except those to which the antibody bound in their own right. 
GM1 GD1a GA1 GD1b Chol SM DCP GalC Sulfatide
X
GM1 X
GD1a X
GA1 X
GD1b X
Chol X
SM X
DCP X
GalC X
Sulfatide X GA1 GM1 GD1b GD1a
A
C
B
G
D
1b
G
D
1b
:G
M
1
G
D
1b
:G
D
1a
G
D
1b
:G
A
1
G
D
1b
:C
ho
l
G
D
1b
:S
M
G
D
1b
:D
C
P
G
D
1b
:G
al
C
G
D
1b
:S
ul
f
Chapter 7 – CHARACTERISATION OF ANTI-GANGLIOSIDE ANTIBODIES 161 
 
The data from the array indicated that the antibody bound to GM1, GA1 and 
GD1b with similar values. The only complexes that appeared to modify these 
binding signals were those containing accessory lipids, which were found to have 
a slightly enhancing effect. In addition to these three gangliosides, weaker 
binding signals were also detected to GD1a and sulfatide. All GD1a complexes 
showed similar values as the single target antigen except GD1a:SM, which 
inhibited antibody binding. In contrast, sulfatide binding signals were completely 
abolished by all lipids except those to which the antibody bound in their own 
right. 
 
Figure 7.3 - GAME-M4 Characterisation on Combinatorial Glycoarray 
A: A representative blot indicates the binding pattern of GAME-M4 to various 
lipids and complexes. Binding was only detected to SM, SM:Chol and SM:GalC. 
Graphs of the raw data indicated that high binding signals were detected against 
SM with lower signals detected against SM:Chol and SM:GalC complexes.  No 
binding was detected against any other lipids or SM complexes.    
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From this data it was concluded that GAME-M3 was likely binding to the terminal 
galactose that was common to all four gangliosides; however, it was also 
possible that it was binding to another non-sialyated component of the 
ganglioside headgroup. The binding to the single sulfatide antigen was, again, 
likely to be due to the sulfatide binding domain common to many anti-
carbohydrate antibodies (Alving, 1986; Townson, Greenshields, et al., 2007).  
7.2.1.3 GAME-M4 
 
GAME-M4 was derived from a GalNAc T-/- mouse that was immunised with GM1-
sulfatide liposomes. As with the previous antibodies, it was partially 
characterised during the hybridoma supernatant screening but a more thorough 
characterisation was performed to further establish its binding pattern (Figure 
7.3).  
The results indicated that the antibody had a very restricted binding fingerprint. 
It only bound to the single SM epitope and SM complexes containing either Chol 
or GalC. Binding was completely abolished in complexes composed of any 
gangliosides, DCP or sulfatide.  
7.2.1.4 GAME-G2 
 
GAME-G2 was derived from a GalNAc T-/- mouse that was immunised with 
GM1:GD1a liposomes. The lipid microarray screening determined that the 
antibody primarily targeted GM1 but the combinatorial glycoarray screening 
established that the antibody also bound to other antigens (Figure 7.4).  
These included GD1b and sulfatide. GM1 binding was found to be enhanced with 
complexes containing Chol, SM, DCP, and sulfatide. A similar pattern was found 
with GD1b although the binding signals were much lower than those found with 
GM1. Both GM1:GD1a and GD1b:GD1a complexes inhibited the binding of GAME-
G2.   
The antibody also produced a minor binding signal against sulfatide, which was 
abolished when sulfatide was in complex with most other lipids. The only 
exceptions were complexes containing gangliosides that were known targets for 
the antibody (GM1 and GD1b) and unusually GA1:sulfatide.    
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As no binding was detected to single GA1, it was concluded that the antibody 
preferentially bound to the internal sialic acid (Neu5Acα3) that is common to 
both GM1 and GD1b. The binding signal that was detected against sulfatide was, 
again, assumed to be the sulfatide binding pocket that was found with the other 
antibodies (Alving, 1986; Townson, Greenshields, et al., 2007).  
 
 
Figure 7.4 - GAME-G2 Characterisation on Combinatorial Glycoarray 
A: A representative blot indicates the binding pattern of the antibody to various 
lipids and complexes. GAME-G2 binds to GM1, GD1b and sulfatide. B: 
Hypothetical binding of the antibodies to the different gangliosides based upon 
their relative intensities. The antibody likely binds to the internal sialic acid 
(Neu5Acα3). C: Graphs of the raw data indicating the antibody’s binding signals.  
GAME-G2 binds to the single GM1 and GD1b epitopes and weakly to sulfatide. 
There is enhancement with GM1 and GD1b complexes that contain Chol, SM, DCP 
and sulfatide. GM1:GD1a and GD1b:GD1a complexes inhibit antibody binding. 
Sulfatide binding is weak and is only present to the single epitope or complexes 
containing the positive binding gangliosides. 
 
 
 
Su
lf
S
ul
f:G
M
1
S
ul
f:G
D
1a
S
ul
f:
G
A
1
S
ul
f:G
D
1b
S
ul
f:C
ho
l
S
ul
f:
SM
Su
lf:
D
C
P
Su
lf:
G
al
C
GM1 GD1a GA1 GD1b Chol SM DCP GalC Sulfatide
X
GM1 X
GD1a X
GA1 X
GD1b X
Chol X
SM X
DCP X
GalC X
Sulfatide X GA1 GM1 GD1b
A
C
B
Chapter 7 – CHARACTERISATION OF ANTI-GANGLIOSIDE ANTIBODIES 164 
 
7.2.2 Tissue Characterisation 
 
Following on from the array characterisation, the antibodies were probed 
against tissue to determine their binding capabilities to biological 
environments.To best achieve this aim, the decision was made to use ex vivo 
preparations of mouse TS. This allowed the antibody to be viewed under 
physiological conditions, unlike sections, which would involve staining pre-fixed 
tissue. The TS was selected as it contains an abundance of easily visualised 
NMJs, which are known to be a rich source of gangliosides (McArdle et al., 1981).  
7.2.2.1 GAME-M1 
 
In order to ascertain the specific targets of GAME-M1 in tissue, a variety of 
different mouse genotypes were probed to determine whether binding was 
taking place. Initial tests were performed with tissue from a WT mouse, which 
was incubated at two different temperatures (4°C or 32°C) to establish the 
optimal conditions for antibody detection. Once the experiment was complete, 
the tissues were imaged and the resultant binding signals overlying the NMJ were 
quantitated. The same tissues were then permeabilised and reimaged to 
determine if any antibody had been internalised (Figure 7.5).  
The binding signals in the unpermeabilised WT tissue were similarly low between 
the 4°C and 32°C experiments after 160 mins. However, following 
permeabilisation with 0.5% Triton X-100, the binding signals increased 
substantially for both temperatures. The median signal in the 4°C experiment 
rose to 162 AU, whilst in the 32°C experiment it rose to 25 AU. This suggested 
that the antibody was being readily internalised in the WT tissue at both 
temperatures, although it appeared that 4°C was optimal for antibody detection.  
In addition to NMJ binding, it was also noted that the antibody bound well to the 
Schwann cell plasmalemma. This binding was found to overly the CFP positive 
axon and extended from the nerve trunk to the terminal heminode (Figure 
7.6).Unfortunately, due to the nature of this binding, it was not possible to 
quantitate these results; however, it was observed that the signals appeared to 
be more intense following permeabilisation (data not shown) 
Having now established that GAME-M1 was capable of binding to live tissue, an  
Chapter 7 – CHARACTERISATION OF ANTI-GANGLIOSIDE ANTIBODIES 165 
 
 
Figure 7.5 - WT Tissue Characterisation of GAME-M1 
Ex vivo WT TS preparations were probed with GAME-M1. The tissue was 
incubated at two different temperatures (4°C and 32°C) to determine the 
optimal binding conditions. It was imaged and the secondary antibody 
fluorescent intensity overlying the NMJ was quantitated. The tissue was then 
permeabilised and reimaged to determine whether antibody was being 
internalised (n=2). A: Illustrative examples of GAME-M1 binding over the NMJ 
indicated higher binding in the permeabilised tissues at both temperatures. B: 
Box and whisker plots of fluorescent intensity indicated weak binding at both 
temperatures in the unpermeabilised tissue. These signals increased 
substantially following permeabilisation and were found to be particularly high 
in the 4°C treated tissue. In addition to binding at the NMJ, it was noted that 
GAME-M1 bound to the Schwann cell plasmalemma under all conditions. 
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Figure 7.6- GalNAc T-/- Tissue Characterisation of GAME-M1 
Ex vivo TS preparations from GalNAc T+/+ and GalNAc T-/- mice were probed 
with GAME-M1 and then permeabilised. In the GalNAc T+/+ tissue, the antibody 
bound strongly to the Schwann cell plasmalemma (arrows), which overlies the 
CFP positive axon. Binding was also detected over the NMJs (asterix). This was 
not replicated in the GalNAc T-/- tissue, which suggests that GAME-M1 is binding 
to complex gangliosides in these structures and not sulfatide.   
 
additional experiment was performed to determine if the antibody was targeting 
complex gangliosides or sulfatide. This was achieved by probing GAME-M1 against 
tissue from a GalNAc T+/+ and a GalNAc T-/- mouse for 160 mins at 32°C, 
followed by permeabilisation (Figure 7.5). The results of this experiment 
indicated that no binding was present in the GalNAc T-/- tissue, whereas strong 
binding signals were detected on the Schwann cell plasmalemma and overlying 
the NMJs in the GalNAc T+/+ tissue (Figure 1.6). This suggested that GAME-M1 
was binding to complex gangliosides on these structures and that no sulfatide 
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Figure 7.7 – GD3 -/- Tissue Characterisation of GAME-M1 
Ex vivo GD3 S -/- TS preparations were probed with GAME-M1. The tissue was 
incubated at two different temperatures (4°C and 32°C) to determine the 
optimal binding conditions. It was imaged and the secondary antibody 
fluorescent intensity overlying the NMJ was quantitated. The tissue was then 
permeabilised and reimaged to determine whether antibody was being 
internalised (n=2). A: Illustrative examples of GAME-M1 binding over the NMJ 
indicated higher binding in the permeabilised tissues. B: The quantitation results 
were graphed and indicated weak binding at both temperatures in the 
unpermeabilised tissue, although the 4°C treated tissue was higher than that 
treated at 32°C. Following permeabilisation, the binding signals substantially 
increased for both temperatures. This was higher in the 32°C treated tissue. In 
addition to binding at the NMJ, it was also noted that GAME-M1 bound in 
differing degrees to the Schwann cell plasmalemma under all conditions. 
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binding was taking place.  
Despite these findings, it was still unclear whether the antibody was targeting 
GD1a, GT1b or both in tissue. To investigate this further, another transgenic 
mouse (GD3 S-/-) was used, which lacks the ability to synthesise b-series 
gangliosides such as GT1b. As a consequence of this modification, the mouse 
overexpresses the a-series gangliosides such as GD1a, which made this tissue 
well suited for investigating this antibody’s targets.  
As with the WT tissue, the experiment was performed at two temperatures to 
determine the optimal conditions for antibody detection (Figure 7.7). All other 
settings remained the same, with the secondary antibody signal overlying the 
NMJ being quantitated, to determine the binding intensities in the different 
tissues. In the unpermeabilised tissue, incubation at 32°C produced similar 
binding to that found in the WT mice, whereas incubation at 4°C produced a 
higher binding signal of 13AU. The permeabilised tissue produced median signals 
of 209 AU and 162 AU in the 32°C and 4°C experiments respectively. The 
elevated binding signal in the 32°C treated tissue suggested that the higher 
temperature was increasing the biological activity of the membrane, which 
resulted in higher levels of antibody internalisation.  
As the binding signals were higher in the GD3 S-/- tissue, it could be proposed 
that GAME-M1 primarily targets GD1a; however, it cannot be definitively stated 
that binding to GT1b does not also occur to a certain degree in the WT tissue.  
7.2.2.2 Removal of Cryptic Epitope  
 
It has previously been established that the in-house antibody – DG1 – is inhibited 
from binding GM1 when it is in complex with GD1a (Greenshields et al., 2009). 
This complex is so ubiquitously expressed in living membranes that the only way 
to achieve DG1 binding is to first treat tissue with neuraminidase, which removes 
the terminal sialic acid of GD1a and converts it to GM1.  As GAME-M1 binds to 
GD1a, it was hypothesised that it may be able to disrupt the GD1a:GM1 complex 
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Figure 7.8 – DG1 does not bind nerve terminals incubated with GAME-M1 
Ex vivo WT TS preparations were probed with GAME-M1. One preparation was 
also probed with DG1 to establish if the GM1 binding epitope had been revealed 
by GAME-M1. Another was probed with DG2 to prove that GM1 was present over 
the NMJ. No DG1 binding was detected but DG2 verified that GM1 was present at 
the NMJ.  
 
interaction and free the GM1 epitope, which would become available for DG1 
binding. 
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Figure 7.9 – DG1 does not bind nerve terminals incubated with GAME-M1 - 
Permeabilised 
Ex vivo WT TS preparations were probed with GAME-M1 and then permeabilised. 
One preparation was also probed with DG1 to establish if the GM1 binding 
epitope had been revealed by GAME-M1. Another was probed with DG2 to prove 
that GM1 was present over the NMJ. No DG1 binding was detected but DG2 
verified that GM1 was present at the NMJ.  
 
To test this theory, tissue from WT mice were probed with GAME-M1 in the 
presence of DG1 (Figure 7.8). Other tissue was probed with the complex 
independent antibody,DG2, to confirm that GM1 was present at the terminal and 
available for binding. Under these conditions, the GM1:GD1a complex was not 
disrupted by GAME-M1 and DG1 binding was not detected. 
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For certainty, the tissue was permeabilised to ensure that DG1 had not bound 
and been internalised (Figure 7.9). As expected, the tissue was still negative for 
DG1 binding, which suggests that GAME-M1 does not modify the configuration of 
GD1a in the GM1:GD1a complex.  
7.2.2.3 GAME-M3 
 
In an effort to establish the specific targets of GAME-M3 in tissue, it was first 
screened against TS collected from GalNAc T-/- and GalNAc T+/+ mice. This 
would determine if the antibody was binding to complex gangliosides or to 
sulfatide.   
Ex vivo preparations of TS were probed with 100µg/ml of antibody for 60 mins at 
4°C, which pilot studies had indicated were the optimal conditions for antibody 
detection (data not shown). Following incubation, the tissues were imaged and 
the secondary binding signals overlying the NMJs were quantitated. The tissue 
was then permeabilised with 0.5% Triton X-100 and reimaged (Figure 7.10).   
The data confirmed that the antibody was preferentially binding to complex 
gangliosides, with the GalNAc T+/+ tissue producing high median binding signals 
of 79 and 108 AU in the pre and post permeabilised tissues respectively. The 
unpermeabilised tissue was found to be significantly higher than the 
unpermeabilised GalNAc T-/- tissue which had a median value of 0 AU (Mann 
Whitney, P<0.05). The permeabilised GalNAc T-/- tissue produced a small level 
of binding with a median signal of 26 AU; however, this was much lower than the 
signals detected in the TS from the GalNAc T+/+ mice. This suggested that a 
small amount of GAME-M3 was binding to sulfatide, a simple ganglioside or 
another unknown antigen.  
To determine which complex gangliosides GAME-M3 was binding in tissue, an 
experiment was devised using GD3 S-/- and GD3 S+/+ TS with and without N’ase 
treatment.  The rationale behind this experiment was to alter the ganglioside 
expression in tissues and use the differences between binding signals to deduce 
which antigen was likely being targeted by the antibody.  The purpose of the 
GD3 S-/- tissue was to eliminate GD1b as a target, whilst the use of the N’ase 
treatment was to remove the terminal sialic acid of GD1a and convert it to GM1.  
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Figure 7.10 – GAME-M3 Binding at GalNAc T-/- and GalNAc T+/+ Mice Nerve 
Terminals 
Ex vivo preparations of TS were probed with GAME-M3. The tissue was imaged 
and the secondary antibody fluorescent intensity overlying the NMJ was 
quantitated. The tissue was then permeabilised and reimaged to determine 
whether antibody was being internalised. A: Illustrative examples show high 
binding signals overlying the NMJ in the GalNAc T+/+ tissues. No binding is seen 
in the GalNAc T-/- tissue. B: High binding signals were found in the GalNAc T+/+ 
mice in both the pre and post permeabilised tissue. The unpermeabilised GalNAc 
T+/+ tissue was significantly higher than the unpermeabilised GalNAc T-/- tissue 
(Mann Whitney, P<0.05). Minor binding was detected in the permeabilised 
GalNAc T-/- tissue but this was much lower than the GalNAc T+/+ tissue (n=5). 
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The tissues were pre-treated with either N’ase or Ringer’s solution and then 
probed with GAME-M3 for 60 mins at 4°C, as per the previous experiment. The 
results indicated that there was very little binding to the N’ase treated tissue in 
either genotype (Figure 7.10). Low binding signals were detected, however, in 
both the untreated GD3 S-/- and GD3 S+/+ tissue with the GD3 S-/- tissue 
showing the highest signal.  
 
Figure 7.11 – GAME-M3 Binding in GD3 S-/- and GD3 S+/+ tissue with and 
without N’ase treatment.  
Ex vivo preparations of TS from GD3 S-/- and GD3 S+/+ mice were probed with 
GAME-M3. Half the tissue had been pre-treated with N’ase whilst the other half 
only received Ringer’s solution. The tissue was imaged and the secondary 
antibody fluorescent intensity overlying the NMJ was quantitated. A: Illustrative 
examples show binding overlying the NMJ in the untreated tissues whereas 
binding is absent in those treated with N’ase. B: The results indicated that low 
binding was detected in the GD3 S-/- and GD3 S+/+ tissues without N’ase, whilst 
binding was mostly absent from the N’ase treated tissue (n=5). 
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In the permeabilised tissue, binding increased in both the untreated GD3  S-/- 
and GD3 S+/+ tissue, which suggested that the antibody had been internalised 
(Figure 7.12). Binding was also detected in the N’ase treated GD3  S-/- tissue; 
however, no binding was detected in the treated GD3 S+/+ tissue.  
Taken together, this data suggested that the antibody preferentially bound to 
GD1a in tissue, which was unexpected as it was not one of the main antigens on  
 
Figure 7.12 - GAME-M3 Binding in GD3 S-/- and GD3 S+/+ tissue with and 
without N’ase treatment - Permeabilised.  
Ex vivo preparations of TS from GD3 S-/- and GD3 S+/+ mice were probed with 
GAME-M3 followed by permeabilisation. Half the tissue had been pre-treated 
with N’ase whilst the other half only received Ringer’s solution. The tissue was 
imaged and the secondary antibody fluorescent intensity overlying the NMJ was 
quantitated. A: Illustrative examples indicate increased binding overlying the 
NMJ in untreated tissues. B: The results indicated that low binding was detected 
in the N’ase treated GD3 S-/- and untreated GD3 S+/+ tissues. A good signal was 
detected in the untreated GD3 S-/- tissue whilst very little binding was detected 
in the N’ase treated GD3 S+/+ (n=5). 
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array. There was still minor binding to GM1 as confirmed by the detection of 
antibody in the N’ase treated GD3 S-/- tissue, which lacked GD1a; however, this 
was surprisingly low considering the high expression of GM1 at the nerve 
terminal (Greenshields et al., 2009).  
These unusual results could be explained if complex interactions were taken into 
account. It is well established that the presence of other lipids can modify the 
headgroup conformation of gangliosides and this can be influenced by the 
density of the molecules (Galban-Horcajo et al., 2014). On array it appears that 
GAME-M3 preferentially binds to the terminal galactose of gangliosides but it is 
not clear how this is presented in tissue. It is possible that in the membrane, the 
headgroup is kinked due to some unknown interaction, which makes it less 
accessible for antibody binding. GD1a contains a terminal sialic acid, which may 
counteract this effect and allow GAME-M3 to bind. Similarly, the signals 
detected in the N’ase treated GD3 S-/- tissue may be due to the overexpression 
of GM1, which is so high that it partially overcomes the complex attenuation of 
the ganglioside.  
Further study would be needed to confirm this hypothesis but this acts as a good 
example of the differences between arrays and tissue and justifies why antibody 
characterisation must be carried out using both methods.  
7.2.2.4 GAME-M4 
 
The anti-SM antibody, GAME-M4, was probed against GalNAc T-/- and GalNAc 
T+/+ tissue to establish if it was capable of binding to a biological environment 
(Figure 7.13). As the array indicated that antibody binding was inhibited in the 
presence of gangliosides, it was thought that tissue from a GalNAc T-/- mouse 
would be optimal for detecting antibody staining.   
Ex vivo preparations of TS were therefore probed with 100µg/ml of GAME-M4 for 
60 mins at 4°C. Examination of the tissue suggested that no GAME-M4 binding 
took place at the nerve terminals or along the axon in either the GalNAc T+/+ or 
GalNAc T-/- TS. Background binding was seen, however, in all tissue but this did 
not appear to be localised to any particular structure and was therefore 
associated with non-specific binding.  The tissue was permeabilised to clarify  
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Figure 7.13 - GAME-M4 Binding in GalNAc T-/- and GalNAc T+/+ Mice 
Ex vivo preparations of TS were probed with GAME-M4. Illustrative examples 
show that only background binding was detected in the GalNAc T-/- and the 
GalNAc T+/+ tissue. Quantitation was not performed due to the absence of a 
visual signal (n=5). 
that the antibody had not been internalised but no binding signal was detected 
(Data Not Shown).     
The lack of antibody detection was presumably due to the restrictive binding 
pattern of the antibody. Gangliosides and sulfatide are abundant in neural tissue 
and presumably form complexes with SM when they are co-localised. This 
severely reduces the availability of the epitope for GAME-M4 to bind, which may 
explain why no signal was detected.  
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It may be worthwhile in future studies, however, to incubate nerve sections with 
GAME-M4 to ensure that the lack of staining was not due to problems with 
antibody penetration.  In addition, it may also be beneficial to co-stain for a 
myelin marker, to definitively prove that no staining was present along any 
myelinated structures in whole mount tissue.  
7.2.2.5 GAME-G2 
 
The anti-GM1/GD1b/sulfatide antibody, GAME-G2, was probed against TS from 
GalNAcT- /- and GalNAc T+/+ mice to determine if the antibody was binding to 
complex gangliosides or sulfatide (Figure 7.14). Analysis of the data, however, 
indicated that the antibody bound poorly to both permeabilised and 
unpermeabilised tissue from both genotypes. There was very low binding in the 
GalNAc T-/- TS; however, the background level of antibody was relatively high in 
some of these tissues, which may have skewed the results.  
Due to the poor binding signals in the GalNAc T+/+ tissue, the antibody was 
probed against GD3 S+/+ and GD3 S-/- tissue with and without N’ase treatment 
to determine if any binding could be detected with enhanced ganglioside 
expression.  
There was very little binding in the unpermeabilised tissue regardless of N’ase 
treatment (Figure 7.15). The only tissue which produced a visible signal was the 
N’ase treated GD3 S-/- TS but even this signal was relatively low. In the post-
permeabilised experiment the binding signals increased for all the tissues, 
although their values were still low (Figure 7.16). The binding was again highest 
in the N’ase treated GD3 S-/- tissue which had a median signal of 37AU.   
As this tissue lacked GD1a, it suggested that GD1a inhibition was preventing the 
binding of GAME-G2 in WT tissue. This was substantiated by the findings of the 
combinatorial glycoarray screening, which indicated that the presence of GD1a 
in complexes inhibited the binding signal of the antibody.  
Even with N’ase treatment, the binding signals were still low, which suggested 
that the antibody may have had trouble accessing its epitope. This may be due 
to its location on the ganglioside, which is in a lower portion of the headgroup 
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and thus less freely available for binding. Further experiments would need to be 
performed, however, to test this theory.  
 
Figure 7.14 - GAME-G2 Binding in GalNAc T-/- and GalNAc T+/+ Mice 
Ex vivo preparations of TS were probed with GAME-G2. The tissue was imaged 
and the secondary antibody fluorescent intensity overlying the NMJ was 
quantitated. The tissue was then permeabilised and reimaged to determine 
whether antibody was being internalised. A: Illustrative example of absent 
GAME-G2 binding over the NMJ in all tissues. B: Box and whisker plots were 
created of the fluorescent secondary binding signals overlying the NMJ. There 
were poor binding in both the GalNAc T-/- and GalNAc T+/+ tissue pre and post 
permeabilisation. Very minor binding was detected in the GalNAc T-/- tissue; 
however, this may have been caused by high background binding of the antibody 
in these tissues (n=5). 
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Figure 7.15 – GAME-G2 Binding in GD3 S-/- and GD3 S+/+ tissue with and 
without N’ase treatment. 
Ex vivo preparations of TS from GD3 S-/- and GD3 S+/+ mice were probed with 
GAME-M3. Half the tissue had been pre-treated with N’ase whilst the other half 
only received Ringer’s solution. The tissue was imaged and the secondary 
antibody fluorescent intensity overlying the NMJ was quantitated. A: Illustrative 
examples indicate GAME-G2 binding over the NMJ in the N’ase treated GD3 S-/- 
tissue. Binding was absent in the other tissues. B: The binding signals were 
generally low for all the tissues regardless of treatment although a small level of 
binding was detected in the N’ase treated GD3 S-/- tissue (n=5). 
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Figure 7.16 - GAME-G2 Binding in GD3 S-/- and GD3 S+/+ tissue with and 
without N’ase treatment - Permeabilised. 
Ex vivo preparations of TS from GD3 S-/- and GD3 S+/+ mice were probed with 
GAME-G2 followed by permeabilisation. Half the tissue had been pre-treated 
with N’ase whilst the other half only received Ringer’s solution. The tissue was 
imaged and the secondary antibody fluorescent intensity overlying the NMJ was 
quantitated. A: Illustrative examples indicate GAME-G2 binding over the NMJ in 
the N’ase treated tissues. Binding was absent in the other tissues. B: The binding 
signals were higher in the permeabilised tissue but the signals were still 
relatively low. The highest signals were detected in the N’ase treated tissues of 
both genotypes but there was no significant differences (n=5). 
 
7.3 Discussion  
 
Mouse anti-ganglioside antibodies are an ideal tool for investigating the 
pathogenesis of autoimmune neuropathies. They are easy to produce and have 
proven useful in identifying specific mechanisms of disease in several studies; 
ranging from the roles of complement in nerve injury, to the localisation of 
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gangliosides within the nervous system (Lunn et al., 2000; O’Hanlon et al., 
2001).  
To fully understand the behaviour of novel antibodies, it is vital that their 
binding properties are fully characterised prior to their use. The newly 
synthesised antibodies, reported in this thesis, underwent this characterisation 
through a robust screening program involving analysis of the antibodies both in 
vitro and ex vivo.  
During the initial cell supernatant screening process, the primary antigen of each 
antibody was identified through tests with ELISA or microarray. Once the 
monoclonal antibodies were produced, however, they were rescreened against a 
panel of lipids to establish their cross reactivities. Traditionally, these initial 
binding specificity assays were carried out using ELISA (Goodyear et al., 1999); 
however, the combinatorial glycoarray has proved to be a superior tool for 
determining the various targets of novel antibodies. It allows for the 
simultaneous screening of a larger number of antigens using a much smaller 
amount of lipid and has the major advantage that it can be used to print 
complexes composed of different combinations of gangliosides and other lipids 
(Rinaldi et al., 2009).  
The identification of complexes was particularly useful here as they established 
which lipids could enhance or inhibit antibody binding prior to tissue studies. 
This allowed for a methodical approach in analysing the behaviours of the 
antibodies and aided in explanations as to the observed binding patterns in 
tissue.  
An example of this was shown with GAME-G2, which had a decreased binding 
signal on arrays when bound to complexes composed of GD1a. As the tissue 
studies indicated that the antibody bound relatively poorly to GD3 S-/- and GD3 
S+/+ tissue, it implied that GD1a inhibition may be preventing antibody binding. 
To test this hypothesis, N’ase was applied to the tissue to remove the terminal 
sialic acid that is common to GD1a and GT1b. Binding signals were detected in 
these treated tissues, which substantiated the initial findings on array that GD1a 
was inhibiting antibody binding.   
The inhibition of anti-GM1 antibodies by GD1a has been reported previously 
(Greenshields et al., 2009; Nobile-Orazio et al., 2010), which highlights how 
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antibody binding is impacted by the local environment of the ganglioside. The 
differences in this environment may explain why cytochemical analysis has been 
unable to adequately explain why similar amounts of GM1 and GD1a are present 
in both motor and sensory nerves, and yet only motor nerves are targeted in 
MMN (Ogawa-Goto et al., 1990; Svennerholm et al., 1992, 1994). It could be 
assumed that in MMN patients, who often have high titres of anti-GM1 antibody, 
injury does not occur in the sensory nerves because they have a high level of cis-
interaction between GM1 and GD1a, which alters the presentation of GM1 to the 
immune system. By contrast the motor nerves may have GM1 and GD1a located 
in separate portions of the membrane, resulting in the normal presentation of 
GM1 to the immune system, which opens it up to attack by antibodies. 
This had been partially shown by other researchers who found that a rabbit 
model of AMAN produced high titres of anti-GM1 antibodies. These antibodies 
were then responsible for high levels of complement deposition and node 
disruption in motor nerves, whilst the sensory nerves remained mostly 
unaffected (Susuki et al., 2012).  This may be due to the cis-inhibition of anti-
GM1 antibodies by the GM1:GD1a complex, although the exact mechanism was 
not established within this experiment.  
This provides a potential use of GAME-G2 in future studies, where it could be 
applied, alongside a complex-independent antibody, to motor and sensory 
nerves. This would establish if the GD1a inhibition was responsible for the lack 
of injury in sensory nerves or if the lack of injury was related to another 
unknown factor.   
Aside from GD1a, the identification of complex enhancement or inhibition was 
also useful in determining which antigens the antibodies were most likely 
binding. GAME-M1, GAME-M3 and GAME-G2 bound to the single sulfatide epitope 
on arrays, which may have led to the assumption that the antibodies were 
binding to sulfatide in tissue. Analysis of the sulfatide complexes on the array, 
however, indicated that binding was inhibited with all complexes except those 
that contained a ganglioside to which the antibody bound in its own right.  
The inhibitory lipids included Chol and SM which are ubiquitously expressed on 
the plasma membrane (Cortes et al., 2013). This makes it highly unlikely that 
any of the antibodies would bind successfully to sulfatide as it would almost 
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always be in a complex with one of these lipids. Immunofluorescent studies 
confirmed this theory and proved that little or no binding was detected in tissues 
lacking complex gangliosides.  
This same analysis was used to determine why GAME-M4 did not bind tissue. On 
array the antibody was inhibited from binding to SM when it was in complex with 
any ganglioside or sulfatide. As these lipids are enriched in neural tissue 
(Molander-Melin, 2003), it was unlikely that GAME-M4 would be capable of 
binding successfully to it. It may be able to bind to other non neural cells; 
however due to time constraints, these were not examined within these 
experiments.  
Although the array tended to correlate well with the immunofluorescence 
results, it was not always an accurate measure of the antibodies targets on 
tissue. On array, GAME-M3 appeared to bind with similar levels to GM1, GA1 and 
GD1b but it also bound weakly to GD1a. As these gangliosides all contained a 
terminal galactose, it was assumed that this was the specific epitope of the 
antibody, although it may well have bound to other non-sialylated components 
of the headgroup.  
When applied ex vivo, it appeared that GAME-M3 was only capable of binding to 
GD1a enriched tissues, which was surprising considering the array results, and 
the fact that the nerve terminal is known to be enriched with both GM1 and 
GD1b (Boffey et al., 2005; Greenshields et al., 2009). In contrast, GA1 is mostly 
absent in the mammalian nervous system and was therefore never considered as 
a potential target of the antibody in tissue (Seyfried et al., 1996).   
The absence of binding to GM1 and GD1b suggested that an unknown cis-
inhibition was occurring between the gangliosides and a component of the 
plasma membrane. It was hypothesised that this interaction was cryptically 
shielding the terminal galactose in such a manner as to prevent antibody 
binding. As GD1a contains a terminal sialic acid, it was postulated that it may be 
able to overcome this shielding and expose the terminal galactose to which 
GAME-M3 could bind.   
This data was at odds, however, with molecular modelling studies, which have 
previously indicated that the terminal galactose lies perpendicular to the plasma 
membrane and is therefore accessible for antibody binding (Patel & Balaji, 
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2008). These models are relatively simple though, and only incorporate one or 
two other lipids, which downplays the complexity of the membrane (Lyubartsev 
& Rabinovich, 2011). It is possible that if all components of the membrane, 
including lipids and proteins, are taken into account that the terminal galactose 
may become somewhat shielded. 
It is also possible that GAME-M3 does not actually bind to it but rather to another 
component of the headgroup (GalNAc, the internal galactose, or glucose). 
Originally it was assumed that the antibody bound to the terminal galactose due 
to the change in the binding signal that was associated with GD1a. As GD1a 
contains a terminal sialic acid, it was assumed that it was most likely influencing 
the presentation of the terminal galactose, but this assumption may be 
incorrect.   
Molecular modelling has indicated that the glucose and internal sialic acid of the 
ganglioside headgroups are unavailable for interaction with macromolecules 
when they are in DPPC membrane bilayers (Humphrey et al., 1996). Further to 
this, they indicated that CTx was unable to bind to these components, due to 
access issues, whereas it could bind to both the terminal galactose and internal 
sialic acid (Neu5Acα3) of GM1 (Merritt et al., 1998; Neu et al., 2008).  
The same effects could occur with GAME-M3 in tissue, where the specific epitope 
is inaccessible due to its location on the headgroup. This would prevent antibody 
binding to a membrane bound ganglioside but it would not necessarily prevent 
binding to a ganglioside printed by array. The reason for this is that the array 
would print lipids as dehydrated monolayers that do not necessarily behave in 
the same way as those in a biological membrane. Further research would need 
to be performed to establish the specific epitope of this antibody, which may aid 
in determining the reasons for the differences between the array and tissue 
results.  
Aside from comparisons between the array and tissue, ex-vivo preparations also 
proved beneficial in establishing which neurological structures the antibodies 
were specifically targeting. This helped determine their pathogenic roles and, by 
extension, their possible uses in future experiments.  
Whilst, GAME-M3 and GAME-G2 were found to bind primarily to the NMJ, GAME-
M1 was found to bind avidly to both the NMJ and the Schwann cell 
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plasmalemma. This has been shown with anti-GD1a antibodies previously, with 
some researchers finding that certain antibodies were able to distinguish 
between motor and sensory nerves depending upon their specific epitope (Gong 
et al., 2002; P. H. H. Lopez et al., 2008). This is interesting from a disease 
perspective as several neuropathies are commonly associated with anti-GD1a 
antibodies (Carpo et al., 1996; Yuki & Hartung, 2012) The symptoms of these 
conditions can vary between patients, which may be due, in part, to the type of 
anti-GD1a antibodies that have arisen. Further research would need to be 
carried out to determine if GAME-M1 was capable of distinguishing between 
nerves, but the potential remains that the antibody could be useful for studying 
paralytic neuropathies.   
Overall, the characterisation of the anti-ganglioside antibodies successfully 
determined their binding patterns both in vitro and ex vivo. This information 
will be essential to determining their use in future experiments.  
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8 PRODUCTION OF ANTI-SULFATIDE ANTIBODIES 
8.1 Introduction 
 
The immunisation experiments of the previous chapters tended to focus on the 
use of GalNAc T-/- mice as hosts for the generation of complex-dependent 
antibodies. These mice were selected for these studies as they lack the ability to 
synthesise complex gangliosides, such as GM1 and GD1a, and have been 
demonstrated to be more effective hosts in antibody generation than their WT 
counterparts (Lunn et al., 2000).   
Although the exact reason for the responsiveness of these transgenic mice to 
immunisation has yet to be fully elucidated, it has been hypothesised that the 
lack of endogenous exposure to complex gangliosides during development 
prevents the formation of immunogenic tolerance (Bowes et al., 2002; 
Goodfellow et al., 2005; Willison & Plomp, 2008). The immune systems of these 
mice would therefore perceive complex gangliosides as foreign antigens, which, 
upon exposure, would result in the production of high titres of anti-ganglioside 
antibodies.  
Whilst these factors made the mice ideal candidates for the production of 
antibodies targeting complexes composed solely of gangliosides, their usefulness 
in producing antibodies against complexes containing other glycolipids was 
questionable. In particular, it was unclear how effective they would be in the 
production of antibodies specifically targeting GM1:GalC or GM1:sulfatide 
complexes.  
In these experiments, consideration was therefore given to transgenic mice that 
lacked the ability to synthesise other glycolipids, specifically GalC and sulfatide 
(Honke et al., 2002; K. Suzuki, 1998). Unlike the GalNAc T-/- mice, however, no 
previous studies had been performed on these mice to assess their receptiveness 
to immunisation against the single glycolipids. 
This information was deemed to be necessary before proceeding with the 
ganglioside complex immunisations, as the mice would be of no use in these 
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studies if they maintained immunological tolerance to the single glycolipid 
species. Whilst it would have beneficial to perform these studies using both 
genotypes of mice, only those lacking sulfatide (CST-/-) were readily available 
within our laboratory, and were therefore the only mice that were examined 
within these experiments.      
In addition to establishing the suitability of the CST-/- mice to immunisation, 
these experiments also sought to produce a series of anti-sulfatide antibodies for 
further study. These antibodies are implicated in a number of demyelinating 
diseases, including GBS and MS, but their roles in these conditions are still 
unclear (Brennan et al., 2011; Carpo et al., 2000; Ilyas, 2003; Petratos et al., 
2000; Souayah et al., 2007). This chapter therefore had two mains aims: to 
establish the susceptibility of CST-/- mice to immunisation with sulfatide 
liposomes; and to produce anti-sulfatide antibodies to establish their roles in 
disease.   
8.2 Results 
8.2.1 Sulfatide Liposome Immunisations 
 
Three different genotypes of mice were employed in the immunisation 
experiments to ascertain whether the absence of sulfatide influenced the 
generation of anti-sulfatide antibodies. These included CST-/-, CST+/+ and DBA 
mice. As already discussed the CST-/- mice were deficient in sulfatide and were 
therefore assumed to produce high titres of antibodies due to a lack of 
immunogenic tolerance. In contrast, the CST+/+ mice had a normal distribution 
of sulfatide throughout their systems and were assumed to be poor antibody 
producers due to endogenous exposure. A third genotype, that had a different 
genetic background than the CST+/+ mice (C57/B6), was also included in these 
experiments to ascertain whether background affected the ability of the mice to 
generate an immune response.  
All the mice were immunised with sulfatide liposomes over a 4 week period as 
per Section 2.7.1. Serum was collected regularly throughout the immunisation 
cycle and was analysed using the combinatorial glycoarray (Figure 8.1).  
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Figure 8.1 - Sulfatide Liposome Immunisations 
The sera were screened against a panel of lipids and complexes using the 
combinatorial glycoarray. A representative blot of the terminal bleed antibody 
binding pattern is displayed for each genotype. The antibody binding signals to 
sulfatide were plotted over time for each genotype and a comparison of the 
terminal antibody binding to sulfatide complexes with the single components 
subtracted is also plotted. A: IgM Results. CST -/- and CST+/+ mice had virtually 
identical responses, displaying a sharp increase in anti-sulfatide antibodies on 
day 14, a small decrease on day 21, followed by a further increase on day 28. 
The antibody levels in the DBA mice increase steadily at each subsequent bleed 
and were found to be significantly higher than both the CST-/- and CST+/+ mice 
on day 21 (Mann Whitney, P<0.05). All genotypes had higher binding signals to 
sulfatide:GalC, sulfatide:Chol and sulfatide:SM complexes compared to the 
single sulfatide antigen. B: IgG Results. Neither the CST-/- or CST+/+ mice had 
detectable anti-sulfatide IgG antibodies at any timepoint. In contrast, the DBA 
mice developed anti-sulfatide antibodies on day 28. Sulfatide:Chol complexes 
appeared to greatly enhance this signal. CST+/+ (n=3), CST-/- (n=6), DBA (n=3).    
*
B
CST -/- CST +/+ DBAA
CST -/- CST +/+ DBA
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The results from these experiments indicated that that there was very little 
difference between the CST+/+ and CST-/- mice. Both groups developed low 
levels of anti-sulfatide IgM antibodies on day 14, followed by a small decrease on 
day 21 and a sharp increase on day 28, reaching a high of approximately 12000 FI 
units. In contrast, the DBA mice developed a low immune response on day 14, 
followed by a substantial increase on day 21 that was significantly higher than 
both the CST+/+ and CST-/- mice (Mann Whitney, P<0.05). This eventually 
reached a plateau on day 28 of approximately 15000 FI units, where it was 
assumed that the antibodies began class switching. All three genotypes of mice 
were found to have higher binding signals to sulfatide:GalC, sulfatide:Chol and 
sulfatide:SM complexes compared to the single sulfatide antigen. 
Analysis of the IgG responses indicated that neither the CST+/+ or CST-/- mice 
developed anti-sulfatide antibodies. In comparison, the DBA mice developed low 
levels on day 28, which correlated with the plateau observed in the IgM results. 
This signal was found to be substantially increased with sulfatide:Chol complexes 
compared to the single antigen.   
Taken together, this data suggested that the CST-/- mice were not better suited 
to the production of anti-sulfatide antibodies than WT mice. This may be related 
to the C57/B6 background in which the mice were raised as the DBA mice were 
shown to be superior in producing both anti-sulfatide IgM and IgG antibodies; 
however, this could not be confirmed. Despite these results, the mice were still 
able to produce anti-sulfatide antibodies and, as such, their spleens were 
harvested and fused with a myeloma cell line to create a hybridoma.   
8.2.2 Hybridoma Screening 
 
Following two weeks of incubation, the supernatant of the hybridoma cells was 
screened for the presence of antibodies using the microarray method developed 
in Chapter 6 (Figure 8.2). This screening indicated that a large number of wells 
were producing both IgM and IgG antibodies against sulfatide and SM. Unlike the 
anti-ganglioside antibodies produced in the previous chapters though, none of 
these antibodies appeared to cross react with other glycolipids.  
The positive wells with the highest binding signals were expanded into 24 well 
plates and incubated for a further three days, followed by removal and  
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Figure 8.2 - Initial Supernatant Screen of sulfatide Immunised Mice 
Hybridoma Cells 
Hybridoma supernatant was screened to determine antibody positive wells. The 
screening was performed two weeks after the initial hybridoma fusion. Several 
wells were found to contain IgM antibodies targeting both sulfatide and SM. IgG 
antibodies were also identified that targeted sulfatide.  
 
replacement of the supernatant. As the aim of these studies was to produce 
anti-sulfatide antibodies, the supernatant was rescreened after a further three 
days of growth using a sulfatide ELISA. As expected, the number of positive 
wellsdropped substantially but the remaining hybridoma cells were expanded 
further and routinely rescreened for antibody activity. This led to the production 
of two IgM and two IgG anti-sulfatide monoclonal antibodies dubbed GAME-M2, 
GAME-M5, GAME-G1 and GAME-G3.  
Following on from their production, the binding behaviours of the antibodies 
were characterised through the use of solid phase assays, cells and tissues. The 
results of these studies are shown in Chapter 9.  
8.3 Discussion 
 
The ability to successfully produce anti-glycolipid antibodies in mice is often 
purported to be related to their glycolipid repertoire. This is based upon the 
findings of several studies, which have shown that mice that lack the ability to 
synthesise particular gangliosides are better hosts for the production of anti-
ganglioside antibodies than their WT counterparts (Bowes et al., 2002; Lunn et 
al., 2000).  
Detection Assay - IgG
Mouse Number
63
9
65
0
63
8
65
4
64
5
0
10
20
30
40
Sulf
SM
Detection Assay - IgM
Mouse Number
63
9
65
0
63
8
65
4
64
5
0
10
20
30
40
Sulf
SM
Chapter 8 – PRODUCTION OF ANTI-SULFATIDE ANTIBODIES 191 
 
The reason behind the superior antibody producing ability of these mice has 
been hypothesised to be due to a lack of endogenous ganglioside exposure, 
which prevents the formation of immunogenic tolerance (Bowes et al., 2002). As 
a result, the immune systems of these mice perceive complex gangliosides as 
foreign antigens and develop high titres of anti-ganglioside antibodies when 
challenged with the glycolipids.  
Based upon this hypothesis, this chapter sought to determine whether sulfatide 
knockout mice behaved in a similar fashion and produced high titres of anti-
sulfatide antibodies. Its findings, however, demonstrated that the knockout mice 
were no better in producing antibodies than their WT counterparts. This 
suggested that the mice had either developed tolerance through a different 
mechanism or that tolerance was not a factor in antibody production.  
As the sulfate group is the only feature that distinguishes sulfatide from GalC, it 
is cogent to assume that it would be the only structure that the immune systems 
of CST-/- mice would perceive as foreign. However, this same sulfate group is 
expressed on a variety of sulfated proteins and lipids to which the mice would 
have developed tolerance. It is therefore possible that they would perceive the 
sulfate group on sulfatide as endogenous and would not develop anti-sulfatide 
antibodies in response to the glycolipid.  
Similarly, it was also possible that sulfatide interacts with its surrounding 
environment in vivo in such a way that the sulfate group is obscured from 
immunogenic exposure.  The molecule would therefore resemble GalC, to which 
the mouse would have already developed tolerance thus preventing a robust 
antibody response.  
Another possibility is that tolerance is not actually a factor in antibody 
generation. As mentioned in Chapter 6, recent work within our laboratory has 
suggested that internalisation may be one of the main mechanisms for the 
removal of circulating anti-ganglioside antibodies (M Cunningham, unpublished 
observations). This has yet to be shown with anti-sulfatide antibodies, but it is 
possible that the glycolipid does not internalise as readily as gangliosides. This 
would account for the lack of difference between the CST-/- and CST+/+ mice, 
as neither would be able to remove anti-sulfatide antibodies from circulation.  
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Aside from glycolipid repertoire, this chapter also explored the effects of 
different genetic backgrounds on antibody generation. It found that DBA mice 
were more effective hosts in producing anti-sulfatide antibodies than both the 
CST+/+ and CST-/- mice that were raised on a C57/B6 background. This 
suggested that the genetic background of mice is a more important factor in 
selecting hosts for antibody generation than glycolipid expression.   
Previous studies supported this finding, as they have found that C57/B6 mice 
have defective secondary immune responses compared to DBA mice (Morokata et 
al., 1999; Pan et al., 2004). This suggests that, although the C57/B6 strain is 
useful for producing transgenic mice, it is not well suited for inducing antibody 
production.  
Despite these issues, the immunisation studies still led to the development of 
several novel anti-sulfatide antibodies. These antibodies are characterised in the 
subsequent chapter, through the use of solid phase assays and ex vivo 
preparations, to determine their roles in both health and disease.  
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9 CHARACTERISATION OF ANTI-SULFATIDE ANTIBODIES 
 
9.1 Introduction 
 
The liposome immunisations of the previous chapters led to the successful 
creation of several anti-sulfatide antibodies. Whilst initial studies demonstrated 
that these antibodies bound to sulfatide and associated complexes, a more 
thorough characterisation was required to establish the binding patterns of the 
antibodies both in vitro and ex vivo to elucidate their roles in disease. This 
chapter therefore explores this characterisation through analysis of the 
antibodies binding behaviours to solid phase assays, cells, fixed tissue sections 
and live tissue preparations.  
9.2 Results 
9.2.1 Combinatorial Glycoarray 
 
Initial studies analysed the binding patterns of the antibodies against a series of 
glycolipid complexes printed using the combinatorial glycoarray. The results of 
these experiments confirmed that the antibodies all bound to sulfatide but 
indicated that there were distinct differences in their fine specificities (Figure 
9.1).  
Closer examination of their binding patterns indicated that the antibodies fell 
into three discrete groups, which varied according to their sulfatide complex 
binding capabilities. The first group of antibodies included GAME-M2, GAME-M6 
and GAME-M7 and were found to bind to the single Chol and sulfatide antigens 
alongside associated complexes.  
The binding signals to the sulfatide complexes were of a particular interest as 
they indicated that the antibodies were capable of binding sulfatide regardless 
of its local microenvironment. Certain complexes, such as those containing GD1a  
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Figure 9.1 – Anti-Sulfatide mAb Characterisation on Combinatorial Glycoarray 
Representative blots indicate the binding patterns of the antibodies to various 
lipids and complexes printed using the combinatorial glycoarray. A: This group 
included GAME-M2, GAME-M6 and GAME-M7. These antibodies bound to Chol as 
well as Chol:GalC and Chol:DCP complexes. Binding was also detected to 
sulfatide and all sulfatide complexes. These signals varied depending upon the 
lipid but no complexes were found to abolish antibody binding. B: This group 
included GAME-M5 and GAME-G3. These antibodies only bound to sulfatide and 
sulfatide complexes. Binding was inhibited by sulfatide:SM and sulfatide:GA1 and 
was abolished by sulfatide:GM1, sulfatide:GD1a and sulfatide:GD1a. C: This 
group comprised solely of GAME-G1. This antibody bound to sulfatide and DCP 
and a few complexes. Binding was abolished in both antigens by complexes 
containing gangliosides or SM.   
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and GD1b, did inhibit antibody binding; however, no complexes were found to 
completely abolish the binding signal altogether.  
In addition to the sulfatide complexes, binding was also detected to Chol:DCP 
and Chol:GalC complexes but this was thought to lack relevance from a 
biological perspective as Chol binding was inhibited in the presence of most 
other lipids.  
The second group of antibodies included GAME-M5 and GAME-G3 and were found 
to bind solely to sulfatide and associated complexes. Unlike the first group of 
antibodies, binding was substantially weaker against sulfatide:GA1 and 
sulfatide:SM complexes and was completely abolished against sulfatide:GM1, 
sulfatide:GD1a and sulfatide:GD1b complexes. This suggested that the length of 
the ganglioside headgroup may interfere with the antibodies abilities to access 
the binding epitopes on the sulfatide molecules.  
The final antibody group comprised solely of GAME-G1 and was found to bind to 
both the single DCP and sulfatide antigens alongside a limited number of 
complexes. Binding was completely abolished when either antigen was in 
complex with gangliosides or SM, which suggested that the antibody may be 
incapable of binding to a biological membrane as these lipids are abundantly 
expressed throughout the body (Pike, 2003).  
To ensure that no potential antigens were being overlooked, additional arrays 
were created that contained a series of other lipids (data not shown). These 
included GM3, GD3, DPPC, PC, SGPG, and LM1. No binding was detected to any 
of these single antigens or to their complexes except those containing sulfatide. 
The binding signals detected against these sulfatide complexes were found to be 
comparable to those detected against the single glycolipid species.   
9.2.2 Cell Characterisation  
9.2.2.1 Oligodendrocyte Progenitor Cells (OPCs) 
 
Oligodendrocyte progenitor cells (OPCs) are a type of glial cell that populate the 
CNS before differentiating into myelinating oligodendrocytes (O’Rourke et al., 
2014). Sulfatide is highly expressed in oligodendrocytes at every stage of 
development but its presence is used specifically as a marker of OPCs in the 
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adult brain (Lee, 2001; Reynolds & Hardy, 1997). These cells were therefore 
deemed to be best suited for determining the binding capabilities of the anti-
sulfatide antibodies to biological membranes. As such, the antibodies were 
probed against rat OPCs as per Section 2.12.3.1. 
Unfortunately quantification of the results was not possible due to the irregular 
binding of the OPC markers NG2 and PLP. As a result, only representative images 
were taken (Figure 9.2).   
Despite these issues, the majority of the antibodies were found to bind well to 
OPCs, with GAME-G3 and GAME-M7 producing the strongest binding signals. The 
only antibody that was not found to bind was GAME-G1. It was postulated that 
this may be related to the findings of the array screening, which showed that 
the antibody was unable to bind sulfatide in the presence of particular lipids.  
9.2.2.2 Schwann Cells 
 
Schwann cells perform a similar supportive role as oligodendrocytes in the 
nervous system but are restricted to the PNS (Nave & Werner, 2014). As with the 
OPCs, the cells express high levels of sulfatide (Mirsky et al., 1990), which 
suggested that they may also be targets of the anti-sulfatide antibodies.   
To confirm this, Schwann cells were grown over a period of several days and 
probed with the antibodies as per Sections 2.12.1 and 2.12.2. In addition to 
those with a normal distribution of sulfatide, cells were also taken from CST-/- 
mice to confirm that the antibodies were targeting the glycolipid and not 
another sulfated protein or lipid.  Unfortunately it was difficult to produce 
enough cells for screening all of the antibodies, so only GAME-M2 was screened 
against cells from both genotypes (Figure 9.3).   
The results from this experiment confirmed that the antibody was primarily 
targeting sulfatide as the CST+/+ cells produced a median signal of 243 FI units. 
This was substantially higher than the signals detected to CST-/- cells, which had 
a median signal of 0 FI units. Although very low levels of antibody deposition 
were detected in these cells, it was attributed to non-specific background 
binding.   
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Figure 9.2 – Anti-sulfatide mAb binding to OPCs 
The anti-sulfatide antibodies were probed against rat OPCs. Representative 
images indicate the relative binding patterns of each antibody. Quantitative 
analysis was not performed. The strongest binding signals were detected with 
GAME-G3 and GAME-M7. Binding was also detected to GAME-M2, GAME-M5 and 
GAME-M6. No GAME-G1 binding was detected to the OPCs whatsoever (n=2).  
 
Chapter 9 – CHARACTERISATION OF ANTI-SULFATIDE ANTIBODIES 198 
 
 
Figure 9.3 – Anti-sulfatide mAb binding to Schwann Cells 
GAME-M2 was probed against Schwann cells grown from CST+/+ and CST-/-mice. 
Representative images of the CST+/+ tissue at 40x magnification and both the 
CST+/+ and CST-/- at 63x magnification indicate the relative binding of GAME-
M2. The antibody was found to bind substantially better to the cells from CST+/+ 
mice producing a median signal of 243 FI units compared to a median signal of 0 
FI units in the CST-/- cells. This confirmed that the antibody was binding to 
sulfatide and not any other target (n=1).  
 
9.2.3 Sciatic Nerve Sections 
 
Whilst characterising the antibodies cell binding behaviours was useful in 
determining how they bound to biological membranes, it was not particularly 
informative in ascertaining how they interacted with real tissue. To address this, 
an experiment was performed in which the antibodies were screened against 
transverse sections of sciatic nerve as per Section 2.13.2.2. As this nerve is 
myelinated it was hypothesised that it would contain an abundance of sulfatide, 
which would lead to high levels of antibody binding.   
As the combinatorial glycoarray screening had established that complex 
ganglioside, such as GD1a and GD1b, inhibited or abolished antibody binding, the 
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decision was taken to include tissue from GalNAc T-/- mice. It was thought that 
the absence of complex gangliosides in this tissue would increase access to the 
sulfatide binding epitope, which would lead to improved antibody binding.  
Similarly, tissue from CST-/- mice was also included in these studies to act as a 
negative control. As the previous experiments had suggested that the antibodies 
bound solely to sulfatide and associated complexes, it was hypothesised that no 
antibody binding would be detected in these tissues.  
The results of the experiment confirmed that all of the anti-sulfatide antibodies, 
except GAME-G1, bound to the endoneurium and adaxonal myelin of the CST+/+ 
and GalNAc T-/- tissue (Figure 9.4). Unfortunately quantification of the results 
was not possible; however, from an observational perspective there did not 
appear to be a substantial difference between the two tissues types.  
As predicted very little binding was detected in the CST-/- tissue, except with 
the preeminent anti-sulfatide antibody, O4, which was found to bind weakly to 
the endoneurium (data not shown).  
9.2.4 Ex vivo screening of anti-sulfatide mAbs 
 
Although the sciatic nerve sections demonstrated the tissue binding capabilities 
of the anti-sulfatide antibodies, they were not representative of the natural 
biological environment and, as such, were not indicative of how the antibodies 
would bind within the body. To determine this, ex vivo preparations of TS were 
created and probed with the monoclonal antibodies as per Section 2.13.1. 
9.2.4.1 CST+/+ vs CST-/- tissue   
 
Despite the evidence from the previous experiments that the antibodies bound 
solely to sulfatide, it was necessary to employ both CST+/+ and CST-/- ex vivo 
preparations in this study, to confirm that the antibodies did not bind to another 
antigen in live tissue. 
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Figure 9.4 – Anti-sulfatide mAb binding to sciatic nerve sections 
The new anti-sulfatide mAbs and O4 were probed against sciatic nerve sections. 
All the antibodies except GAME-G1 were found to bind to the adaxonal myelin in 
both the CST+/+ and GalNAc T-/- tissue. Very little binding was detected in the 
CST-/- tissue with any of the antibodies except O4, which weakly bound to the 
endoneurium.  
GalNAc T-/-CST+/+ CST-/-
GAME-M2
GAME-M2
Myelin
GAME-M2
Myelin
GAME-M2
Myelin
10μm 10μm 10μm
GAME-M5
GAME-M5
Myelin
GAME-M5
Myelin
GAME-M5
Myelin
10μm 10μm 10μm
GAME-M6
GAME-M6
Myelin
GAME-M6
Myelin
GAME-M6
Myelin
10μm 10μm 10μm
GAME-M7
GAME-M7
Myelin
GAME-M7
Myelin
GAME-M7
Myelin
10μm 10μm 10μm
GAME-G1
GAME-G1
Myelin
GAME-G1
Myelin
GAME-G1
Myelin
10μm 10μm 10μm
GAME-G3
GAME-G3
Myelin
GAME-G3
Myelin
GAME-G3
Myelin
10μm 10μm 10μm
O4
O4
Myelin
O4
Myelin
O4
Myelin
10μm 10μm 10μm
Chapter 9 – CHARACTERISATION OF ANTI-SULFATIDE ANTIBODIES 201 
 
Based upon the previous findings and the knowledge that sulfatide is enriched in 
Schwann cells (Mirsky et al., 1990), it was hypothesised that the antibodies 
would bind to the Schwann cell plasmalemma in a similar manner as GAME-M1; 
however, this was not found to be the case.  
The majority of the antibodies were instead found to bind specifically to a 
Schwann cell that lay on the periphery of the NMJ (Figures 9.5 and 9.6). The 
subsequent characterisation of this cell found that it was the terminal 
myelinating Schwann cell, which it shall be referred to as from hereon in.  
Quantification was performed on these results by counting the number of 
antibody bound cells in a total of 100 NMJs. The total number was then 
expressed as a percentage. Examination of this data found that GAME-M2, GAME-
M5, GAME-M6, GAME-M7 and GAME-G3 all bound to a significantly higher number 
of cells in the CST+/+ tissue compared to the CST-/- tissue (Fisher’s exact test, 
P<0.0001).  In fact, the antibodies were not found to bind to the CST-/- tissue 
whatsoever, confirming that they were only targeting sulfatide. 
Neither GAME-G1 nor O4 were found to bind the terminal myelinating Schwann 
cells in either tissue type, which suggested that the antibodies were unable to 
access their binding epitopes on these cells.  
9.2.4.2 GalNAc T+/+ vs GalNAc T-/- Tissue 
 
As the previous studies had demonstrated that the anti-sulfatide antibodies were 
inhibited by certain complex gangliosides, an experiment was derived in which 
the antibodies were probed against both GalNAc T+/+ and GalNAc T-/- tissue. It 
was hypothesised that the antibodies would bind to a higher number of terminal 
myelinating Schwann cells in the GalNAc T-/- tissue, as the absence of these 
gangliosides would better expose the sulfatide binding epitope.  
The results of the experiment, however, did not fully support this hypothesis 
(Figures 9.7 and 9.8). Whilst GAME-M2 and GAME-G3 were found to bind to a 
significantly higher number of cells in the GalNAc T-/- tissue, the number of 
GAME-M5 and GAME-M6 bound cells did not appear to differ significantly 
between either tissue type (Fisher’s exact test, P<0.01).  
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Figure 9.5 – Anti-sulfatide mAb binding to CST+/+ and CST-/- ex vivo 
preparations. 
GAME-M2, GAME-M5, GAME-G1 and GAME-G3 were probed against ex vivo 
preparations of CST+/+ and CST-/- tissue. The antibodies were found to bind to 
a Schwann cell on the periphery of the NMJ (arrows). 100 NMJs were examined 
for each tissue section and the number of bound cells were counted and 
expressed as a percentage. GAME-M2, GAME-M5 and GAME-G3 were found to bind 
to these cells significantly higher in CST+/+ tissue compared to CST-/- tissue. 
(Fisher’s exact test, P<0.0001) (n=2) GAME-G1 was not found to bind the cell in 
either tissue type.  
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GAME-M7 actually had the opposite effect and bound to a higher number of cells 
in the GalNAc T+/+ tissue (Fisher’s exact test, P<0.001). This suggested that the 
antibody preferentially bound to sulfatide molecules that were in a complex 
 
 
Figure 9.6 - Anti-sulfatide mAb binding to CST+/+ and CST-/- ex vivo 
preparations. 
GAME-M6, GAME-M7 and O4 were probed against ex vivo preparations of CST+/+ 
and CST-/-. The antibodies were found to bind to a Schwann cell on the 
periphery of the NMJ (arrows). 100 NMJs were examined for each tissue section 
and the number of bound cells were counted and expressed as a percentage. 
GAME-M6 and GAME-M7 were found to bind to these cells significantly higher in 
CST+/+ tissue compared to CST-/- tissue. (Fisher’s exact test, P<0.0001) (n=2) 
O4 was not found to bind the cell in either tissue type.  
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ganglioside rich microenvironment, contrary to the findings of the combinatorial 
glycoarray screening.  
GAME-G1, as demonstrated previously, was incapable of binding to either tissue 
type, suggesting that the sulfatide molecule was being obscured by another, 
non-ganglioside, lipid.  
Taken together, this data suggested that the biological binding patterns of the 
antibodies were more complex than they appeared using the combinatorial 
glycoarray. Future studies may therefore wish to examine the binding patterns 
of these antibodies against a range of transgenic mice to further clarify how 
complex gangliosides impact antibody binding. Further to this, it may also be 
worthwhile to repeat the experiment to confirm these initial findings, as it was 
only performed twice within this study due to tissue availability.  
9.2.5 Terminal Myelinating Schwann Cell Characterisation 
 
The specific binding of the anti-sulfatide antibodies to the terminal myelinating 
Schwann cell has, to our knowledge, not been demonstrated previously. This 
novel finding was therefore particularly interesting from an autoimmune 
neuropathy perspective, as it is currently unclear what targets these antibodies 
bind in tissue and how they bring about neurological injury.   
The properties of this cell were therefore characterised to ascertain whether the 
antibodies were capable of specifically injuring it. This was carried out by 
employing one of the anti-sulfatide antibodies to act as a cell marker, followed 
by the application of a series of protein or lipid markers that indicated different 
cellular subtypes. Due to the abundance of available antibody stock, GAME-M7 
was selected for this role.   
9.2.5.1 Cell Markers 
 
The experiments were carried out as per Section 2.13.1.5. The use of 
fluorescent mice in the previous antibody characterisation studies had already 
established that the cell was S100 positive, which indicated that it was a 
Schwann cell (Jessen & Mirsky, 2005; Zuo et al., 2004). To determine whether it  
Chapter 9 – CHARACTERISATION OF ANTI-SULFATIDE ANTIBODIES 205 
 
 
Figure 9.7 - Anti-sulfatide IgM mAb binding to GalNAcT-/- and GalNAcT+/+ ex 
vivo preparations 
GAME-M2, GAME-M5, GAME-M6 and GAME-M7 were probed against ex vivo 
preparations of GalNAc T+/+ and GalNAc T-/-. The antibodies were found to bind 
to a Schwann cell on the periphery of the NMJ (arrows). 100 NMJs were 
examined for each tissue section and the number of bound cells were counted 
and expressed as a percentage. There was no difference between the tissue for 
GAME-M5 and GAME-M6. GAME-M2 was found to bind significantly better to the 
cells in the GalNAc T-/- tissue whereas GAME-M7 was found to bind significantly 
better to GalNAc T+/+ tissue. (Fisher’s exact test, **=p<0.01, ***=p<0.001) (n=2) 
GAME-M6
GAME-M7
GAME-M5
GalNAc T-/-GalNAc T+/+
GAME-M2
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Figure 9.8 - Anti-sulfatide IgG mAb binding to GalNAcT-/- and GalNAcT+/+ ex 
vivo preparations 
GAME-G1 and GAME-G3 were probed against ex vivo preparations of GalNAc T+/+ 
and GalNAc T-/-. The antibodies were found to bind to a Schwann cell on the 
periphery of the NMJ (arrows). 100 NMJs were examined for each tissue section 
and the number of bound cells were counted and expressed as a percentage. No 
binding was detected to GAME-G1 in either tissue configuration. GAME-G3 was 
found to bind significantly better to GalNAc T-/- tissue. (Fisher’s exact test, 
****=p<0.0001) (n=2) 
 
 
was a myelinating or unmyelinating Schwann cell, it was necessary to probe the 
tissue with an anti-GD3 antibody called R24. Previous studies had established 
that this antibody specifically binds to unmyelinated cells, known as perisynaptic 
Schwann cells (pSc) (Halstead, Morrison, et al., 2005). 
The results of the experiment showed that there was no co-localisation of R24 
and GAME-M7, which clearly demonstrated that the cell was not a pSc (Figure 
GAME-G1
GAME-G3
GalNAc T-/-GalNAc T+/+
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9.9) The cells position also substantiated this finding, as it was always present 
outwith the NMJ, whereas pScs would overly the junction (Kang et al., 2004). 
Building upon this observation, it was hypothesised that the cell may have a role 
in myelination.  As such, an ex vivo TS preparation was probed with GAME-M7 
and either an anti-MAG or anti-MBP antibody (Quarles, 2007). The results of this 
experiment found that both MAG and MBP stained the axon leading to the NMJ 
but not the cell body of the terminal myelinating Schwann cell (Figure 9.10).  
GAME-M7 staining was polarised towards the NMJ, however, suggesting an 
overlap with both the MBP and MAG proteins. It is therefore possible that the 
cell is responsible for myelinating the axon, although further experiments would 
need to be performed to confirm this hypothesis. 
As discussed previously, it was thought that the cell may have a role in 
maintaining or repairing the nerve terminal. To examine whether this was true, 
the TS was probed with GAME-M7 and an anti-glial fibrillary acidic protein 
(GFAP) antibody to determine if it was a reactive Schwann cell (Court et al., 
2008). 
The results indicated that the anti-GFAP antibody stained the NMJ but was not 
enriched within the terminal myelinating Schwann cell itself (Figure 9.11). It was 
therefore concluded that the cell was not reactive. It may be worthwhile in 
future studies, however, to injure the nerve terminal and apply an anti-nestin 
antibody.  If the cell was reactive it would upregulate the protein, which could 
then be bound by the antibody (Hayworth et al., 2006). This was not performed 
in these experiments due to time constraints but would be useful for confirming 
the anti-GFAP findings.  
9.2.5.2 Incubation Conditions  
 
As the experiments proceeded, questions were raised about whether the 
antibody’s specific binding to the cell was a result of the blood nerve barrier 
(BNB). In particular, the observation that GAME-M7 was polarised towards the 
NMJ, suggested that, under standard conditions, the BNB may be preventing the 
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Figure 9.9 - Terminal Myelinating Schwann Cell Characterisation – 
perisynaptic Schwann cell exclusion 
Ex vivo preparations of TS were probed with GAME-M7 and R24. R24 was found to 
bind specifically to GD3 on the perisynaptic Schwann cells. GAME-M7 was not 
found to co-localise with the R24 staining, which indicated that the cell was not 
a pSc. 
 
antibody accessing other binding sites. To overcome this, changes were proposed 
in the incubation conditions, such as applying the antibody for a longer period of 
time or permeablising the tissue prior to its addition.  
For the longer incubation experiment, GAME-M7 was applied to an ex vivo 
preparation of WT TS for 5 hours at 37°C. Following incubation, the tissue was 
imaged, permeabilised with 0.5% Triton X-100 and then re-imaged. The purpose 
of the permeabilisation step was to ensure that the absence of antibody binding 
was not due to internalisation. The results indicated little difference between 
the two treatments, as antibody binding was only detected on the terminal 
myelinating Schwann cells in both the pre and post permeabilised tissue (Figure 
9.12).  
 
DAPI
Glia
GAME-M5
R24
Axon
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Figure 9.10 – Terminal Myelinating Schwann Cell Characterisation – Myelin 
Markers 
Ex vivo preparations of TS were probed with GAME-M7 (100µg/ml) for 1 hour and 
permeabilised. Anti-MAG or Anti-MBP antibodies were then applied overnight. A: 
The axon was MAG positive but the cell body of the terminal myelinating 
Schwann cell was not. B: The axon was also MBP positive but the cell body was 
not. There appeared to be a degree of polarisation of sulfatide positivity 
towards the NMJ in both tissues.  
 
Two possible reasons were given for these findings; either incubation times are 
irrelevant in overcoming the BNB or the antibody does not bind other Schwann 
cells.  
The pre-permeabilisation experiment sought to address which of these two 
reasons were valid. Ex vivo preparations of WT TS were therefore permeabilised 
and probed with GAME-M7 to establish if other sites could be targeted by anti- 
DAPI BTx
GAME-M7MAG
DAPI
MBP
BTx + S100
GAME-M7
A
B
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Figure 9.11 –Terminal Myelinating Schwann Cell Characterisation – GFAP 
An ex vivo preparation of TS was probed with GAME-M7 (100µg/ml) for 1 hour 
and permeabilised. An anti-GFAP antibody was applied to determine if the cell 
was a reactive Schwann cell. The antibody stained the NMJ but did not appear to 
be focussed on the terminal myelinating Schwann cell, which indicated that it 
was not reactive.  
 
sulfatide antibodies. It was hypothesised that if the BNB was responsible for 
restricting antibody access, binding would be detected on the other Schwann 
cells surrounding the axon.  
The results of the experiment, however, disproved this hypothesis. No binding 
was detected on any of the other myelinating Schwann cells but binding was 
detected on the pSc and their processes (Figure 9.13). This was unexpected as 
the pSc had been demonstrated to lack sulfatide. Although this binding 
behaviour was only detected in a few of the NMJ, a possible explanation was 
that the permeabilisation process had damaged the tissue.  
Previous research on the NMJ had established that when the axon is damaged, 
the terminal myelinating Schwann cell will extend processes into the junction to 
aid in repair (Brill et al., 2011). This appears to explain the observations from 
this experiment and corroborates the belief that the cell was responsible for 
maintaining and repairing the nerve terminal. 
 
DAPI BTx
GAME-M7GFAP
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Figure 9.12 – Longer Incubations of GAME-M7 with ex vivo preparations of WT 
TS.  
Ex vivo preparations of WT TS were incubated with GAME-M7 for 5 hours. 
Following incubation, the tissue was imaged and then permeabilised with 0.5% 
Triton X-100 and reimaged. Binding was only found to occur on the terminal 
myelinating Schwann cells (arrows) in both the pre and post permeabilised 
tissue.   
 
9.2.5.3 Complement Mediated Injury 
 
Whilst, the previous experiments confirmed that GAME-M7 was specifically 
targeting the terminal myelinating Schwann cell, it was still unclear if the 
antibody itself was able to induce an injury. To address this, a complement kill 
was performed in which the antibody and normal human serum (NHS) were 
applied to tissue, alongside a control that contained NHS only. A nucleus marker, 
EthD-1, was then applied and the number of positive nuclei were counted on 
each tissue section. 
300 mins
300 mins
+ 0.5% Triton
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Figure 9.13 – Binding of GAME-M7 to Permeabilised Tissue 
Ex vivo preparations of WT TS were light fixed in 1% PFA, followed by incubation 
with GAME-M7. No binding was detected to myelinated Schwann cells but binding 
was detected on the pSc and their processes. This only occurred infrequently in 
the tissue.  
 
As GAME-M7 was not applied to the control tissue, the kink in the axon as it 
joined the NMJ was used to estimate the position of the terminal myelinating 
Schwann cell (Figure 9.14). The results of these counts indicated that GAME-M7 
killed a significantly higher number of cells compared to NHS alone (Fisher’s 
exact test, P<0.0001).    
This data therefore confirmed that the antibody was pathogenic, which 
suggested that these cells may be the target of immune mediate injury in 
patients with high titres of anti-sulfatide antibodies. Further experiments will 
need to be performed to verify these findings and determine the relevance of 
the terminal myelinating Schwann cells in maintaining and repairing the NMJ in 
health and disease.  
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Figure 9.14 –GAME-M7 induced complement kill of Terminal Myelinating 
Schwann Cell 
An ex vivo preparation of WT TS was probed with GAME-M7. Control tissue was 
probed with Ringer’s solution alone. Normal human serum (NHS) was then 
applied to both tissues, followed by the application of EthD-1. As the control 
tissue did not contain the mAb, the kink in the axon as it joined the NMJ was 
used to estimate the position of the terminal myelinating Schwann cell. The 
number of EthD-1 positive nuclei in these positions was counted on each tissue. 
The experiment indicated that GAME-M7 injured a significantly higher number of 
terminal myelinating Schwann cells (arrow) than NHS alone (Fisher’s exact test, 
P<0.0001) (n=2) 
 
Unfortunately, these experiments could not be performed within the context of 
this thesis due to time restrictions but would be beneficial to furthering our 
understanding of the pathogenicity of anti-sulfatide antibodies.  
9.3 Discussion 
 
Although anti-sulfatide antibodies have long been associated with a wide range 
of demyelinating conditions (Alpa et al., 2007; Andersson et al., 2002; Ilyas, 
****
NHS OnlyGAME-M7 + NHS
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2003; Souayah et al., 2007), little is known about their specific mechanisms of 
action or whether they are in fact responsible for bringing about neurological 
injury.  
This, in part, is due to the discrepancy between animal and human studies. 
Whilst the preeminent mouse anti-sulfatide antibody, O4, has been 
demonstrated to bring about demyelination and dysmyelination in CNS cultures 
(Elliott et al., 2012; Rosenbluth & Moon, 2003), there has been difficulty in 
replicating the same findings using patient derived antibodies.  
Although some researchers have shown that these antibodies bind the sulfatide 
enriched myelin membrane (Petratos et al., 2000), others have found that 
binding could not be detected in either live CNS myelin or cells from the 
oligodendrocyte lineage (Brennan et al., 2011).  
The disparity between these findings is difficult to explain, but has been 
attributed to differences in the fine specificities of anti-sulfatide antibodies. O4, 
for example, has been shown to bind specifically to a sulfatide:SM complex, 
which is thought to form on the surface of the myelin sheath (Brennan et al., 
2011). If human antibodies are unable to bind this same complex, then it would 
be unlikely that they could bind tissue, raising the possibility that O4 is not 
entirely representative of the antibodies that arise in neuropathies.  
In an attempt to address the issue of antibody diversity, we generated several 
anti-sulfatide antibodies in the hope of creating one that more closely 
resembled those found in natural disease states. The aim of this chapter was to 
characterise the binding behaviours of these antibodies, through the use of both 
in vitro and ex vivo techniques, to establish their pathogenicity and whether 
they were representative of those antibodies that arise in demyelinating 
neuropathies.  
The initial characterisation experiments focussed on establishing the antibodies 
binding patterns to sulfatide and associated complexes. These studies 
demonstrated how the binding signals of the different antibodies were affected 
by the presence of different glycolipids, particularly gangliosides and SM.  
The inhibitory behaviour of gangliosides such as GD1a and GD1b, was similar to 
that observed with anti-ganglioside antibodies (Greenshields et al., 2009; Nobile-
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Orazio & Gallia, 2013). This suggested that the terminal sialic acid of the 
ganglioside headgroup was interacting with the sulfatide molecule, in a similar 
manner as it did with GM1, to obscure the binding epitope.  
Similarly, the presence of other gangliosides and lipids with long fatty acid 
chains, such as SM, would likely prevent certain antibodies accessing the 
sulfatide molecule, due to steric hindrance (Alving & Richards, 1977). These 
inhibitions varied between the different antibodies, however, with GAME-M2, 
GAME-M6 and GAME-M7 showing only slight inhibition with GD1a and GD1b, 
whilst the binding signal of GAME-G1 was completely abolished by all complex 
gangliosides and SM.  
Unusually, the ganglioside cis-inhibitions did not directly translate into 
differences in tissue binding patterns. In fact the only antibody that was found 
to be incapable of binding most, if not all, tissue was GAME-G1. It was 
hypothesised that this may be related to the presence of sulfatide:SM complexes 
in the plasma membrane. As indicated by the combinatorial glycoarray 
screening, these complexes would prevent antibody binding, which is consistent 
with the observations made using human derived anti-sulfatide antibodies 
(Brennan et al., 2011). This strongly supports the theory that sulfatide:SM 
complexes, rather than sulfatide, are the true targets of demyelinating 
antibodies in tissue.  
Aside from GAME-G1, the new anti-sulfatide antibodies behaved in a similar 
manner as O4. They were found to bind sulfatide enriched cells and tissues, 
including OPCs, Schwann cells and sciatic nerves (Mirsky et al., 1990; O’Rourke 
et al., 2014) but did not appear to differ substantially in their relative binding 
intensities. It was only when applied to ex vivo preparations of TS that the new 
antibodies were found to behave in a different manner.  
In this tissue, they appeared to bind exclusively to a cell on the periphery of the 
NMJ, known as the terminal myelinating Schwann cell. In contrast, O4 was not 
found to bind this cell whatsoever, suggesting that the presence of an 
unexamined lipid or protein was inhibiting the antibody from accessing its 
binding epitope.   
This novel finding was particularly interesting, as it suggested that more diverse 
anti-sulfatide antibodies existed than had previously been described. 
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Furthermore, the discovery that these antibodies bound exclusively to a cell in 
proximity to the NMJ, suggested that they may have a role in paralytic 
neuropathies.   
To further clarify these roles, experiments were performed to characterise this 
cell and its properties. The use of CST-/- mice confirmed that the antibodies 
were specifically binding to sulfatide, whilst the use of markers proved that it 
was indeed a Schwann cell. Preliminary investigations into its other functions 
were inconclusive but suggested that it may have roles in myelinating the axon.  
Examination of the literature found little mention of the cell but limited work, 
using laser ablation of individual Schwann cells at the NMJ, had suggested that it 
may function to repair the axon during Wallerian degeneration (Brill et al., 
2011). Further to this, it appears that it forms tight paranodal adhesions with 
the axon to prevent retrograde growth of the pScs suggesting that it may also 
have a major role in maintaining normal NMJ morphology.  
Through the use of a complement kill, it was confirmed that GAME-M7 was 
pathogenic and that the terminal myelinating Schwann cell can be the target of 
immune mediated injury. If this translates into human disease, it suggests that 
the cell may be targeted and injured in patients with high titres of circulating 
anti-sulfatide antibodies, which may result in a degree of dysfunction.   
Unfortunately, time constraints limited further characterisation of both the anti-
sulfatide antibodies and the terminal myelinating Schwann cell. However, the 
cells and particularly the antibodies hold great potential for investigating the 
roles of sulfatide in health and disease and should certainly be employed in 
future studies.  
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10 DISCUSSION 
 
10.1 Main Findings  
 
Multifocal motor neuropathy has been associated with anti-GM1 antibodies since 
its original conception in 1988 (Pestronk et al., 1988). Whilst the enhancing 
effects of accessory lipids, such as GalC and sulfated cholesterol, were noted 
not long after (Pestronk et al., 1997), it was not until recently that researchers 
began to intensify the use of ganglioside complexes in the interest of improving 
antibody detection (Galban-Horcajo et al., 2013; Nobile-Orazio & Gallia, 2013). 
As with the original studies, these experiments found that GM1:GalC complexes 
were capable of greatly improving the antibody detection rate; however, an 
interesting observation was made regarding an antibody subset. Whereas, most 
antibodies bound to both the single ganglioside and the complex, this subset 
appeared to only be capable of binding to the latter. This led some researchers 
to postulate that these antibodies may be binding to a neo-epitope formed by 
the combination of two different lipids (Rinaldi et al., 2010).  
If this hypothesis was correct, then it would suggest that a new class of antibody 
may exist that is complex-dependent. As serum studies detected higher levels of 
binding to these complexes than to GM1, it also raised the possibility that 
GM1:GalC complexes may be the true targets of immune mediated injury in 
MMN.  Based upon this premise, the main aim of this thesis was to either isolate 
one of these antibodies from patient serum or produce one through active 
immunisations with mice.  
As the thesis evolved, however, it became apparent that this premise may have 
been misguided. Analysis of the binding patterns of human monoclonal 
antibodies, patient sera studies and mouse immunisations indicated that what 
appeared to be complex-dependent antibodies were more likely low 
concentrations of normal antibodies that were cis-enhanced by particular lipids.  
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Despite not achieving its main aim, this thesis still furthered knowledge within 
the field of neuroimmunology through several novel findings. These included 
determining how the concentration of accessory lipids in complexes influences 
antibody binding, improvements in hybridoma production and the creation of 
several new anti-ganglioside and anti-sulfatide antibodies. These findings, along 
with their impact on current MMN research, are summarised here.  
10.1.1 The binding signals of human monoclonal anti-ganglioside  
  antibodies can be influenced by the presence of    
  secondary lipids 
  
The work carried out in the first sections of this thesis focussed on assessing the 
cis-inhibitions and cis-enhancements of several human monoclonal antibodies. 
Despite being employed in vast amounts of research (O’Hanlon et al., 1996, 
1998; Paterson et al., 1995; Willison et al., 1994), the fine specificities of these 
antibodies had yet to be fully elucidated, which impacted on determining their 
roles in disease.  
The results from these experiments confirmed many of the findings of previous 
research. In particular, they demonstrated that gangliosides containing terminal 
sialic acids, such as GD1a and GD1b, can obscure binding epitopes on the 
headgroup of GM1 molecules to prevent antibody binding (Greenshields et al., 
2009; Nobile-Orazio et al., 2010). This finding, more than any other, may explain 
the restricted injury experienced in MMN. 
Assuming that the monoclonal antibodies are representative of those found in 
patient sera, it could be postulated that the expression of GM1 in the absence of 
GD1a leaves certain tissue vulnerable to immune mediated attack. In contrast, a 
level of protection may be bestowed upon those tissues, which contain 
GM1:GD1a complexes, as the interaction of the two gangliosides will shield 
particular GM1 binding epitopes from the immune system. This will prevent 
certain antibodies from binding the tissue, thus preventing injury.  
This theory is somewhat supported by experimental data, as it has been 
demonstrated that anti-GM1 antibodies preferentially target the myelin and 
nodes of Ranvier (NoR) in motor nerves (Gong et al., 2002; Susuki et al., 2012). 
However, a sufficient explanation for why these sites are targeted and other 
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GM1 enriched tissues are spared has yet to be elucidated. The GM1:GD1a 
complex theory may offer a possible explanation but requires further study to 
verify this assumption.    
Aside from gangliosides, the antibodies binding signals were also found to be 
influenced by the presence of other lipids, including Chol, GalC, sulfatide, PS, 
SM and PC. Whilst the enhancing effect of GM1:GalC and GM1:sulfatide had been 
demonstrated previously (Galban-Horcajo et al., 2013, 2014; Nobile-Orazio et 
al., 2013), little data could be found on the abilities of the other lipids to 
enhance antibody binding.    
Based upon their comparatively small size and their expression in plasma 
membranes(Brown & Rose, 1992; DeBruin et al., 2005; Pike et al., 2002; M. 
Simons et al., 2000), however, it was hypothesised that they improved binding 
signals through their interactions with the ganglioside headgroup. Evidence from 
previous research supported this theory, as it has been shown that the various 
functional groups of lipids can form hydrogen bonding networks with gangliosides 
to alter their configuration (Lin et al., 2008; Lingwood & Simons, 2010; Lingwood 
et al., 2011; Mombelli et al., 2003; Stoffel & Bosio, 1997). This results in the 
exposure or concealment of different binding epitopes, which can affect the 
binding capabilities of anti-ganglioside antibodies.  
As GalC contains a higher number of hydrogen donors and acceptors than the 
other lipids (Hall et al., 2010), it is likely that it is able to confer a specific 
orientation upon a ganglioside. Certain antibodies may bind to epitopes that are 
optimally exposed in this orientation, which may explain the high levels of 
enhancements that clinical studies have found using GM1:GalC complexes.  
This finding, however, cast doubt upon the theory that neo-epitope formation is 
responsible for antibody enhancement.  In fact, the similar enhancing ability of 
the different accessory lipids was much more supportive of the theory of 
conformational modulation.  If this process is in fact responsible for antibody 
enhancement, then it suggests that the gangliosides local microenvironment is 
an important factor in determining the binding abilities of anti-ganglioside 
antibodies and the vulnerability of tissues to immune mediated attack.  
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10.1.2 The concentration of accessory lipids in complexes have   
  differing effects on antibody binding  
 
Subsequent chapters expanded on these findings further by analysing the effects 
differing concentrations of accessory lipids had upon antibody binding. This is a 
concept that has garnered little attention in array design, which is surprising 
considering that the proportions of lipids will differ in tissues in relation to their 
function and location. The results from these studies clearly demonstrated that 
higher concentrations not only enhanced certain binding signals but also 
distinguished the binding patterns of similar looking antibodies from one 
another.   
This led to the antibodies being classified as either concentration-dependent or 
concentration--independent based upon their abilities to bind ganglioside 
complexes containing high concentrations of accessory lipids. Under the 
assumption that these differences were related to the accessibility of the 
binding epitopes, it was hypothesised that varying the concentrations of 
accessory lipids had differential effects on the ganglioside headgroup 
orientation. This would result in the exposure of concealment of certain binding 
epitopes, which would alter the binding abilities of anti-ganglioside antibodies.   
The mechanism behind this interaction was again thought to be conformational 
modulation (Harschnitz et al., 2014). High concentrations of accessory lipids 
would form a considerably larger hydrogen bonding network with gangliosides 
than lower concentrations (Hall et al., 2010). As a result, they would be able to 
pull the ganglioside headgroup into a position more parallel to the membrane, 
which would optimally expose previously hidden binding epitopes. It was 
assumed that the concentration-dependent antibodies bound to these epitopes, 
whereas the concentration-independent antibodies bound to those that were 
readily available when the headgroup was perpendicular to the membrane 
(Figure 10.1).  
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Figure 10.1 – The concentration of accessory lipids has differing effects on 
antibody binding 
Both the concentration-dependent (orange) and concentration independent 
(blue) antibodies bind to different epitopes on the GM1 headgroup. When low 
proportions of GalC are added to the complex, the gangliosides change 
configuration, which improves the presentation of both binding epitopes. This 
enhances the binding ability of both antibodies. When the concentration is 
increased further, the ganglioside is pulled parallel to the membrane, better 
exposing the concentration-dependent epitope. As a result the binding signals of 
the concentration dependent antibodies increase further. In contrast, the 
binding signals of the concentration-independent antibodies do not change as 
the ganglioside epitope is already as well presented as possible.  
 
This demonstrated that these antibodies, which appeared very similar on ELISA, 
behaved completely differently when the lipid concentrations of the local 
microenvironment were modified. This was a concept that had not been 
explored previously but had repercussions, not only in assessing the diversity of 
antibodies, but also in determining their targets in vivo and the vulnerability of 
tissues to immune mediated attack. Furthermore, it also suggested that the -
standard 1:1 w:w complex configurations employed in clinical assays (Nobile-
Orazio & Gallia, 2013; Rinaldi et al., 2009) may be insufficient for detecting all 
classes of antibody.  
GM1 GM1:GalC 1:32 mol:molGM1:GalC 1:1 mol:mol
Galactose GalNAc
Glucose Ceramide
N-acetylneuraminic acid
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Although we were unable to demonstrate this using MMN patient serum 
ourselves, it does not mean that lipid concentration is not an important factor in 
antibody detection. In fact, parallel developments during the creation of this 
thesis showed that increasing the concentration of GalC in complexes improved 
the detection of anti-GM1 antibodies (Delmont et al., 2015), which corroborates 
this research. 
Taken together, these results suggest that the binding specificities of anti-
ganglioside antibodies are much more complicated than previously appreciated. 
The key to identifying biomarkers in patient sera therefore lies in creating 
diverse sets of antigens that resemble the endogenous plasma membrane as 
closely as possible. The work contained within this thesis and carried out within 
our laboratory (Halstead, unpublished data) are beginning to show the 
advantages of using these techniques, but researchers are going to have to 
increase the complexity of assays to further improve disease diagnosis. 
10.1.3 Conformational modulation is responsible for antibody   
  enhancement 
 
Although not demonstrated at a molecular level, the results from these studies 
provided strong evidence that conformational modulation, rather than neo-
epitope formation, was responsible for antibody enhancement. This was further 
confirmed through our attempts to clone a complex-dependent antibody directly 
from patient sera (data not shown). Whilst this attempt failed, analysis of the 
screening techniques indicated that antibodies that had previously been 
designated complex-dependent were actually standard antibodies that were cis-
enhanced.   
This strongly suggested that neo-epitope formation and complex-dependent 
antibodies were not responsible for the pathogenesis found in MMN. It is key to 
note, however, that this thesis did not prove this definitively.  These antibodies 
may still exist but may require more specialised techniques to isolate and 
identify them.  
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10.1.4 Improvements in hybridoma screening aid in identifying   
  larger numbers of antibodies 
 
Despite not achieving our main aim of producing a complex-dependent antibody, 
substantial improvements were still made in hybridoma production. These were 
necessary as the traditional ELISA method for antibody detection (Goodyear et 
al., 1999) was found to be insufficient for the aims of this thesis. This was due to 
the limitations of the technique, which could only be used to screen one 
antibody isotype against one target antigen.  
This was particularly problematic for high throughput screening, as the 
requirement to use high levels of supernatant, compounded with the quick 
growth rates of the hybridoma cells, made it impossible to successfully rescreen 
supernatant twice.  
To overcome these issues, we employed the use of the lipid microarray. This 
technique operated on a similar principle as the combinatorial glycoarray 
(Rinaldi et al., 2010) but worked on a much larger scale. Whereas the 
combinatorial glycoarray could print multiple targets to screen 12 samples in one 
run, the microarray was capable of printing a higher number of targets for 
screening up to 320 samples. 
In addition, the microarray employed the use of fluorescent antibodies as a 
secondary detection method, whereas ELISA used HRP-conjugated secondary 
antibodies. As a result the microarray was able to screen for two different 
antibody isotypes simultaneously, which allowed for the production of a larger 
number of antibodies from one mouse.   
This technique also allowed for an antibody to be partially characterised prior to 
the cloning step of production. Antibodies could therefore be selected for 
cloning based upon their desired binding patterns, which could be particularly 
useful for quickly selecting antibodies of interest.  
Overall, the improvements in screening were substantial. Through the use of the 
lipid microarray, supernatant could be screened quickly, larger numbers of 
antibodies could be detected and different isotypes could be selected. Whilst 
other researchers have produced similar techniques utilising their own bespoke 
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equipment (De Masi et al., 2005; Staudt et al., 2014), this appears to be the first 
time, to our knowledge, that a lipid microarray has been employed for the 
production of anti-carbohydrate antibodies.  
10.1.5 The combination of different characterisation methods   
  aids in determining the binding behaviours of anti-   
  carbohydrate antibodies  
 
Although it was not our original intention to create more antibodies against 
single lipid antigens, the success of the hybridoma fusions led us to produce a 
series of antibodies targeting gangliosides, glycolipids and sphingolipids. 
Subsequent studies determined the binding behaviours of these antibodies 
through the combination of various characterisation methods, including solid 
phase assays and immunofluorescence.  
One of the main benefits of combining different techniques was that they could 
be used to reconcile differences in antibody binding patterns. For example, the 
anti-GM1 antibody, GAME-G2, was found to be incapable of binding tissue unless 
it was first treated with neuraminidase. Examination of this antibody on solid-
phase assays explained this behaviour as it was demonstrated that the antibody 
was incapable of binding to GM1 when it was in complex with GD1a. By treating 
the tissue with neuraminidase, the sialic acid of GD1a was cleaved and the 
ganglioside was converted to GM1, thus allowing binding to take place.  
This same approach aided in explaining the tissue binding patterns of the other 
antibodies, which helped determine their potential uses in future research. 
Detailed descriptions of these uses are provided within Chapters 7 and 9 but 
they range from localising gangliosides within the plasma membrane to 
determining the vulnerability of particular tissues to antibody induced injury.  
10.1.6 Antibody diversity is an important factor in determining   
  the pathogenicity of anti-sulfatide antibodies  
 
Despite their implication in many demyelinating conditions, few monoclonal 
anti-sulfatide antibodies have ever been produced (Somner & Schachner, 1981). 
This, in part, is due to the success of the preeminent antibody, O4, which has 
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been shown to induce demyelination of sulfatide enriched cells and tissues both 
in vitro and in vivo (Elliott et al., 2012; Rosenbluth & Moon, 2003; Rosenbluth et 
al., 2004).  
The downfall of restricting research to just one anti-sulfatide antibody, 
however, is that antibody diversity will not be taken into account with the 
results. Not all antibodies will bind tissue in the same manner, raising questions 
about how representative O4 is of the general anti-sulfatide population.  
To address these issues, we generated a series of anti-sulfatide antibodies and 
probed them against various cells and tissues. As predicted, these antibodies 
displayed differential binding patterns, with some binding avidly to plasma 
membranes whilst others were incapable of binding at all.   
Analysis of the antibodies binding specificities in solid phase assays indicated 
that they differed in their abilities to bind sulfatide in the presence of other 
lipids. This suggested that they may bind to different components of the 
sulfatide molecule and may differ from O4.   
This was further confirmed through comparisons of the antibodies binding 
patterns in ex vivo preparations of mouse TS. In this tissue, the new anti-
sulfatide antibodies were found to bind to the terminal myelinating Schwann 
cell, whereas no binding was detected with O4.   
This suggested that some unknown lipid or protein in the local microenvironment 
of this cell was preventing O4 from accessing its binding epitope. This clearly 
demonstrated that the new antibodies, although similar to O4, were distinct in 
their ability to bind certain tissues.  
This has ramifications in assessing the pathogenicity of anti-sulfatide antibodies 
in various neuropathies. As GAME-M7 was shown to bind and injure the cell, it 
could be postulated that similar antibodies may arise in patients to bring about a 
form of neurological dysfunction not experienced by patients with antibodies 
that resemble O4.  
On the other side of the spectrum was the antibody GAME-G1, which was shown 
to be incapable of binding to any form of tissue. As discussed earlier, anti-
sulfatide antibodies were isolated from the CSF of MS patients but were found to 
be incapable of binding sulfatide enriched cells or tissues (Brennan et al., 2011). 
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It is likely that GAME-G1 resembles these antibodies, as both were shown to be 
incapable of binding sulfatide in the presence of SM.  
The absence of tissue binding antibodies could suggest that anti-sulfatide 
antibodies are not pathogenic in neuropathies but the work of a colleague that 
was produced in conjunction with this thesis may offer a possible explanation.  
She demonstrated that pathogenic antibodies are likely to bind tissue, illicit 
injury and be internalised, whereas non pathogenic antibodies will remain in the 
circulation (Cunningham, unpublished observations). 
It is therefore possible that antibodies, such as O4 and GAME-M7 bind and injure 
sulfatide enriched tissue and become internalised, whereas antibodies like 
GAME-G1 arise but remain in the circulation as they are unable to bind the 
glycolipid in the plasma membrane. Further work would need to be performed to 
confirm this hypothesis but the fact remains that anti-sulfatide antibodies may 
well be major factors in immune mediated injury in a variety of neuropathies.   
10.2 Future Work 
10.2.1 Improvements in the reliability of biomarkers 
 
The results within this thesis provided strong evidence that the configuration of 
a gangliosides local microenvironment has a large influence on the binding 
abilities of anti-ganglioside antibodies. This has been a concept that has been 
largely overlooked in neuropathy research despite ganglioside complexes being 
used in clinical studies since 2004 (Kaida et al., 2004). 
This is due to researchers focussing on associating particular antibody 
enhancements with different disease subtypes and outcomes rather than the 
composition of the complexes themselves (Créange et al., 2014; Kaida & 
Kusunoki, 2010; Notturno et al., 2009). However, this is an aspect of research 
that must be taken into consideration if we are to improve the reliability and 
effectiveness of biomarkers in disease diagnosis.  
Our laboratory has recently developed a lipid microarray technique, which 
allows serum to be screened against up to 400 separate targets simultaneously 
(Halstead, unpublished data). This equipment has allowed us to increase the 
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complexity of ganglioside complexes, by taking factors such as concentration 
and content into consideration.  
Ideally, complexes should resemble the plasma membrane as closely as possible. 
To achieve this, researchers are going to have to create antigen combinations 
consisting of a number of different gangliosides and accessory lipids at varying 
concentrations. By creating antigens that closely mimic the site of injury, it is 
much more likely that antibodies can be detected in sera that are reliable 
indicators of disease.  
This work, however, relies on the assumption that circulating anti-ganglioside 
antibodies are pathogenic. As discussed previously, a colleague’s work has 
suggested that pathogenic antibodies bind to gangliosides, elicit injury and are 
removed by internalisation (Cunningham, unpublished data). The remaining 
antibodies would therefore be unable to bind tissue and would remain in the 
circulation.  
If this same process is demonstrated in humans, then it would suggest that using 
patient serum to diagnose autoimmune neuropathies may be unreliable. Non-
binding antibodies may still be generated in certain conditions and may act as 
indicators of disease; however, further work needs to be performed to 
determine the validity of anti-ganglioside antibodies in the diagnosis of 
autoimmune neuropathies.   
10.2.2 Determining the existence of neo-epitopes and complex-  
  dependent antibodies 
 
The evidence from these studies provides strong support that conformational 
modulation is responsible for the enhancement produced by GM1:GalC 
complexes with MMN patient serum. However, despite the work carried out 
within this thesis, we were unable to demonstrate the interactions of these 
lipids at a molecular level.  
It is still possible that gangliosides may interact with one another to form neo-
epitopes, however, the abundance of these formations within the plasma 
membrane and their relevance in disease are unclear. The ideal method for 
elucidating whether antibodies could arise against these neo-epitopes would be 
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active immunisations with complexes consisting of covalently linked 
gangliosides.  
These complexes have been created by groups as this thesis was developed 
(Mauri et al., 2012); however, no immunisations have been performed to 
determine whether specific complex-dependent antibodies can be produced. 
This would be a worthwhile pursuit as the only way to prove or disprove the 
existence of these antibodies is to induce their generation in vivo. If these 
antibodies could be produced and were found to bind specific sites in the plasma 
membrane then it would suggest that they may well arise in humans and may be 
responsible for the pathogenesis of various autoimmune neuropathies.  
10.3 Closing Statement 
 
Overall this thesis was able to shed some light on the complexities of anti-
glycolipid antibodies. Through the analysis of their binding behaviours in solid 
phase assays and tissues, we were able to elucidate how the local 
microenvironment influences epitope access and how this affects the 
pathogenicity of these antibodies in disease.  
Furthermore, in our attempt to isolate a complex-dependent antibody, we were 
able to generate 10 new monoclonal antibodies targeting various gangliosides 
and glycolipids. These antibodies, particularly those targeting sulfatide, may be 
very useful in furthering our understanding of immune mediate attack in 
different neuropathies.  
Most importantly, this thesis demonstrated that diversity is an important factor 
in understanding the binding behaviours of different antibodies. This is a concept 
that is only truly beginning to be appreciated but has implications in 
understanding the roles that these antibodies have in both health and disease.  
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